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Abstract 
Plasmodium falciparum remains the most virulent cause of malaria. With increasing drug 
resistance to artemisinin and other antimalarial drugs, combined with an absence of an 
effective vaccine, there’s a critical need for new agents to complement existing treatment and 
prophylaxis. Therefore, the aim of the study was to evaluate the in vitro antimalarial activity 
and potential toxicity to mammalian cells of select synthetic and natural colourants, 
nucleoside and imidazo[1,2a]pyridine (IP) analogues on the erythrocytic stages of the 3D7 
chloroquine-sensitive strain of P. falciparum. The P. falciparum 3D7 strain was maintained in 
vitro according to standard methods. Quinine and chloroquine were used as positive controls. 
The tritiated hypoxanthine incorporation assay was used for evaluating the ability of test 
compounds to inhibit the growth of P. falciparum. Active test compounds were tested in 
combination studies with quinine. Uninfected human red blood cell (RBC) toxicity was 
analysed spectrophotometrically. The ability of test compounds to inhibit β-haematin 
formation, a metabolic pathway that sequesters toxic haem within the parasites, was 
determined. Cytotoxic activity of active compounds was evaluated on two human cell lines 
(HEK293 and K562) using the [3H]-thymidine incorporation assay. Data was analysed using 
the one-way ANOVA test and reported as the mean ± standard deviation of at least triplicate 
experiments and significant difference when p < 0.05. Of the 56 compounds tested, the 
synthetic colourants showed the most potent antimalarial activity. Methylene blue and 
safranin O were most potent with IC50 values of 4.19 ± 0.16 nM and 86.50 ± 2.61 nM, 
respectively, compared to quinine (IC50: 103.90 ± 8.30 nM), and displayed negligible toxicity 
to uninfected human RBCs. Combination studies with methylene blue and quinine 
demonstrated a synergistic interaction. Methylene blue also demonstrated the highest 
selectivity indices (480 and 968) compared to quine (180). Curcumin (diferuloylmethane), a 
natural extract was active (IC50: 2.29 ± 0.18 µg/ml) against P. falciparum, but significantly (p 
< 0.05) less potent than quinine. Curcumin was 78-fold more active in inhibiting β-haematin 
formation than quinine, indicating of a possible mechanism of action. The most active 
nucleoside analogue, JLP118.1 (IC50: 1.79 ± 0.12 µM), demonstrated inhibitory activity 
against the trophozoite stage of P. falciparum. The imidazopyridine analogue, IP-4, displayed 
the least potent antimalarial activity (IC50: 15.3 ± 0.41 µM) of the synthetic compounds 
tested, with low selectivity indices < 1. The study has confirmed the potent antimalarial 
activity and relative safety of methylene blue as well as its potential as an antimalarial drug. 
The nucleoside and imidazopyridine analogues showed promising activity and with structural 
modification their potency and selectivity indices may be enhanced. 
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Chapter 1 Introduction 
1.1 The malaria epidemic 
Malaria is a vector-borne parasitic disease that presents as a febrile illness and may cause 
dysfunction in organs such as the spleen, liver and the brain in its severe and chronic form 
(Miller et al., 2002). Malaria parasites are transmitted to humans by the bite of infected 
female mosquito vectors of the Anopheles species (WHO, 2013). Malaria is caused by five 
species of parasites of the genus Plasmodium that affect humans: P. falciparum, P. vivax, P. 
ovale, P. malariae and P. knowlesi (WHO, 2013). Of these Plasmodium species, P. 
falciparum and P. vivax are the most prevalent and virulent, accounting for more than 95% of 
malaria in Africa, East Asia countries and India (Micale, 2012). In 2012, the global estimate 
of people at risk of malaria was 3.4 billion, with populations living in the African and South-
East Asia regions having the highest risk of acquiring malaria (WHO, 2012). In addition the 
World Health Organisation (WHO) reported an estimate of 207 million cases of malaria 
globally, and 627 000 deaths worldwide in 2012 (WHO, 2013). Of the estimated deaths, most 
occurred in sub-Saharan Africa (90%) and mostly in children under 5 years of age (77%) 
(WHO, 2013). Globally, malaria is ranked fifth as a cause of death from an infectious disease 
after respiratory infections, human immuno-deficiency virus/acquired immuno-deficiency 
syndrome (HIV/AIDS), diarrhoeal diseases and tuberculosis (Centers for Disease Control, 
2011).  
 
The economic burden in Africa alone is estimated at 12 billion US dollars annually in direct 
losses due to morbidity and premature death (Roll Back Malaria Partnership, 2008). The 
disease burden especially in sub-Saharan African countries is compounded by poor socio-
economic conditions and healthcare systems, migration to malarial regions, changing 
agricultural and environmental landscape (Sachs and Malaney, 2002). In addition, climate 
change may be considered a possible contributing factor particularly to the proliferation and 
spread of the mosquito vector (Sachs and Malaney, 2002). Provided the interventions 
currently recommended by the WHO are implemented, malaria can easily be prevented 
(WHO, 2012). These prevention interventions include vector control through the use of 
insecticide-treated nets and indoor residual spraying. Chemopreventative measures for the 
most vulnerable populations, particularly pregnant women and infants, as well as early 
malaria diagnosis and timely treatment, are critical (WHO, 2012). 
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1.2 Malaria in South Africa 
Malaria risk areas in South Africa include north-eastern KwaZulu-Natal, the low altitude 
areas of Mpumalanga and Limpopo provinces, particularly those along the borders of 
Zimbabwe, Mozambique and Swaziland (National Department of Health, 2010). Only 4% of 
the population is at high risk of malaria and 6% at low risk, while 90% live in malaria-free 
areas (WHO, 2012). Between the year 2000 and 2011, steady progress has been made in 
controlling malaria. During this period the malaria cases in South Africa decreased by 85% 
(from 64,622 cases to 9,866) and the mortality rate greatly decreased by 81% (from 458 
deaths to 89) (National Department of Health, 2012). Generally adults living in malaria 
endemic areas such Mozambique, Malawi and Tanzania may acquire partial immunity 
subsequent to long-term and repeated exposure to P. falciparum infection (Sachs and 
Malaney, 2002). However, South Africans are not immune to malaria and therefore at risk of 
developing cerebral malaria, which can be fatal (National Department of Health, 2010). In 
most cases, increased morbidity and mortality is a culmination of delayed diagnosis and 
inappropriate treatment (National Department of Health, 2010). In South Africa, malaria is a 
notifiable medical condition requiring health workers and local authority or hospitals to 
record cases and deaths for regional planning and monitoring of the disease (National 
Department of Health, 2010). Chloroquine, sulphadoxine or pyrimethamine monotherapies 
were used as first line of treatment for uncomplicated P. falciparum malaria until treatment 
failure rates above 10% were detected (Mullick et al., 2011). In response to the increasing 
drug resistance, the WHO recommended the use of artemisinin-based combined therapy 
(ACT) (WHO, 2010). Chloroquine-resistance in South Africa was first observed in KwaZulu-
Natal and later in Mpumalanga (National Department of Health, 2010). This resulted in a 
change in the treatment policy with the use of sulphadoxine-pyrimethamine as first line 
treatment for early stage or uncomplicated P. falciparum in KwaZulu-Natal in 1988 and 
Mpumalanga in 1997 (National Department of Health, 2010). The development of significant 
sulphadoxine-pyrimethamine resistance in KwaZulu-Natal led to a further policy change in 
2001 with artemether-lumefantrine replacing sulphadoxine-pyrimethamine as first line 
treatment (National Department of Health, 2009). The increase in drug resistance initiated a 
successful inter-governmental initiative such as the Lubombo Spatial Development Initiative 
involving Mozambique, South Africa and Swaziland (Sharp et al., 2007). This collaboration 
successfully resulted in a 78% reduction in malaria cases in Mpumalanga between 1999 and 
2005 by reducing cross-border infections, implementing indoor residual spraying and first line 
therapy with ACT (Sharp et al., 2007; National Department of Health, 2010).  
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1.3 Clinical signs and symptoms of malaria 
The signs and symptoms of malaria are non-specific (Table 1.1) and malaria is clinically 
suspected on the basis of fever or a history of fever, as well as travelling to malaria endemic 
regions (WHO, 2010). Presentation of P. falciparum malaria mimics many other diseases 
including influenza, viral hepatitis, meningitis, septicaemia, typhoid, tick-bite fever, 
gastroenteritis, viral haemorrhagic fever, trypanosomiasis, HIV sero-conversion illness, 
urinary tract infection and relapsing fever (National Department of Health, 2010). Malaria 
symptoms may present as early as 7 days after exposure, usually 10-21 days after being bitten 
by an infected mosquito. Longer incubation periods may occur in patients who have failed 
chemoprophylaxis due to poor compliance or inappropriate prophylaxis regimen, or have 
been on an antibiotic course not prescribed for malaria. Malaria due to infections with P. 
vivax, P. ovale, or P. malariae, can take up to 12 months to first manifest clinically (National 
Department of Health, 2010). Another clinical manifestation of malaria is placental malaria. 
This is of particular danger for primigravidae (a woman pregnant for the first time) and is due 
to P. falciparum adherence to chondroitin sulphate-A in the placenta (Vinetz et al., 2011). 
This often leads to severe complications, including miscarriage. When treated early, 
symptoms of malarial infection usually improve within 24-48 h (Vinetz et al., 2011). Patients 
with uncomplicated malaria are at a risk of developing severe P. falciparum malaria with life-
threatening complications as a result of delay in diagnosis and/or treatment of an 
uncomplicated infection, or the use of ineffective therapy (WHO, 2010). 
 
Table 1.1 Signs and symptoms of malaria (National Department of Health, 2010). 
 
Uncomplicated malaria:
• Fever
• Headache
• Rigors (cold and shiver or hot sweats)
• Myalgia
• Dizziness
• Loss of appetite (or poor feeding)
• Diarrhoea, nausea and vomiting
• Cough
• Splenomegaly
Severe malaria:
• Prostration
• Impaired consciousness
• Multiple convulsions
• Circulatory collapse
• Acute respiratory distress syndrome (ARDS); 
hypoxia
• Abnormal bleeding; Disseminated 
intravascular coagulation (DIC)
• Jaundice
• Haemoglobinuria
• Hypoglycaemia
• Renal and Hepatic impairment
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1.4 Drugs used in the management of malaria 
Currently available antimalarial drugs can be categorised according to their drug classes and 
into four groups according to their biological activity against specific developmental stages of 
the parasite (Vinetz et al., 2011). These include drugs that eliminate liver tissue schizonts, 
dormant liver forms or hypnozoites (for casual prophylaxis and to prevent relapse), blood 
schizontocides and gametocytocides (Vinetz et al., 2011). Currently there is no antimalarial 
drug that kills sporozoites, so drugs used for chemoprophylaxis can only prevent the 
development of symptomatic malaria caused by asexual erythrocytic forms. Patterns of 
clinically effective drugs can be categorised into three general classes based on the stages of 
the life-cycle they are active against, as well as their mechanism of action (Table 1.2) 
(Parkinson, 2010; Vinetz et al., 2011). 
 
Table 1.2 Currently available drug classes for treatment of malaria (Parkinson, 2010; 
Rossiter, 2012). 
Drug class Examples Mechanism of action 
4-Aminoquinolines Chloroquine, amodiaquine,  
Prevent detoxification of haem by 
the parasite 
Quinoline methanol Quinine, mefloquine, quinidine 
8-Aminoquinolines Primaquine 
Bisquinoline Piperaquine 
Amyl alcohol Lumefantrine 
Anti-folates Sulphadoxine, pyrimethamine, proguanil 
Inhibit dihydrofolate reductase, 
interfering with Plasmodium 
pyrimidine synthesis 
Napthoquinones  Atovaquone Inhibit mitochondrial function of 
the parasite 
Artemisinin 
derivatives 
Artemisinin, 
dihydroartemisinin, artemether, 
artesunate, artemotil/arteether 
Sesquiterpene lactone 
endoperoxides that produce free 
radicals in the parasite food 
vacuole 
Antibiotics Tetracycline, doxycycline, 
clindamycin 
Inhibit parasite apicoplast 
organelle function 
 
1.4.1 Class I agents: blood schizontocides and gametocytocides 
The drug action of these antimalarial agents (artemisinin, chloroquine, mefloquine, 
quinine/quinidine, pyrimethamine, sulfadoxine and tetracyclines) is mainly directed against 
the asexual erythrocytic forms, except for artemisinin which acts as both a blood 
schizontocide and gametocytocide. Chloroquine, quinine or quinidine show low to moderate 
activity against gametocytes. This class of drugs treat, or prevent clinically symptomatic 
malaria (Vangapandu et al., 2007; Rossiter, 2012). 
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1.4.2 Class II agents: blood and liver schizontocides 
Typically atovaquone and proguanil target both the asexual erythrocytic forms and the liver 
tissue schizonts of P. falciparum. Their activity reduces the required period for post-exposure 
chemoprophylaxis from 4 to 1 week (Vinetz et al., 2011). 
1.4.3 Class III agents: liver schizontocides, hypnozontocides and gametocytocides 
This class currently comprises solely of primaquine, which is effective against liver schizonts 
and latent, hypnozoites liver stages as well as gametocytes. Primaquine is used most 
commonly to eradicate the intra-hepatic hypnozoites of P. vivax and P. ovale that are 
responsible for relapsing infections, but not used in the treatment of symptomatic malaria 
(Vangapandu et al., 2007; Vinetz et al., 2011). 
1.5 Clinical management of P. falciparum infections 
The differential diagnosis between uncomplicated and severe malaria is critical in selecting an 
appropriate therapeutic strategy for effective treatment; where severe malaria is characterised 
as having a parasitaemia > 4%, haematocrit < 20% and haemoglobin < 6 g/dl (National 
Department of Health, 2010). Artemisinin-based combination therapies are used for the 
treatment of uncomplicated P. falciparum malaria (National Department of Health, 2010; 
WHO, 2012). The recommended drug treatment for P. falciparum infections is the 
administration of an artemisinin-lumefantrine combination or alternatively, quinine plus either 
doxycycline or clindamycin for 7 days to avoid quinine-induced adverse effects (National 
Department of Health, 2010). 
1.5.1 Management of severe malaria 
Intravenous quinine is the preferred treatment for severe malaria in South African children 
and adults who have no immediate access to intravenous artesunate (National Department of 
Health, 2010). The WHO recommends intravenous artesunate as the treatment of choice for 
severe malaria in adults (WHO, 2012). Once the patient is able to tolerate oral therapy, 
artemether-lumefantrine or quinine plus either doxycycline or clindamycin, should be 
administered (National Department of Health, 2010). 
1.5.2 Management of mixed Plasmodium infections 
When a mixed infection of P. falciparum with either P. vivax or P. ovale is confirmed or 
suspected, the standard therapy for uncomplicated or severe P. falciparum malaria infection is 
recommended, along with a follow-up of course of primaquine (National Department of 
Health, 2010).  
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1.5.3 Chemoprophylaxis of malaria 
In addition to preventative measures such as mosquito repellents and use of bed nets, 
prophylactic regimens using mefloquine, doxycycline and atovaquone are recommended by 
the South African Department of Health (Baker, 2009; National Department of Health, 2010). 
1.6 Challenges in the management and eradication of malaria 
Resistance to chloroquine is most prevalent, while resistance to other antimalarial drugs such 
as quinine, mefloquine, halofantrine, atovaquone, sulfadoxine and pyrimethamine have been 
progressively spreading (Vangapandu et al., 2007; O'Neill et al., 2012). The development of 
most of the vaccine candidates is still underway or in clinical trials. Given the complexity of 
the malaria parasite life-cycle, a malaria vaccine needs to encompass various strategies of 
stimulating the immune responses in order to achieve a high degree of efficacy (PATH, 2007; 
Birkett et al., 2013; Riley and Stewart, 2013).  
1.6.1  Mechanism of chloroquine-resistance 
Chloroquine was first synthesised in 1934 and became the gold standard treatment by the 
1940s for malaria with good clinical efficacy, limited toxicity at an affordable cost of 
treatment in Africa (O'Neill et al., 2012). After about a decade of use, chloroquine-resistance 
emerged in South-East Asia, South America, and the Western Pacific region (Ecker et al., 
2012). The first incidences of malaria parasite resistance to chloroquine were reported in 1957 
(O'Neill et al., 2012). Chloroquine-resistance spread progressively throughout malaria 
endemic areas including Africa, where surges in mortality rate were reported (Ecker et al., 
2012). Chloroquine-resistance (mechanism model shown in Figure 1.1) is putatively acquired 
via mutations in the P. falciparum parasite that caused the efflux of chloroquine out of the 
digestive vacuole of the parasite, at a rate 40 to 50-fold faster compared to chloroquine-
sensitive strains (Krogstad et al., 1987; Ecker et al., 2012).  
 
A P. falciparum P-glycoprotein homologue-1 (Pgh-1), known as the chloroquine-resistant 
transporter (PfCRT), modulates drug uptake by transporting drugs in and out of the parasites’ 
digestive vacuole (Vangapandu et al., 2007). The major mutation (K76T) implicated in 
chloroquine-resistance is due to the lysine76 (K76) amino acid substitution with threonine (T) 
(Ecker et al., 2012). Moreover, PfCRT is a transmembrane protein localised within the 
digestive vacuole membrane and is expressed from the ring stage through to the trophozoite 
stage where there is maximal haemoglobin digestion (Ecker et al., 2012). Thereby, preventing 
the accumulation of chloroquine within the digestive vacuole, via passive diffusion down the 
pH gradient (Ecker et al., 2012). As a result, binding of chloroquine to the haemoglobin 
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breakdown product to form toxic drug-haem complexes is also reduced (Fidock et al., 2000). 
However, chloroquine-resistance has been shown to be reversed to a certain degree by 
calcium-channel blockers such as verapamil, cyproheptadine and hydroxyzine by interfering 
with the efflux pump (Martin et al., 1987).  
 
 
Figure 1.1 Mechanism of PfCRT-mediated chloroquine-resistance associated with 
hydrogen-ion leak in P. falciparum (adapted from Lehane et al., 2008 and Fidock et al., 
2008). Uncharacterised outward leak pathway of H+ (1), leads to alkanisation of the digestive vacuole 
(DV) upon inhibition of V-type H+-ATPase pump by concanamycin A. Neutral form of chloroquine 
(CQ), diffuses through the RBC down the pH gradient into the DV. In CQ-sensitive strains di-
protonated, less membrane-permeant CQ (CQH22+) accumulates within the DV. Whereas in CQ-
resistant strains, mutant PfCRT-mediated efflux of CQH22+ occurs in symport with H+ ions. This 
efflux of CQH22+ can be reversed by verapamil. The H+ leak pathway (2) would explain the higher rate 
of alkalinisation after PfCRT inhibition with verapamil observed in CQ-strains. 
 
1.6.2 Multi-drug resistance 
Although the presence of a PfCRT K76T mutation increases the risk of chloroquine treatment 
failure by 2.1-fold on day-14 post-treatment and by 7.2-fold on day-28, some patients in high-
transmission areas infected with malaria parasite strains containing mutant PfCRT, seem to 
respond adequately to chloroquine perhaps partially due to acquired-immunity (Ecker et al., 
2012). However, a secondary determinant of chloroquine-resistance in P. falciparum has been 
attributed to a multidrug-resistance (PfMDR1) transmembrane localised within the digestive 
vacuole membrane. PfMDR1 is an orthologue of mammalian P-glycoproteins that mediate 
verapamil-reversible tumour multidrug-resistance (Ecker et al., 2012). However, although 
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PfMDR1 mutations alone appear to be insufficient to confer chloroquine-resistance, it is 
suggested they can modulate the degree of mutant PfCRT-mediated chloroquine-resistance, 
dependant on the parasite strain (Ecker et al., 2012). P. falciparum resistance to sulfadoxine-
pyrimethamine is associated with mutations in the dihydrofolate reductase (PfDHFR) gene 
and to a lesser extent in the dihydropteroate synthase (PfDHPS) (Wang et al., 1997; Osman et 
al., 2007). Reduced susceptibility of P. falciparum to the potent short-acting artemisinin 
derivatives has been observed in South-East Asia, Cambodia-Thailand region (Dondorp et al., 
2011).  
1.6.3 Vaccine development 
The strategic goals of current malaria vaccine initiatives are aimed at the induction of 
immunity to prevent clinical malaria, as well as the interruption of transmission, thereby 
supporting elimination and eradication efforts (Birkett et al., 2013). Sustained immunity to P. 
falciparum infection has  been induced in volunteers without prior exposure using live, 
attenuated sporozoites delivered by irradiated mosquitoes, while simultaneously preventing 
disease with chloroquine prophylaxis (Roestenberg et al., 2011). Subunit vaccines (as 
opposed to attenuated whole-parasite vaccines), have previously shown lower efficacy than 
whole-parasite vaccines, but are simpler to clinically deliver (Greenwood et al., 2008). 
However one subunit vaccine candidate RTS,S developed by GlaxoSmithKline Biologicals, 
has shown promising results in Phase IIb clinical trials and currently undergoing Phase III 
evaluation (Birkett et al., 2013). However, following vaccination over the 12-month period 
during the clinical trials, RTS,S only conferred 50% protection in children aged 5-17 months 
and approximately 30% protection in children aged 6-12 weeks across 13 clinical sites in 
eight African countries (Birkett et al., 2013). Key barriers to the development of more highly 
efficacious vaccines than RTS,S include: lack of well characterised target immunogens in all 
the stages of P. falciparum life-cycle, limited number of safe and effective delivery systems 
and adjuvants that induce potent long-lasting protective immunity, be it by antibody, CD4+ 
and/or CD8+ T-cell responses (Birkett et al., 2013). These complexities in malaria vaccine 
development demonstrate the critical need for the development of new novel drugs that may 
be used in combination with existing drugs and even with a licensed vaccine candidate to 
control the malaria disease and even sensitise resistant strains. 
1.7 Malaria parasite developmental life-cycle 
The life-cycle of P. falciparum (Figure 1.2) is complex and characterised by developmental 
stages that have distinct morphological forms adapted to different microenvironments in the 
human and mosquito hosts (Arnot and Gull, 1998; Bannister et al., 2005). The Plasmodium 
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sporozoites from the salivary glands of an infected female Anopheles mosquito are injected 
into the bloodstream of the human host during a blood meal ① and migrate to the liver where 
they invade hepatocytes and asexually multiply ② (Arnot et al., 2011; Centers for Disease 
Control, 2011). This stage forms the exo-erythrocytic schizogony phase, which is 
asymptomatic. During the liver schizont stage ③, nuclear division completes and the parasite 
undergoes nuclear segmentation giving rise to daughter merozoites. Upon the rupture of the 
hepatocytes, the mature schizonts release several thousand merozoites ④ into the bloodstream 
where they rapidly invade red blood cells (RBCs) ⑤. Post-invasion, the parasite undergoes a 
46-48 h intra-erythrocytic schizogony cycle with distinct morphological forms: the ring form, 
which matures into a trophozoite, which in turn forms a schizont that gives rise to 16-32 
daughter merozoites. Deoxyribose nucleic acid (DNA) synthesis begins during the trophozoite 
stage after the appearance of the malaria pigment (haemozoin) from RBC haemoglobin 
digestion (Arnot et al., 2011). 
 
The schizont-infected RBC is ruptured, releasing the extracellular merozoites into the 
bloodstream where they infect new RBCs ⑥. This intra-erythrocytic cycle represents the 
pathogenic phase of the malaria disease (Bannister et al., 2005; Arnot et al., 2011). A fraction 
of the parasites within the RBCs undergo cell cycle arrest or differentiate into sexual 
erythrocytic stage known as gametocytes ⑦, which take approximately 8-12 days to mature 
(Bannister et al., 2005; Dixon et al., 2008). The gametocytes are ingested by the female 
mosquito vector when biting an infected human host ⑧. While in the mosquito's stomach, the 
microgametes penetrate the macrogametes generating zygotes⑨. The zygotes develop into 
motile and elongated ookinetes ⑩, which invade the mid-gut epithelial wall of the mosquito 
and develop into oocysts ⑪. The oocysts grow, rupture, and release sporozoites, which 
migrate to the mosquito's salivary glands ⑫ and are inoculated into a new human host ①, 
thus perpetuating the malaria life-cycle (Bannister et al., 2005).  
 
The complex life-cycle of P. falciparum, proteomic expression and metabolic pathways are 
unique to that of the human host. These characteristics of the malaria parasite provide various 
targets for therapeutic intervention (Florens et al., 2002; Doerig et al., 2010). Therefore, the 
sections that follow evaluate the nucleotide synthesis and haemozoin formation metabolic 
pathways that are established drug targets and a literature review of some selected and 
structurally related test compounds on their putative antimalarial activity. 
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Figure 1.2  The malaria parasite life-cycle (Centers for Disease Control, 2011). 
 
1.8 Plasmodium life-cycle regulatory protein kinases as drug targets 
The intra-erythrocytic cycle of the Plasmodium parasite varies greatly from that of the typical 
cell cycle observed in higher eukaryotes. For instance, in higher eukaryotic cells, there is a 
single round of DNA replication per cell cycle, resulting in two identical daughter cells 
subsequent to mitosis (Geyer et al., 2005). In contrast, the genome of the parasite undergoes 
multiple rounds of DNA replication and nuclear division, generating a single multinucleate 
cell called a schizont (Arnot et al., 2011). At least five phases of DNA synthesis within the P. 
falciparum life-cycle have been identified. These occur during the micro-gametogenesis or 
male gametocytes formation, meiosis and sporogeny (sexual cycle) within the mosquito 
vector, intra-hepatic schizogony in the liver and erythrocytic schizogony (asexual cycle) 
within the human host (Arnot and Gull, 1998). Higher eukaryotic cell cycle (Figure 1.3) is 
divided into the G1 (G-gap), S (DNA synthesis) and G2 phases that make up the interphase, 
as well as the mitotic (M) phase (Alberts et al., 2008a). The majority of cells in living 
organisms are in a quiescent G0 phase (Donovan et al., 2005). The transition between these 
phases is tightly regulated by positive effectors, cyclins and cyclin-dependent kinases 
(CDKs), and families of negative protein regulators  that inhibit CDKs (Kong et al., 2003; 
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Alberts et al., 2008a). Mammalian CDKs comprise a family of 10 serine-threonine protein 
kinases (CDK1-10) that catalyse different cell cycle transitions. A CDK molecule binds to an 
activator molecule, a cyclin forming a protein complex (Donovan et al., 2005; Alberts et al., 
2008a). This CDK-cyclin binding is a requisite for activation. Cell division cycle (Cdc) 
phosphatases, are responsible for removing phosphates from CDK binding sites to allow for 
further activation, thereby enabling the continuation of the cycle (Donovan et al., 2005). 
Deregulation of the cell cycle marks the initiation and progression of cancer or neoplastic 
transformation of eukaryotic cells (Moniz et al., 2011).  
 
 
Figure 1.3 The P. falciparum cell cycle in comparison to the mammalian cell cycle 
(adapted from Arnot et al., 2011; www.usma.edu). Mammalian cell cycle (inner blue circle) 
and P. falciparum (outer red circle). The free circulating haploid merozoites are in a G0-like state with 
condensed chromatin. The early trophozoite stage is similar to the G1-phase of mammalian cells. The 
S-like stage where DNA synthesis occurs begins soon after the appearance of malaria pigmentation 
(haemozoin) and continues throughout late trophozoite into the early schizont stage. Progression from 
G2-like stage to the mitotic-like stage is not discretely defined. Genomic segregation is rapid and may 
occur in 8-10 h. DNA segmentation occurs and merozoites are prominent in mature, late schizonts 
(Arnot and Gull, 1998; Arnot et al., 2011). 
 
P. falciparum homologues of several genes that encode critical regulators of DNA replication 
including CDKs and cyclins, have been identified (Doerig et al., 2010). The first CDK-related 
protein kinase to be reported in P. falciparum was PfPK5 which showed homology to CDK1 
(human cdc-2 protein) and CDK5 (Ross-Macdonald et al., 1994; Doerig et al., 2002). PfPK5 
is putatively involved in the regulation of the S-like phase during trophozoite stage (Figure 
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1.3) in P. falciparum (Graeser et al., 1996). PfPK6 mRNA has been detected in parasites 
undergoing ring to schizont transition and showed homology to CDK1 and mitogen-activated 
protein kinases (Bracchi-Ricard et al., 2000). PfPK6 does not require cyclin binding for 
kinase activity in vitro, whilst PfPK5 is able to autophosphorylate in the presence of a cyclin 
(Bracchi-Ricard et al., 2000; Le Roch et al., 2000). A MO15-related kinase, Pfmrk, has been 
detected in both asexual intra-erythrocytic forms and gametocytes (at higher levels), and is 
most closely related to CDK7, the kinase responsible for the activation of CDK1 (Li et al., 
1996). PfPK7, an orphan protein kinase with maximal homology to MEK3/6, has been shown 
to be involved in a pathway that regulates parasite asexual proliferation and sexual 
development. Genetically re-engineered clones without the PfPK7 gene have shown a 
decrease in erythrocytic asexual growth associated with reduced number of daughter 
merozoites produced per schizont (Dorin-Semblat et al., 2008). In addition, PfPK7-negative 
parasites have also shown a reduction in the ability to produce oocysts in the mosquito vector 
during the sexual developmental stages (Dorin-Semblat et al., 2008). Pfcrk-1 (P. falciparum 
cdc2-related protein kinase), closely related to the p58 gene subfamily, members of which are 
negative regulators of cell growth in vertebrates, has been detected in gametocytes (Doerig et 
al., 1995). PfNek-4, a Never-in-mitosis Aspergillus nidulans (NIMA)-related kinase, has been 
detected and putatively involved in regulating gametocytogenesis and the maturation of the 
zygote of the P. falciparum parasite (Reininger et al., 2012). Several compounds have been 
found to be selectively active against CDKs and other kinases. Purine analogues, which are 
structurally related to ATP, the natural substrate for kinases, are such a class of compounds 
(Harmse et al., 2001). 
1.9 Targeting the nucleoside metabolic pathway in P. falciparum parasites 
Studies on the metabolism of pyrimidines nucleosides in humans started as early as 1927 
(Rose and Coe, 2008). Research on the potential therapeutic role of nucleosides continued in 
1929 focusing on the effects of purinergic compounds on the cardiovascular system (Rose and 
Coe, 2008). This interest in metabolism of nucleic acids combined with the discovery of the 
double helix structure of DNA led to studies in nucleoside analogues and anti-metabolite 
therapeutic agents. For instance, 6-mercaptopurine, a nucleoside analogue drug developed by 
Nobel Prize award recipients, Elion and Hitchings, is still an approved agent for human 
leukaemias (Bruce et al., 2011). Elion and Hitchings work also led to the development of 
drugs for immunosuppression (azathioprine) and anti-viral chemotherapy (acyclovir, 
ganciclovir, vidarabine and zidovudine) (Bruce et al., 2011). The development of allopurinol, 
a hypoxanthine analogue, was based on the same work. Allopurinol is used to treat 
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hyperuricaemia in patients with gout and acts by inhibiting xanthine oxidase, thus preventing 
the synthesis of urate from hypoxanthine and xanthine (Grosser et al., 2011). In order to 
survive, the P. falciparum parasite has evolved and developed a unique life-cycle and 
metabolic pathways, different from that of its human host (Baldwin et al., 2007). Therefore, 
these biochemical pathways such as energy metabolism, protein synthesis, lipid biosynthesis, 
nucleic acid synthesis and folate metabolism have been previously identified as drug targets 
(Mishra et al., 2006). Nucleoside analogues are designed to interfere with the synthesis of 
nucleic acids in P. falciparum (Gero et al., 2003). Some synthetic purine-derived CDK-
inhibitors such as olomoucine and roscovotine show activity against P. falciparum (Harmse et 
al., 2001). 
1.9.1 Nucleosides, nucleic acid precursors 
Nucleosides formed by the combination of a purine or pyrimidines nitrogenous base with a 
pentose sugar, either ribose or 2-deoxyribose, are critical in prokaryotic and eukaryotic cells 
as precursors of nucleotides (Figure 1.4) and nucleic acids for cell replication and survival 
(King et al., 2006; Alberts et al., 2008b). Nucleotides such as ATP provide cellular energy  
(King et al., 2006). DNA is a double helix polymer structure with two antiparallel strands, 
sense strand in the 5-prime to 3-prime direction and the anti-sense strand in the opposite 
direction. The DNA chain is composed of four types of deoxyribonucleotide subunits 
containing bases adenine (A), cytosine (C), guanine (G) and thymine (T). In the ribonucleic 
acid (RNA) single strand chain, the thymine nucleotide subunit is substituted by uracil (U) 
(Alberts et al., 2008b). According to the Watson-Crick base pair model, the purine bases (A 
and G) on one chain and pyrimidines bases (T or U and C) on the other chain pair in a 
complimentary manner (Alberts et al., 2008b). 
 
 
Figure 1.4 Nucleotide structure (adapted from Alberts et al., 2008b). A nucleotide 
comprises a phosphate, sugar (deoxyribose or ribose) and a nitrogenous base, in this case guanine (a 
purine). In DNA the deoxyribose sugar lacks a hydroxyl (-OH) group on the second carbon atom. A 
nucleoside is a combination of the sugar and the base, a purine or pyrimidine (Alberts et al., 2008b). 
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1.9.2 Cellular nucleoside transport 
Plasma membrane transporters are specialised proteins that facilitate the movement of lipid-
insoluble molecules with a large molecular size that cannot diffuse into prokaryotic or 
eukaryotic cells (Rose and Coe, 2008). Non-infected human RBCs express both the 
endogenous equilibrative nucleoside transporter (hENT1), encoded by SLC29A1 gene and 
facilitative  nucleobase transporter (hFNT1) proteins (Quashie et al., 2010). The ENT family 
of transporters is restricted to eukaryotes and hENT1 is  found in the heart and central nervous 
system tissues (King et al., 2006). Post-infection (10-20 h) during the trophozoite stage, the 
RBC expresses new permeation pathways (NPP) on the plasma membrane (Figure 1.5) 
(Baldwin et al., 2007).  
 
 
Figure 1.5 Nucleoside transporters and permeation pathways in the human RBC 
infected by P. falciparum during the parasite’s trophozoite stage (adapted from Baldwin 
et al., 2007). hENT1, human equilibrative nucleoside transporter 1; NPP, new permeation pathway; 
PVM, parasitophorous vacuole membrane; PPM, parasite plasma membrane; PfENT1, P. falciparum 
equilibrative nucleoside transporter 1.  
 
NPPs are non-saturable channel-like systems that transport low molecular weight compounds 
including purines (Quashie et al., 2010). The compounds moving between the RBC and the 
parasite have to cross a series of three membranes, the host RBC membrane, the 
parasitophorous vacuole membrane (PVM) and the parasite plasma membrane (PPM) (Figure 
1.5) (Gero et al., 2003; Baldwin et al., 2007). Previous studies have  demonstrated that NPPs 
are sensitive and may be inhibited by chloride-channel inhibitors such as furosemide and 5-
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nitro-2-(4-phenylbutylamino) benzoic acid (Baldwin et al., 2007). The parasitophorous 
vacuole membrane is proposed to possess non-selective channels. Permeation of nucleosides 
through the parasite plasma membrane is then mediated by PfENT1 transporter proteins into 
the parasite itself (Gero et al., 2003). In addition to nucleosides, there is  increased 
permeability of nutrients, such as carbohydrates, amino acids, cations: sodium (Na), 
potassium (K), zinc (Zn), iron (Fe), small peptides, several antimalarial drugs as well as an 
increased efflux of lactate (Gero et al., 2003).  
1.9.3 Plasmodium nucleotide biosynthesis 
Nucleotides are either anionic or polyanionic and therefore are not permeable to cellular 
membranes (Gero et al., 2003). However, nucleosides and their analogues are neutral 
molecules which can cross cell membranes and need to be intracellularly phosphorylated into 
their respective nucleotides (Gero et al., 2003). P. falciparum is a purine auxotroph or lacks 
the ability to biosynthesize purine nucleotides de novo and instead relies upon the purine 
nucleosides and nucleobases salvaged from the host RBC (Baldwin et al., 2007; Cassera et 
al., 2011). Genomic sequencing of P. falciparum has shown that nine of the ten enzymes 
required for the biosynthesis of inosine monophosphate (IMP), a metabolic precursor for all 
purine nucleotides required for nucleic acid synthesis, are not encoded for (Baldwin et al., 
2007). Instead, hypoxanthine salvaged from the host is  phosphorylated by a hypoxanthine-
guanine-xanthine phosphoribosyl transferase (PfHGXPRT) enzyme within the parasite to 
form IMP (Figure 1.6) (Cassera et al., 2011). RBCs contain concentrations of ATP in 
equilibrium with adenosine diphosphate (ADP) and adenosine monophosphate (AMP), which 
placed no evolutionary pressure on the parasite to retain its de novo purine synthetic pathways 
(Cassera et al., 2011). 
1.9.3.1 Purine salvage and metabolic pathway 
Hypoxanthine is the key precursor for all purine synthesis in Plasmodium metabolism, which 
is another reason why hypoxanthine is commonly added as a nutritional supplement in 
malaria parasite culture media (Cassera et al., 2011). The source of hypoxanthine in vivo is 
the RBC purine pool where ATP is metabolically exchanged with hypoxanthine (Figure 1.6) 
(Cassera et al., 2011). Human RBCs  lack de novo purine biosynthesis, but maintain low 
concentrations of adenine nucleotide by salvaging adenosine via human adenosine kinase 
(hAK) enzyme (Cassera et al., 2011). P. falciparum lacks adenosine kinase activity, but can 
salvage adenosine by conversion to inosine by adenosine deaminase (PfADA) and 
subsequently to hypoxanthine by purine nucleoside phosphorylase (PfPNP) kinase activities 
(Figure 1.6) (Cassera et al., 2011). Hypoxanthine is then converted to IMP by PfHGXPRT. 
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Since P. falciparum cannot convert adenosine to AMP, it takes up AMP synthesised in the 
RBC, inducing more RBC AMP production (Cassera et al., 2011). 
 
 
Figure 1.6 Enzymatic purine salvage and de novo pyrimidine metabolic pathways 
(adapted from Cassera et al., 2011). Purine pathway: AMP, adenosine 5′-monophosphate; ADP, 
adenosine 5′-diphosphate; ATP, adenosine 5′-triphosphate; IMP, inosine 5′-monophosphate; XMP, 
xanthosine 5′-monophosphate; GMP, guanosine 5′-monophosphate; hADA, human adenosine 
deaminase; MTA, methylthioadenosine; MTI, methylthioinosine; Ads, adenoylsuccinate; hPNP, 
human purine nucleoside phosphorylase; hHGPRT, human hypoxanthine-guanine phosphorybosyl 
transferase; hAK, human adenosine kinase; hAMPDA, human adenosine 5′-
monophosphatedeaminase; hAPRT, human adenine phosphoribosyl transferase; PfADA, P. 
falciparum adenosine deaminase; PfPNP, purine nucleoside phosphorylase; PfHGXPRT, 
hypoxanthine-guanine-xanthine phosphoribosyl transferase; PfAMPDA, adenosine 5′-
monophosphatedeaminase; PfIMPDH, inosine 5′-monophosphate dehydrogenase; PfGMPs, guanosine 
5′-monophosphate synthase; PfAdSS, adenylosuccinate sythetase; PfAdSL, adenylosuccinate lyase. 
Pyrimidine pathway: OMP, orotidine 5′-monophosphate; UMP, uridine 5′-monophosphate; UTP, 
uridine 5′-triphosphate; CTP, cytidine 5′-triphosphate; PfCPSII, carbamoyl phosphate synthetase II; 
PfATCase, aspartate carbamoyltransferase; PfDHOase, dihydroorotase; PfDHODH, dihydrooratate 
dehydrogenase; PfOPRT, orotate phosphoribosyltransferase; PfODC, orotidine 5′-monophosphate 
decarboxylase; PfCTPs, cytidine 5′-triphosphate synthase. The bold arrows on reversible steps, 
indicate the metabolically favoured direction. Nucleoside/nucleobase transporters are indicated on 
each membrane: hENT, human erythrocyte nucleoside transporter (brown); PfNT1, P. falciparum 
nucleoside transporter 1 (purple) and adenisone 5′-monophosphate transporter (red) (Cassera et al., 
2011). 
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1.9.3.2 De novo pyrimidine synthesis pathway 
Unlike purines that are in abundance in human RBCs, pyrimidines exist in small 
concentrations (Cassera et al., 2011). As a result P. falciparum has retained its capacity for de 
novo synthesis of pyrimidines and therefore lacks pathways for the salvage of pyrimidines 
from the host RBC (Reyes et al., 1982; Cassera et al., 2011). Instead, the de novo pathway is 
the only route available for the synthesis of pyrimidine nucleotides (Figure 1.6), as well as 
synthesis from pyrimidine substrates such as thymidine, cytidine, deoxycytidine, uridine and 
uracil (Reyes et al., 1982). The de novo synthesis of pyrimidines from carbamoyl phosphate 
and aspartic acid follows the same metabolic pathway found in other eukaryotic cells and the 
human host RBC (Cassera et al., 2011). P. falciparum cell growth and division demand 
sufficient purine and pyrimidine supplies, in particular deoxyadenosine triphosphate (dATP) 
and deoxythymidine triphosphate (dTTP), since the parasite contains the most (A+T)-rich 
(approximately 80%) genome sequenced to date (Cassera et al., 2011). 
1.10 CDK inhibition and antiprotozoal activity of imidazopyridines 
Imidazo[1,2-a]pyridine is a bicyclic system with a bridgehead nitrogen atom (Figure 1.7), first 
described by Chichibabin in 1925 (Enguehard-Gueiffier and Gueiffier, 2007).  
 
 
Figure 1.7 Parent chemical structure of the imidazopyridine (imidazo[1,2-a]pyridines) 
analogues. The imidazopyridine group is boxed. 
 
Some imidazole pyrimidine analogues described by Enguehard-Gueiffier & Gueiffier (2007) 
demonstrated diverse pharmacological activities, including inhibition of enzymes involved in 
cell cycle regulation, receptor ligands of eukaryotic cells, anti-viral and antiprotozoal activity 
(Enguehard-Gueiffier and Gueiffier, 2007; Jones et al., 2008). Other drug formulations 
containing imidazo[1,2-a]pyridines currently available on the market include alpidem 
(anxiolytic), zolpidem (hypnotic) and zolimidine (anti-ulcer) (Rousseau et al., 2007). 
Antiprotozoal activity demonstrated by imidazopyridine analogues includes Trypanosoma 
brucei rhodesiense, Trypanosoma cruzi, Plasmodium falciparum, Toxoplasma gondii and 
coccidiosis (Enguehard-Gueiffier and Gueiffier, 2007). The suggested mechanism of action of 
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these imidazo[1,2-a]pyridine analogues involved the inhibition of parasite specific cyclic 
guanosine monophosphate (cGMP)-dependant protein kinase, although the parasites  tested 
positive for mutagenesis (Enguehard-Gueiffier and Gueiffier, 2007). In the field of anti-cancer 
drugs, development of a series of imidazopyridine analogues targeting cyclin-dependant 
kinases has led to the discovery of drugs with anti-proliferative activity against various cell 
cancer lines. The proposed in vitro antiproliferative mechanism of action of 6-substituted 
imidazo[1,2-a]pyridines on HT-29 and Caco-2 cancer cell lines has been proposed to be 
mediated via the intrinsic apoptotic pathway (Dahan-Farkas et al., 2011). Several other 
imidazo[1,2-a]pyridines and related imidazo[1,2-a]pyrimidines have been reported to be 
selective CDK-inhibitors, bradykinin B2 receptor antagonists, gamma-aminobutyric acid and 
benzodiazepine receptor agonists (Rousseau et al., 2007). In addition, a high-throughput 
screen of the AstraZeneca compound library identified a series of imidazo[1,2- a]pyridines as 
potent inhibitors of CDK2 and CDK4 (Anderson et al., 2003; Enguehard-Gueiffier and 
Gueiffier, 2007). 
1.11 Targeting the haemozoin formation pathway 
Since the discovery of the malaria parasite in the 18th century, the malaria pigment 
(haemozoin), observed during the trophozoite stage, has played a role in revealing the life-
cycle of the parasite (Ross and Smyth, 1897; Egan, 2008a). Slater et al. (1991) confirmed that 
indeed haemozoin consists of ferriprotoporphyrin-IX (Fe3+-PPIX) and that it is identical to 
synthetic β-haematin (Slater et al., 1991). During its pathogenic asexual erythrocytic stage, 
the RBC cytoplasm is ingested into the parasite by a cytostome and transported to the 
digestive vacuole by double membrane bound transport vesicles (Figure 1.8) (Egan, 2008a). 
The P. falciparum parasite degrades up to 65-75% of the hosts’ RBC haemoglobin during 
intra-erythrocytic growth (Skinner-Adams et al., 2010). Inside the digestive vacuole, 
haemoglobin is digested by proteolytic enzymes; namely aspartic proteases (plasmepsins I, II, 
IV and histo-aspartic protease), cysteine proteinases (falcipains 2, 2´ and 3), metallo-protease 
(falcilysin), dipeptidyl aminopeptidases I or cathepsin c to small peptides (Figure 1.8) 
(Skinner-Adams et al., 2010). These small peptides are then exported to the parasite cytosol 
and finally degraded to amino acids by aminopeptidases (Skinner-Adams et al., 2010). Free 
haem containing Fe2+-PPIX is released following haemoglobin digestion, and is 
spontaneously oxidised to form haematin, Fe3+-PPIX and toxic hydrogen peroxide (H2O2) by-
products, capable of destroying the parasite membrane through oxidative stress, resulting in 
parasite death (Egan, 2003). In order to sequester and protect itself from this free toxic 
haematin, the parasite polymerises up to 95% of the haematin into the inert, microcrystal 
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structure known as haemozoin or malaria pigment. Haemozoin is a a yellow-brown water-
insoluble crystal, that is clearly visible, within the digestive vacuole (Egan, 2003; Egan, 
2008b).  
 
Figure 1.8 Haem metabolic pathway within a P. falciparum-infected RBC (adapted from 
Ginsburg, 2013). Hb, haemoglobin; Fe2+-PPIX, ferriprotoporphyrin-IX or haem; Fe3+-PPIX, 
haematin; H2O2, hydrogen peroxides; O2-, superoxide anion; HRP, histidine-rich protein; HDP, haem 
detoxification protein; GSH, reduced glutathione; GSSG, oxidised glutathione;  HMS, hexose 
monophosphate shunt; NADPH, nicotinamide adenine dinucleotide phosphate (Müller, 2004; Egan, 
2008a; Skinner-Adams et al., 2010; Ginsburg, 2013).  
 
Haemozoin formation is susceptible to numerous therapeutic drugs. Quinolines and 4-
aminoquinolines, such as quinine and chloroquine, respectively, are known to act by 
inhibiting the haemozoin formation pathway by forming haem-drug complexes, thus 
preventing the polymerisation of haem into haemozoin (Kumar et al., 2007; O'Neill et al., 
2012). For instance, chloroquine is a weak base and in its non-ionised form can readily 
traverse down the pH gradient, from the RBC cytosol across the membranes into the acidic 
digestive vacuole where it is ionised (O'Neill et al., 2012). In its ionised form, chloroquine 
then becomes less lipophilic and becomes trapped inside the digestive vacuole where it 
accumulates - a phenomenon called “ion-trapping” (Section 2.1.2) (Krogstad et al., 1987; 
O'Neill et al., 2012). Ionised chloroquine then pharmacologically acts by binding to 
monomeric units of haematin and preventing it from polymerising into haemozoin (Egan, 
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2006; O'Neill et al., 2012). As a result the amount of free toxic haematin increases, generating 
reactive oxygen species which in turn causes oxidative stress to the parasite. Oxidative stress 
may lead to lipid peroxidation of cell membranes, DNA damage and protein-carbonyl 
formation, which could eventually lead to parasite death (Kumar et al., 2007). The first 
synthetic antimalarial drug, methylene blue, a phenothiazinium dye and related synthetic 
colourants, and natural colourants such as curcumin have been shown to possess antimalarial 
activity, possibly by inhibiting haemozoin formation by complexation with haem, in a similar 
manner to chloroquine (Vennerstrom et al., 1995). 
1.12 Antimalarial activity of some colourants 
Methylene blue, a phenothiazinium dye, is commonly used as a dye in various biological 
staining procedures in bacteriology and cytological studies. The components of the blood 
stain, eosin and methylene blue, were introduced by Baeyer and Caro, respectively (Krafts et 
al., 2011). Methylene blue was used primarily for detecting Mycobacterium tuberculosis, until 
Ehrlich, in 1880, mixed methylene blue with acid fuchsin to produce a stain which allowed 
differentiation of blood cells (Krafts et al., 2011).  
 
Colourants are widely used in various industries including the textile, printing, 
pharmaceutical, cosmetic and food industries, as well as in laboratories as biological staining 
agents and pH indicators (Chung et al., 1992). Scientists soon realised that some dye 
derivatives could selectively stain different cell types (Wainwright, 2008). In addition, these 
dyes could modify physiological processes like motility of microorganisms such as bacteria 
and protozoa. Ehrlich and Guttman (1891) introduced the idea that these compounds could be 
used in chemotherapy when they successfully treated a patient infected with malaria with 
methylene blue (Wainwright and Amaral, 2005; Wainwright, 2008).  
1.12.1 General chemistry of colourants 
Colourants possess colour due to the following chemical properties: (i) absorb light in the 
visible range (400 – 700 nm) of the electromagnetic spectrum; (ii) have at least one colour-
bearing group (chromophore); (iii) have a conjugated system of alternating double and single 
bonds, and (iv) exhibit resonance of electrons, which provide stability in organic compounds 
(IARC, 2010). In addition to chromophores, most colourants  contain auxochrome groups 
(Figure 1.9) which act as electron donors (Zollinger, 1987). Chromophores are a group of 
atoms in a molecule responsible for the absorption of radiation, such as carbonyl groups, 
nitriles and azo groups. Auxochromes (colour helpers) on the other hand enhance or even shift 
the colour of a colourant, but do not impart colour and include carboxylic acid, sulfonic acid, 
21 
amino and hydroxyl groups (Zollinger, 1987). Auxochromes are most often used to influence 
dye solubility (IARC, 2010).  
 
Figure 1.9 Chromophore and auxochromes of acid red azo compound (adapted from 
Verma et al., 2012). The boxed azo group gives the acid red colourant its red colour. The circled 
functional groups are auxochromes that intensify the colour of the chromophore (Verma et al., 2012). 
 
Organic and inorganic colourants can be subdivided into natural and synthetic colourants 
(Zollinger, 1987). The majority of natural colourants used prior to the 19th century have been 
replaced by synthetic dyes due to the cost-effectiveness of production and stability of 
synthetic dyes (Gordon and Gregory, 1983). 
1.12.2 Synthetic colourants 
Synthetic dyes can be generally classified into eight main groups: (i) azo, (ii) anthroquinone, 
(iii) vat, (iv) indigoid, (v) polymethine, (vi) aryl-carbonium, (vii) phthalocyanine and (viii) 
nitro dyes (Gordon and Gregory, 1983). A prominent class of synthetic dyes, namely the azo 
dyes make up over 50% of the total dyes used worldwide (Gordon and Gregory, 1983; 
Zollinger, 1987). This can be largely attributed to the low cost production technique (azo 
coupling) that allows for a wide variation of di-azo compounds (Gordon and Gregory, 1983). 
1.12.2.1 Azo dyes 
Azo dyes are widely used in various industries such as textile, printing, pharmaceutical, 
cosmetic and food industries, and in research laboratories as previously indicated (Zollinger, 
1987; Tsuda et al., 2000). Azo dyes contain an azo group (Figure 1.10) that consists of two 
nitrogen atoms linked by a double bond (R–N=N–R´) with mostly aromatic side chains, either 
benzene or naphthalene rings (Zollinger, 1987). The azo group appears to be an electron 
acceptor. These can be further classified according to the number of azo groups, for example 
diazos (Figure 1.10) have two linked nitrogen atoms as a terminal reactive group (R2C=N2) 
(Zollinger, 1987). Since the discovery of macrozamin in 1951, a number of natural occurring 
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azoxy (R-N=N(O)-R´) compounds such as cycasin, elaiomycin, maniwamcyin, azoxybacillin 
and valanimycin have been discovered (Zollinger, 1987; Engel et al., 2003).  
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Figure 1.10 Chemical structures of azo, di-azo and axozy compounds (Zollinger, 1987). 
 
1.12.2.1.1 Discovery of sulfa drugs from azo dyes 
Sulfadiazine is indicated for treatment of burns, while sulfadoxine in combination with 
pyrimethamine has antimalarial activity, although wide-spread parasite resistance has been 
associated with the latter combined drug therapy (Shapiro and Goldberg, 2006; Wainwright, 
2008). Azo-polymers have been utilised in the design of drug delivery systems for localised 
therapy. Pro-drugs such as sulfasalazine were developed for delivery of 5-aminosalicylic acid 
specifically to the colon for localised effect in inflammatory bowel disease (Jain et al., 2006). 
1.12.2.1.2 Metabolism of food colourants 
Colourants are added to various types of foodstuffs including beverages, confectioneries and 
processed meats in order to increase their appeal (Zollinger, 1987). Most food colourants have 
no nutritional value and their use is regulated in most countries to prevent food toxicity. The 
concentration of dyes in coloured foods is usually only 0.005 to 0.03% by weight (Zollinger, 
1987). Natural food dyes either extracted from plants or synthesised chemically as natural by-
products are an expensive alternative and are usually unstable, thus making synthetic dyes 
more attractive from a manufacturing perspective (Zollinger, 1987). Ingested azo dye 
compounds are metabolised in humans by azoreductase enzymes found in the liver, 
gastrointestinal microflora and eliminated by renal excretion (Golka et al., 2004). Intestinal 
azoreductase activity has however been found to be reduced by various dietary factors such as 
fibre, Lactobacilli live culture supplements and antibiotics (Chung et al., 1992). The 
azoreductase reaction (Figure 1.11) may yield active and carcinogenic metabolites such as 
benzene and naphthol depending on the azo dye’s chemical structure (Li et al., 2007).  
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Figure 1.11 Azoreduction of methyl red (adapted from Chen et al., 2005). The mechanism 
of action of azoreductase in the reduction of methyl red involves oxidation of NADPH, which acts as 
an electron donor and reductive agent. The reaction results in metabolites, N,N-dimethyl-p-
phenylenediamine and 2-aminobenzoic acid. 
 
1.12.2.2 Phenothiazinium and related dyes 
In 1891, Ehrlich and Guttman reported antimalarial activity of a synthetic phenothiazinium 
dye, methylene blue, after oral administration to two patients who were clinically cured. The 
only side-effect was described as “spastic  irritation of the bladder” (Vennerstrom et al., 
1995). Previous to this, Ehrlich had successfully treated neuralgias with methylene blue, but 
this was the first documented cure of malaria with a synthetic chemical. Although methylene 
blue itself was not as efficient a stain for normal RBCs as its derivatives, it had previously 
demonstrated specific staining of Plasmodium species (Vennerstrom et al., 1995; Wainwright 
and Amaral, 2005). 
1.12.2.2.1 Methylene blue  
Methylene blue (CAS 61-73-4) is a phenothiazinium salt and the earliest reported synthetic 
antimalarial drug (Wainwright and Amaral, 2005). At room temperature it appears as a solid 
dark green powder, but turns blue when in solution. In its reduced-form, methylene blue 
appears colourless (Figure 1.12) (Schirmer et al., 2003). It is suggested that it is the 
spontaneous cycling between the oxidised and reduced forms of methylene blue (or 
leucomethylene blue) (Figure 1.12) that make it an effective reduction-oxidation (redox) 
reagent (Atamna and Kumar, 2010). Methylene blue is clinically indicated for 
methaemoglobinaemia therapy, the prevention of ifosfamide-induced encephalopathy and has 
demonstrated neuroprotective activity in Alzheimer’s disease (Schirmer et al., 2003; Atamna 
and Kumar, 2010).  
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Figure 1.12 Redox reaction of methylene blue (adapted from Schirmer et al., 2005). The 
redox reaction of methylene blue involves the oxidation of riboflavins, flavin adenine dinucleotide 
(FADH2) and nicotinamide adenine dinucleotide (NADPH). 
 
1.12.2.2.2 Safranin O 
Safranin O (CAS 477-73-6; Figure 1.13), a cationic phenazinium dye structurally related to 
methylene blue, is commonly used in histochemical staining (Rosenberg, 1971). In its 
application it has been used in combination with fast green as a counterstain and  with iron-
haematoxylin to stain nuclei (Rosenberg, 1971). It has  been particularly useful in differential 
staining of tissue polyanions in pathological studies of articular cartilage degradation such as 
in rheumatoid arthritis (Rosenberg, 1971). The antimalarial activity of phenazinium dyes such 
as Janus green B, phenosafranin, methylene violet 3RAX and indoine blue, safranin O and its 
analogues were reinvestigated for their in vitro inhibitory effect on the D6 and chloroquine-
resistant W2 strains of P. falciparum parasite growth (Vennerstrom et al., 1995). 
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Figure 1.13 Chemical structure of safranin O (PubChem Compound, 2013c). 
 
1.12.3 Natural compounds as a source for antimalarial drugs 
Plants have been a source of medicine throughout history and continue to serve as a source for 
many pharmaceutical agents today (Ginsburg and Deharo, 2011). The medicinal properties of 
plants have been described as early as 2000 B.C. and documented in early Egyptian, 
Ayurvedic, Chinese traditional medicine, and various European documents and 
pharmacopoeia (Patwardhan, 2005; Kong et al., 2009). The medicinal use of the cinchona tree 
(Cinchona ledgeriana) from South America, Peru, dates back more than 350 years, for curing 
fever and shivers. Only in 1820, the antimalarial drug quinine was isolated from the powdered 
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bark of the cinchona tree by Pelletier and Caventou (Vinetz et al., 2011). Another potent 
antimalarial drug, artemisinin (qinghaosu) was derived from the plant qing hao (Artemisia 
annua) and has been recognised for its medicinal properties for more than 2000 years by the 
Chinese (Vinetz et al., 2011). In some Asian and African countries, 80% of the population 
relies on traditional medicine for primary health care (Ginsburg and Deharo, 2011). 
Authorities have also raised concerns regarding counterfeit, contaminated herbal products 
with insufficient toxicity data that pose serious patient safety threats (Newton et al., 2010). 
Whilst the WHO and its Member States are co-operating in promoting the use of traditional 
medicine, the African Network for Drugs and Diagnostics Innovation seems to be poised to 
address toxicity testing protocols, as well as preserving knowledge of indigenous medicinal 
herbs (Nwaka et al., 2010). 
1.12.3.1 Therapeutic activity of some natural colourants 
Certain plant and animal colour extracts are not only used as food additives, but have been 
used in traditional medicine as well. For instance, the chemotherapeutic properties of the 
active constituent in turmeric, curcumin (diferuloylmethane), has been extensively 
investigated and published in 6,360 papers (Shishodia et al., 2007; PubMed, 2014). Among its 
numerous therapeutic roles, curcumin has demonstrated activity against chloroquine-resistant 
P. falciparum, various cancers and tumours, ulcerative colitis, hypercholesterolaemia, 
atherosclerosis, pancreatitis and Alzheimer’s disease in various clinical trials (Lim et al., 
2001; Duvoix et al., 2003; Reddy et al., 2005; Goel et al., 2008). In vivo studies have 
indicated that an artemisinin or arteether combination therapy with curcumin has the potential 
to prevent parasite recrudescence and relapse of P. berghei-infected mice, as well as provide 
protection against cerebral malaria (Reddy et al., 2005; Nandakumar et al., 2006; 
Padmanaban et al., 2012; Vathsala et al., 2012). In addition, in vitro studies by Reddy et al. 
(2005) and Nandakumar et al. (2006) demonstrated the inhibitory activity of curcumin against 
the chloroquine-resistant P. falciparum strains. 
1.12.3.1.1 Curcumin 
Curcumin (diferuloylmethane; CAS 458-37-7; food additive E100) is found in turmeric 
(Curcuma longa) powder (Goel et al., 2008). The turmeric plant (Figure 1.14) is a stemless, 
leafy perennial herb of the ginger (Zingiberaceae) family (Van Wyk and Wink, 2004; 
Brittanica, 2013c). The plant has broad hairless leaves arising from near ground level with 
white and yellow flowers borne in oblong spikes. The rhizomes are fleshy, smooth and bright 
orange inside and are the source of turmeric (Van Wyk and Wink, 2004). Turmeric is an 
ancient spice and vegetable dye thought to have originated in India (Van Wyk and Wink, 
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2004; Goel et al., 2008). In addition, Curcuma species are widely used for their benefits in 
stimulating bile secretion, the healing of peptic ulcers and carminative (release of gastric gas) 
effects (Van Wyk and Wink, 2004; Goel et al., 2008). A daily intake of 2 g of dried rhizome 
and up to 9 g of fresh rhizome is recommended (Van Wyk and Wink, 2004). The yellow, non-
volatile pigments (3-5% of dry weight) in turmeric are called curcuminoids and include 
curcumin, monodesmethoxycurcumin and bisdesmethoxycurcumin, of which curcumin is pre-
dominant (Lucas et al., 2001; Van Wyk and Wink, 2004). The essential oil (2-7% dry weight) 
is rich in bisabolane, guaiane and several germacrane-type sesquiterpenes including ar-
turmerone, α-turmerone, β-turmerone, carlone and zingiberene (Van Wyk and Wink, 2004; 
Funk et al., 2009). Curcumin was first isolated in 1815, obtained in crystalline form in 1870 
and ultimately identified as diferuloylmethane (Figure 1.15) (Goel et al., 2008). In 1910, the 
feruloylmethane skeleton of curcumin was confirmed and synthesised.  (Goel et al., 2008). 
Curcumin has a chemical formula of C21H20O6, and a molecular weight of 368.37 g/mol.  
 
 
Figure 1.14 Curcuma longa plant and ground powder prepared from dried rhizomes 
(adapted from Goel et al., 2008; Britannica, 2013c). 
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Figure 1.15 Chemical structure of curcumin (Goel et al., 2008; PubChem Compound, 
2013b). In solution, curcumin exists in enolic and β-diketonic forms, but primarily exists in enolic 
form. 
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Pharmacological activity of curcumin and related compounds include anti-inflammatory, anti-
oxidative, anti-microbial, anti-plasmodial and cytotoxicity toward tumour cells, but is 
contraindicated in cases of bile duct obstruction or gallstones (Van Wyk and Wink, 2004; 
Shishodia et al., 2007; Goel et al., 2008). In a study by Funk et al. (2009), turmeric essential 
oils demonstrated potent anti-inflammatory activity. As an anti-oxidant, curcumin is 
suggested to be even more potent than Vitamin E (Lim et al., 2001). These anti-inflammatory 
and free radical scavenging properties were demonstrated in inhibiting inflammatory and 
oxidative damage that occur as a response to β-amyloid plagues in the transgenic mouse 
model carrying a human familial Alzheimer’s disease gene (Lim et al., 2001). Of greater 
importance to the current study, curcumin has  previously demonstrated antiprotozoal effects 
against Leishmania, Trypanosoma, P. falciparum and P. berghei (Reddy et al., 2005). 
1.12.3.1.2 Annatto 
Annatto (CAS 6983-79-5, food additive E160b) is red-yellow colourant extract from mature, 
dry seed pericarp (Figure 1.16) of the achiote tree, Bixa orellana (Bautista et al., 2004). 
Annatto extract contains 80% bixin (Figure 1.17), a lipid-soluble carotenoid along with 
norbixin (Figure 1.17) which is a water-soluble hydrolysed derivative of bixin (Bautista et al., 
2004). In 1982, the WHO Expert Committee on Food Additives reduced the acceptable daily 
intake (ADI) of bixin (27%) from 1.25 mg/kg to 0.065 mg/kg body weight, which is 
significantly lower than the ADI of most synthetic colourants which is set at 0.5 mg/kg body 
weight due to insufficient toxicity data (Bautista et al., 2004). Annatto (E160b) is a permitted 
food colorant under the European Community guidelines (Lucas et al., 2001). 
 
 
Figure 1.16 Bixa orellana plant seeds in an open seed pod (Brittanica, 2013c). 
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Figure 1.17 Chemical structures of the constituent of annatto namely, bixin (~80%) and 
its hydrolysed derivative, norbixin (adapted from Evans, 1996). 
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1.12.3.1.3 Cochineal  
Cochineal (CAS 1260-17-9, food additive E120) is extracted from a dried female insect, 
Dactylopius coccus (formerly called Coccuss cacti) which contains red pigmented eggs and 
larvae (Figure 1.18) (Evans, 1996). Cochineal was historically used as a dye in England as 
early as the 15th century. The D. coccus insects are indigenous to Central America and are 
usually found on cactus plants of the genus Opuntia, where they normally breed (Evans, 
1996). Following fertilisation, the female insect swells up to double its former size due to the 
eggs (60 to 450 eggs) and developing larvae (Evans, 1996). The red-coloured larvae mature in 
14 days and escape the body of the dead female insect. The insects are harvested by brushing 
the cacti plants. The red pigment is obtained by boiling the insects in water, or by exposure to 
the fumes of burning sulphur or charcoal (Evans, 1996). Cochineal contains about 10% 
carminic acid (Figure 1.19), a brilliant purple, water-soluble colouring matter, which is a C-
glycoside anthroquinone derivative. The insects contain about 10% fat and 2% wax (Evans, 
1996). 
 
 
Figure 1.18 (a) Cochineal insects, (b) Dactylopius coccus, forming white clusters 
on Opuntia cactus (Brittanica, 2013b). 
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Figure 1.19 Chemical structure of carminic acid (PubChem Compound, 2013a). 
 
1.12.3.1.4 Carmine 
Carmine (food additive E120) is a purplish-red dye with an aluminium mordant, prepared 
from cochineal insects and contain about 50% carminic acid (Evans, 1996). The food 
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colourant carminic acid produces free radicals and in the presence of iron salts, readily 
damage membrane lipid and degrade carbohydrate deoxyribose (Gutteridge and Quinlan, 
1986). A case of anaphylactic reaction was reported in a patient after ingestion of a generic 
carmine-coated azithromycin tablets suggesting carmine hypersensitivity in some patients 
(Greenhawt et al., 2009). In the latter study, a skin-prick test including two brands of 
uncoated zithromax and azithromycin, isolated carmine-coating, commercial grade carmine 
and cochineal insect extract controls, showed reactivity to both the isolated carmine-coating 
and carmine solution within 30 min (Greenhawt et al., 2009). In contrast, the patient showed 
no significant reaction to the cochineal insect extract control. Subsequently the patient took 
the zithromax tablet (without carmine coating) orally without adverse reactions (Greenhawt et 
al., 2009). 
1.12.3.1.5 Safflower 
Safflower (CAS 8001-23-8) or Carthamus tinctorius L. is a member of the family Compositae 
(Dajue and Mündel, 1996). The safflower plant (Figure 1.20a) is an annual herb with toothed 
leaves and yellow flower heads (Van Wyk and Wink, 2004). The fruits are small, white nuts 
(achenes) that contain a single seed (Figure 1.20b).  
 
 
Figure 1.20 The (a) safflower (Carthamus tinctorius L.) plant, (b) seeds and (c) dried 
flowers (Van Wyk and Wink, 2004). 
 
Traditional uses of the flower extracts in Chinese medicine include the treatment of 
gynaecological ailments, inflammation, heart disorders and fever. Other uses of the flower 
extracts include relief of lower abdominal pain, to clean and treat wounds, scars, swellings 
and sprains. Dried flowers (Figure 1.20c) are prepared as tea infusions and tinctures or 
alcohol extracts (Van Wyk and Wink, 2004). The yellow pigments in the flowers are 
glycosylated dichalcones such as carthamin, safflower yellow B, safflornin C, hydroxysafflor 
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yellow A, and tinctormine (Van Wyk and Wink, 2004). Present in the flowers are numerous 
flavonoids (mainly quercetin and luteolin), α-tocopherol, triterpene alcohols (mainly helianol) 
and polysaccharides. The flowers are a source of yellow or red dye used to colour butter, 
liqueurs, confectionery and cosmetics (Van Wyk and Wink, 2004).  
 
Pharmacologically, both the flowers and the oil have cholesterol lowering effects, while the 
polysaccharides are reported to act as immune stimulants (Van Wyk and Wink, 2004). The 
flavonoids and α-tocopherol possess anti-oxidant effects, whilst the triterpene alcohols are 
reported to be anti-inflammatory (Van Wyk and Wink, 2004). Alpha-tocopherol is reported to 
possess a vitamin E-like effect that is not only limited to protection against oxidative stress, 
but  plays a role in cellular signalling functions in vascular smooth muscle and  generates a 
metabolite that facilitates natriuresis (Brigelius-Flohe and Traber, 1999). The seed oil extract 
has the highest linoleic acid content of any seed oil and is used as a source of this acid in the 
health food industry (Van Wyk and Wink, 2004). Conjugated linoleic acid has been reported 
to have anti-carcinogenic, anti-obese, anti-diabetic and anti-cancer effects (Nagao and 
Yanagita, 2005). 
1.12.3.1.6 Carbon black 
Carbon black or vegetable black (CAS 1333-86-4, food additive E163) is a black powder of 
elemental carbon usually manufactured by the combustion of vegetable material at a high 
temperature to produce a black powder for food use (Wellmann et al., 2006). However, oils 
with high aromatic hydrocarbon content are the preferred raw material for high production of 
carbon black (Wellmann et al., 2006). Carbon black as a food additive is used in sugar and 
flour confectioneries (European Food Safety Authority, 2012). The IARC categorised carbon 
black as a Group 2B (meaning it is possibly carcinogenic to humans) colouring agent in 1995 
(Wellmann et al., 2006). Benzo[α]pyrene, a polycyclic aromatic hydrocarbon found in 
charbroiled food, environmental and tobacco smoke can be enzymatically metabolised into 
mutagenic and highly carcinogenic metabolites possibly associated with colon and lung 
cancers (Denissenko et al., 1996; Le Marchand et al., 2002; Jiang et al., 2007). However, use 
of vegetable-derived carbon black (E153) containing 0.1-1 µg/kg of residual carcinogenic 
polycyclic aromatic hydrocarbon, expressed as benzo[α]pyrene, has not been a safety concern 
(European Food Safety Authority, 2012). 
1.12.3.1.7 Beetroot 
The plant order, Centrospermae consists of ten families which produce red and yellow 
pigments collectively known as betalains (Harmer, 1980; Britton, 1983). Betalains include 
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two pigment classes, the red-violet betacyanins  and the yellow betaxanthins (Strack et al., 
2003). Betalamic acid (Figure 1.21a) is the chromophore common to all betalain pigments 
(Strack et al., 2003). Betalains are water-soluble and show some similarity to anthocyanins, 
however both pigment groups occur mutually exclusive to plants (Harmer, 1980; Britton, 
1983). Most natural betacyanins (Figure 1.21b) are structurally based on two aglycones, 
namely betanidin and its epimer (different chirality at one carbon), isobetanidin (Britton, 
1983). The addition of certain residues to betalamic acid determines whether the pigment may 
be classified as a betacyanin or betaxanthin (Figure 1.21c). Betalains are mostly restricted to 
higher plants in certain families of the Centrospermae including cacti, and are present in 
flowers, leaves and fruits or roots (Britton, 1983). The most commercially exploited betalain 
crop is red beetroot (food additive E162), Beta vulgaris (Figure 1.22a), which contains two 
major soluble pigments, betanin (red in colour) and vulgaxanthine I (yellow) (Azeredo, 2009).  
 
N
H
N+
COOH
O
HOOC COOH
O
OR2OH
OH
O
R1
N
H
O
COOHHOOC N
H
N+
COOHHOOC
H R3
(a) (b) (c)
 
Figure 1.21 General chemical structures of (a) betalamic acid, (b) betacyanins and (c) 
betaxanthins (adapted from Strack et al., 2003). Betanin: R1 = R2 = H. Betaxanthine: R3 = 
amine or amino acid group.  
 
Betalains are added to foods such as desserts, confectioneries, dry mixes, dairy and meat 
products, and used as a pharmaceutical colourant (Evans, 1996; Azeredo, 2009). The spray-
drying method used to obtain powdered beetroot (Figure 1.22c) yields approximately 1% 
betanin, whereas spray-drying which involves prior aerobic fermentation of the aqueous 
extraction may yield up to 8% betanin (Harmer, 1980).  
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Figure 1.22 Ground red powder from the bulbs of the Beta vulgaris plant (Brittanica, 
2013a). 
 
The potent free radical scavenging activity of betalains is well known and based on in vitro 
tests, some reports rank beets among the ten most potent vegetables with respect to their anti-
oxidant activity (Azeredo, 2009). Betanin has demonstrated efficacy in the suppression of 
skin and liver tumours induced by different chemical carcinogens in mice (Kapadia et al., 
2003). Both betanin and betanidin have shown the ability to inhibit lipid peroxidation and 
haem decomposition in vitro (Kanner et al., 2001). Interestingly, human RBCs incorporate 
dietary betalains which may protect the cells and avoid oxidative haemolysis (Tesoriere et al., 
2005). Betanin has shown to be effective in scavenging hypochlorous acid, the most powerful 
oxidant produced by human neutrophils. In addition, betanin acts as a reducing agent of the 
redox intermediates of myeloperoxidase, which catalyses the production of hypochlorous acid 
(Allegra et al., 2005). 
1.13 Problem statement 
The drug research and development (R&D) process from compound screening to 
commercialisation and ultimate health impact is typically 10 to 15 years and costs ranging 
between 500 and 800 million US dollars (Nwaka et al., 2009). Research and new drug 
development appears to be bias towards ailments such as hypertension, depression, 
tuberculosis and HIV/AIDS. Malaria is often regarded as one of the neglected diseases 
afflicting poor populations in developing countries (Nwaka et al., 2009). Although malaria 
has in recent years received significant funding, the drugs expected from the existing R&D 
portfolio are a combination of current drugs such as the potent artemisinin derivatives, along 
with new novel agents. But even artemisinin-based drugs are threatened by resistance (Nwaka 
et al., 2009; Dondorp et al., 2011). Therefore, with the increasing resistance of P. falciparum 
to classical drugs such as mefloquine and artemisinin, and with the absence of a malaria 
vaccine that can deliver effective protection, there is a critical need in identifying new drugs 
with novel mechanism of actions. In addition, combination studies involving existing 
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effective drugs with these new drugs, is essential to delay or prevent the evolution of new 
resistance pathways (WHO, 2012). 
1.14 Aims and objectives of the study 
To this end, the aim of the study was to investigate the in vitro antimalarial activity of 56 
select compounds (synthetic and natural colourants, novel nucleoside analogues and 
imidazopyridine analogues), taking into account the selectivity index (for malaria) of the most 
active test compounds, as well as elucidate a potential drug target such as haemozoin 
formation or the NIMA-related PfNek-4 protein kinase enzyme. 
 
In order to accomplish this, the main objectives of the study were as follows: 
• Determine the anti-plasmodial activity of the test compounds on the asexual, intra-
erythrocytic stages of P. falciparum over a single 48 h developmental cell-cycle. 
• Analyse drug combination interactions of the most active compounds and classical 
antimalarial agent, quinine. 
• Determine the selectivity index of most active compounds for P. falciparum parasites 
compared to transformed human epithelial cells and cancer cell line. 
• Evaluate the ability of the lead compounds to inhibit haemozoin formation. 
• Study the developmental stage-sensitivity of the asexual forms of the P. falciparum 
parasites to lead compounds. 
• Express PfNek-4, a NIMA-related protein kinase putatively involved in the formation 
of gametocytes or conversion to the sexual stages of P. falciparum; as well as 
determine the inhibitory effects of most active compounds on the protein kinase 
activity of PfNek-4. 
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Chapter 2 Antimalarial activity 
2.1 Introduction 
New drugs for P. falciparum malaria infections should ideally be efficacious against drug-
resistant strains and eliminate the disease within a reasonable time to ensure good compliance 
(Fidock et al., 2004). Although, efficacy cannot be at the expense of toxicity, therefore the 
drugs need to be safe, suitable for small children and pregnant women and have appropriate 
formulations for oral use. In addition, these new drugs must be affordable so that they may be 
accessible to many who desperately need them, especially in Africa where most people must 
survive on less than 15 US dollars per month (Winstanley, 2000; Fidock et al., 2004). 
However, the challenge of any drug discovery effort is to identify and develop compounds 
with properties that have predictive efficacy and safety in humans (Winstanley, 2000; Fidock 
et al., 2004).  
2.1.1 Approach to antimalarial drug screening 
Screening of compounds may involve computational assessment of their physicochemical 
properties against molecular targets, in vitro or in vivo activity against the malaria parasite 
(Lipinski et al., 2001; Fidock et al., 2004). The compounds’ in vitro activity may be measured 
by determining the concentration of the compound required for 50% inhibition (IC50) of 
malaria parasite growth or survival (Fidock et al., 2004). In order to ensure efficacy early on 
in the development of a drug, cut-off concentration values are used to narrow the search 
during high-throughput screening of compounds. These cut-off values vary depending on the 
class of the compounds or  computational decisions, which should be in the range of less than 
1 to 5 µM for in vitro screens and less than 5 to 25 mg per kg (oral or subcutaneous) for in 
vivo screens (Fidock et al., 2004). In addition, there is a general consensus that drug 
combinations are essential for the optimal control of malaria in developing countries and in 
replacing existing monotherapies or combination therapies, such as chloroquine or 
sulphadoxine-pyrimethamine, respectively, that have low efficacy against resistant strains 
(Fidock et al., 2004; National Department of Health, 2010; WHO, 2013). 
2.1.2 pH-Dependent sensitivity of P. falciparum parasites 
Drug absorption is determined by the drug's physicochemical properties, formulation, and 
route of administration (Rang et al., 2012b). Unless given intravenously, a drug must cross 
several semi-permeable cell membranes before it reaches the systemic circulation. These cell 
membranes are biologic barriers that selectively inhibit passage of drug molecules. The 
membranes are composed primarily of a lipid bilayer with intramembranous proteins, which 
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determine membrane permeability. Drugs may cross cell membranes by passive diffusion, 
facilitated passive diffusion, active transport, pinocytosis, or intramembranous receptors 
(Rang et al., 2012b). A complicating factor in relation to membrane permeation is that many 
drugs are weak acids or weak bases, which means that depending on the pH, they exist in 
varying ratios in both non-ionised lipid-soluble form and ionised lipid-insoluble form when in 
solution (Rang et al., 2012b). Approximately 95% of drugs on the market, are either weak 
acids (20%) or weak bases (75%) and are ionisable (Bhal et al., 2007). Chloroquine (Figure 
2.1), a 4-aminoquinoline schizontocidal agent and weak base is predominantly non-ionised at 
a neutral pH (7.0) and can therefore diffuse freely into the parasite digestive vacuole as it 
traverses down the pH gradient (Krogstad et al., 1987; O'Neill et al., 2012; Rang et al., 
2012a). Then at the acidic pH (4.8-5.2) of the digestive vacuole (chloroquine’s site of action), 
chloroquine is converted to a di-protonated, membrane-impermeable form and is “trapped” 
inside the parasite as it cannot translocate across the vacuole membrane (Krogstad et al., 
1987; Rang et al., 2012a). 
 
 
 
Figure 2.1 “Ion-trapping” of chloroquine within the malaria parasite digestive vacuole 
(adapted from O’Neill et al., 2012). Non-ionised chloroquine (CQ), a weak base, diffuses through 
the RBC and parasite plasma membranes down the pH gradient and ionises at an acidic pH within the 
digestive vacuole leading to increased accumulation of the ionised or di-protonated drug (CQ++). The 
secondary and tertiary amine groups both accept a single proton. The resulting quaternary amine 
putatively binds to β-haematin thus inhibiting haemozoin formation. 
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2.1.3 pKa and degree of drug ionisation 
The pH-partition hypothesis of Shore et al. (1957) proposed that highly ionised drugs are 
either poorly absorbed or not absorbed at all, as illustrated with chloroquine in Figure 2.1 
(Shore et al., 1957; Disanto and Wagner, 1972). The relative concentrations of the ionic and 
molecular forms of the drug depend on the pKa (relative acid-base strength) of the drug and 
the pH of the medium (Knittel and Zavod, 2008). In addition, most drugs are absorbed by 
passive diffusion of the non-ionised form (Rang et al., 2012b), therefore the degree of 
ionisation of a drug at a certain pH is of great importance. Based on the Brönsted-Lowry 
Theory, a drug that is a weak acid can reversely dissociate into an anion (negatively charged) 
and a proton (H+) and a weak base forms a cation (positively charged) by accepting a proton 
(Rosenthal, 2007). The Henderson-Hasselbalch equation (Equation 2.1) relates the ratio of 
protonated (conjugate acid) to unprotonated (conjugate base) species of weak acids or bases to 
the drug’s pKa (negative logarithm of the dissociation constant, Ka) and the pH (negative 
logarithm of the H+ or acid concentration) of the medium (Aulton, 2002; Rosenthal, 2007). 
 
pKa  = pH +	 log
[acid]
[base] 
Equation 2.1 The Henderson-Hasselbalch equation. 
 
There is therefore a direct link between the degree of ionisation of a drug and its solubility in 
aqueous medium (Figure 2.2). In addition, the degree of ionisation of a drug (Section 2.3.14) 
in a solution can be derived from the Henderson-Hasselbach equation (Equation 2.1) if the 
pKa value of the drug and the pH of the solution are known (Aulton, 2002). The pKa of a drug 
influences solubility, protein binding and permeability, which in turn directly affects 
pharmacokinetic characteristics such as absorption, distribution, metabolism and excretion 
(ADME) (Manallack, 2007). The strong association between pKa and the pharmacokinetics of 
most drugs has resulted in measurement of pKa values as a regulatory requirement by the 
Food and Drug Administration in the USA (Manallack, 2007). It is however conceded that 
pKa values in isolation maybe limited. Therefore an estimate of likely ADME characteristics 
can be obtained using pKa values in combination with other physicochemical properties such 
as molecular weight (MW), logarithm of partition coefficient or octanol (organic)-water 
distribution coefficient of a compound (log P), number of hydrogen donors and hydrogen 
bond acceptors, as well as the polar surface (the total number of hydrogen bonds) of the drug 
molecule (Lipinski et al., 1997; Manallack, 2007). A variety of computational approaches 
exist and a number of algorithms and qualitative structure-activity relationship (QSAR) 
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models are used within commercial software packages such as ACD/Labs that identify 
ionisable groups and predict principal pKa (acid or base) values (Manallack, 2007). So taking 
pKa values into account when screening compounds, allows for early ADME profiling during 
the drug discovery process. 
 
 
Figure 2.2 Change in ionisation and relative solubility of weakly acidic and weakly basic 
drugs as a function of pH (adapted from Aulton, 2000). 
 
2.1.4 Lipinski’s Rule of 5 as a measure of ‘drug-likeness’ 
The drug-like properties of the most active test compounds were assessed using a non-
empirical, in silico or computational approach, known as the Lipinski’s Rule of Five (Ro5), 
first published by Lipinski et al. (1977). This approach was adopted by the Pfizer Research 
Centre and is widely accepted by the pharmaceutical industry for drug-likeness profiling of 
orally administered therapeutics that are passively transported to the site of action (Lipinski et 
al., 2001; Bhal et al., 2007). With the advent of computational high-throughput screening 
(HTS) techniques, it has become feasible to screen hundreds of compounds using the Ro5 and 
other new profiling tools and quickly eliminate lead candidates that have poor 
physicochemical properties for oral bioavailability (Lipinski, 2004; Bhal et al., 2007). The 
term “drug-likeness” specifically refers to drug-like permeability properties (Lipinski, 2004; 
Bhal et al., 2007). High oral bioavailability is a critical factor when developing therapeutic 
agents and it is enhanced when there is a balance between the compound’s solubility and 
lipid-solubility (Lipinski, 2004; Salahuddin et al., 2013). Bioavailability is influenced by 
good intestinal absorption, reduced molecular flexibility (or low number of rotatable bonds), 
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low polar surface area (Salahuddin et al., 2013). The four key physicochemical parameter 
ranges used to describe drug-likeness using the Ro5 are the molecular weight (MW) < 500, 
the logarithm value of the partition coefficient (log P) < 5, hydrogen bond donors (HBDs) < 
5, hydrogen bond acceptors (HBAs: a sum of nitrogen and oxygen atoms) < 10, in this case 
10 being a multiple of 5 (Lipinski et al., 1997, 2001). Although the Lipinski’s Ro5 has no 
range limit for log P, negative log P value (log P < 0) implies the compound is hydrophilic, 
the larger the log P value (log P > 0) the greater its lipophilicity (Khanna and Ranganathan, 
2009). Therefore, log P is often taken into consideration with the molecular weight of the 
compound since smaller molecules (MW < 500) may diffuse across cellular membranes 
(Leeson and Springthorpe, 2007). The log P, octanol/water partition  coefficient of a 
compound, is a predictor of lipid-solubility and widely accepted as having a significant 
impact on the ADME properties of compounds (Bhal et al., 2007). However, the application 
of log P is limited to compounds in their neutral state. The changing pH environment for 
orally administered drugs along the gastrointestinal tract varies from the stomach to the colon, 
meaning that compounds will often be in a mixture of ionic species (Bhal et al., 2007). Oral 
drug absorption occurs in the small intestines at approximately pH 5.5. In order to account for 
the mixture of ionic species, log D (distribution constant) a pH-dependant parameter is often 
used in physiological systems (Bhal et al., 2007).  
2.2 Objectives 
The objectives were to evaluate: the antimalarial activity of all test compounds, the combined 
effect of the most active synthetic and natural colourants with quinine, and to assess possible 
mechanism(s) of action and cytotoxicity of all the lead compounds. Initially, the antimalarial 
activity of the test compounds was screened at a maximum final concentration of 100 µM for 
synthetic compounds and 100 µg/ml for natural compounds. The IC50 values for the active 
compounds, that inhibited parasite growth by at least 80% or more, were determined. The 
active compounds (IC50 values < 100 µM for synthetic compounds and 100 µg/ml for natural 
compounds) were included for further pharmacological action studies.  
 
Although the screening concentration of a 100 µM used in the current study was above the 1-
5 µM concentration range stated by Fidock et al. (2004), the objective was to narrow down 
the search for more active compounds since there was a chance that a large number of the test 
compounds could be inactive and as such further studies could be done to determine the IC50 
values on these select compounds. 
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2.3 Methodology 
2.3.1 Preparation of test compounds 
A total of 56 test compounds were screened in the current study. The azo dyes (28) were 
acquired from Dr Laurent Meijer (Station Biologique de Roscoff, France) as a gift and the 
other synthetic colourants (3) including methylene blue, safranin O and mercury orange were 
acquired commercially from Sigma-Aldrich. The novel nucleoside analogues (8) and 
imidazopyridines (8) were donated by Professor Charles De Koning (School of Chemistry, 
University of the Witwatersrand). The novel nucleoside analogues (Appendix A1) based on 
purine (guanosine and inosine) pyrimidine (uridine and cytosine) nucleobases, were 
synthesised using the ring closing metathesis methodology and fully characterised by 
spectroscopic methods by Dr Jenny-Lee Panayides under the supervision of Professor Willem 
A.L. van Otterlo at the School of Chemistry, University of the Witwatersrand (van Otterlo et 
al., 2003; Panayides, 2012). The structure-activity relationship strategy approach for the JLP 
series compounds was based on a pyrimidine scaffold with substitutions of various reactive 
groups. The imidazopyridine analogues (Appendix A2), designated IP, were synthesised using 
a multicomponent coupling reaction by Dr Amanada L. Rousseau under the supervision of 
Professor Charles De Koning (Rousseau et al., 2007). A cyclohexane ring at position R1 in 
compounds IP-2 to IP-4 of the imidazopyridine analogue series was substituted with a 1,3-
dimethylbenzene ring in IP-5 to IP-8. 
 
Natural colourants (9): curcumin, paprika powder extract, beet-P3006 powder extract, beet-
0611, carbon black, safflower, annatto, cochineal and carmine, were donated by Phytone 
(Ltd.). Stock solutions of 10 mg/ml for natural compounds and 10 mM of all synthetic test 
compounds including quinine hydrochloride (Sigma-Aldrich) were prepared in 100% (v/v) 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich). Serial dilutions of test compounds were 
prepared using experimental medium. The final % DMSO used in the experiments did not 
exceed 1% such as not to have an inhibitory effect on the P. falciparum parasites. 
2.3.2 P. falciparum parasite culture maintenance 
The chloroquine-sensitive (3D7) strain of P. falciparum was cultured (Biosafety clearance 
number: 20090503, Appendix B1) aseptically according to the method of Trager and Jensen 
(1976) and departmental protocol modified by Van Zyl et al. (2010). Parasitised human RBCs 
were maintained in vitro at 5-10% parasitaemia and 5% leukocyte and platelet-free 
haematocrit in Rosewell Park Memorial Institute (RPMI)-1640 culture medium (Section 
2.3.3). The culture (20 ml) was flushed with a gas mixture of 5% CO2, 3% O2 and 92% N2 
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(Afrox) and incubated at 37ºC in a 75 cm3 culture flask. Spent culture medium was replaced 
daily and uninfected RBCs added every 48 h when the parasites where in trophozoite to 
schizont stages. All experiments were conducted using cultures synchronised (Section 2.3.8) 
in the ring stage (Trager and Jensen, 1976; Freese et al., 1988; Van Zyl et al., 2010). 
2.3.3 Preparation of culture medium 
The incomplete RPMI-1640 (Gibco) culture medium was prepared as directed by dissolving 
5.9 g/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (Merck), 4.0 g/l 
D-glucose (Merck), 44.0 mg/l hypoxanthine (Sigma-Aldrich) and 0.01% (v/v), 50 mg/l 
gentamicin sulphate (Sigma-Aldrich) into 1 litre of Milli-Q® water. The incomplete culture 
medium was sterilised by filtration through a 0.22 µm pore size Millipore™ membrane 
(Merck) and stored at 4ºC. Aliquots of this culture medium were incubated at 37°C for 48 h to 
ensure there was no contamination prior to use. The culture medium used to maintain the 
parasites was completed by adding 10% (v/v) human plasma (Section 2.3.4) and 4.2 % (v/v) 
sterile filtered NaHCO3 (Merck), to give a final pH of 7.4. The experimental medium did not 
contain hypoxanthine and gentamycin. Incomplete experimental medium (used for serial 
dilutions of test compounds) excluded human plasma, hypoxanthine and gentamycin. 
2.3.4 Preparation of human plasma 
Human plasma was acquired from the South African National Blood Service (SANBS) 
(Ethical clearance number: WCJ-131030-1, Appendix B2). At least three bags of plasma were 
aseptically pooled and heat-inactivated at 56ºC in a pre-heated water bath for 2 h, whilst 
agitating every 10-15 min. The heat-inactivated plasma was centrifuged at 1,877 x g 
(SORVALL® T6000D) for 10 min and the supernatant aliquoted and stored at -20ºC. Prior to 
use, the plasma was thawed and pre-warmed to 37ºC. 
2.3.5 Preparation of buffered solution 
Phosphate-buffered saline (PBS, pH 7.4) contained 8.0 g/l NaCl (Merck), 0.3 g/l KCl, 0.73 g/l 
Na2HPO4.2H2O (Merck) and 0.2 g/l KH2PO4 (Merck) in Milli-Q® water and sterilised by 
autoclaving at 120ºC for 20 min. 
2.3.6 Preparation of red blood cells 
Whole blood was drawn from healthy human donors (Ethical clearance number: M090532, 
Appendix B3) and stored at 4°C for at least two weeks in blood tubes (BDH) containing 
citrate phosphate dextrose adenosine to prevent coagulation. The blood was centrifuged at 834 
x g for 5 min and the plasma and buffy coat discarded. The packed RBCs were washed three 
times by centrifugation with PBS (Section 2.3.5). The RBCs were diluted to 50% (v/v) with 
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incomplete experimental medium (Section 2.3.3). The RBC suspension was used for at least a 
week to maintain the parasite culture before being discarded. 
2.3.7 Blood smear slide preparation and parasite assessment 
The percentage parasitaemia and erythrocytic developmental growth stages were assessed 
daily using light microscopy. A thin blood smear was prepared and air-dried prior to staining 
with a rapid Giemsa stain kit, RapiDiff™ staining kit (Global Diagnostics), containing a 
fixative solution (thiazine dye in methanol), eosin Y in phosphate buffer to stain the 
cytoplasm, and Giemsa to stain the parasites’ nuclei. The slide was examined with a light 
microscope (Nikon) at 1000x magnification under oil immersion. Infected RBCs and 
uninfected RBCs from ten fields of view were counted and the average percentage 
parasitaemia calculated. 
2.3.8 Synchronisation of parasite culture 
The parasite culture was synchronised using 5% (w/v) D-sorbitol lysis when in the ring stage 
(Lambros and Vanderberg, 1979). The D-sorbitol solution was sterile filtered through a 0.22 
µm pore size Millipore™ filter unit and stored at 4ºC. Cultures were centrifuged at 469 x g 
for 5 min and the spent medium discarded. The pellet was re-suspended in 10 volumes of pre-
warmed 5% D-sorbitol and left for 20 min at room temperature. The more permeable RBCs 
infected with mature parasites were lysed, killing trophozoite and early-to-mid schizont 
stages. The culture was centrifuged at 469 x g for 5 min and the D-sorbitol discarded. The 
culture was re-suspended in pre-warmed complete culture medium, gassed with 5% CO2 and 
maintained routinely without addition of erythrocytes (Section 2.3.2). 
2.3.9 Tritiated hypoxanthine incorporation assay 
Incorporation of [3H]-hypoxanthine into parasitic DNA provides a direct measure of the 
number of infected RBCs in culture and quantification of parasite growth (Desjardins et al., 
1979; Fidock et al., 2004). This incorporation of [3H]-hypoxanthine is enhanced by the 
enzymatic purine salvage pathway facilitated by nucleoside transporters expressed on the P. 
falciparum parasite membrane since the parasite lacks the ability to synthesise purines de 
novo (Baldwin et al., 2007). 
2.3.9.1 Preparation of parasite suspension and plate layout 
Test compound solutions (25 µl) were added to the first row (row-A) in triplicate and serially 
diluted (1:2 dilutions in incomplete experimental medium) down the 96-well microtitre plate 
(rows A to G), such that 4 compounds were tested per plate (Figure 2.3). Row-H was reserved 
for the uninfected RBCs (wells 1-4) in order to reduce isotope residue that could bind non-
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selectively to the RBCs, and the 100% parasite growth (wells H5-H12) controls where the test 
compound was substituted with 25 µl incomplete experimental medium. The synchronised 
parasite culture was adjusted to 0.5% parasitaemia and 1% haematocrit in complete 
experimental medium. The parasite suspension (200 µl) was transferred to all the wells 
excluding the uninfected RBC control wells. The microtitre plate was incubated for a total 
period of 48 h at 37°C under micro-aerobic conditions in a humidified desiccated candle jar. 
Within the initial 24 h incubation period, 25 µl of 5 mCi/ml [3H]-hypoxanthine isotope 
(Amersham), pre-diluted at a ratio of 1:270 in incomplete experimental medium, was added to 
a final concentration of 1.85 µCi/ml per well. The microtitre plate was then incubated for a 
further 24 h period. The classic antimalarial drug quinine (Sigma-Aldrich) was used as a 
reference drug (Trager and Jensen, 1976; Desjardins et al., 1979). 
 
 
Figure 2.3 Design of [3H]-hypoxanthine assay in a 96-well microtitre plate (adapted from 
Desjardins et al., 1979). 
 
2.3.9.2 Harvesting parasitic 3H-labelled DNA 
The parasitic 3H-labelled DNA was harvested onto Wallac™ Betaplate glass fibre filter mats 
using a multichannel Titertek™ semi-automatic cell harvester. The filter mats were allowed to 
air-dry overnight at room temperature. 
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2.3.9.3 Scintillation counting of radiolabelled DNA 
The mats were transferred to plastic sample bags containing 10 ml of Betaplate™ scintillation 
liquid (Perkin-Elmer) and the sample bags heat-sealed. In order to measure the [3H]-
hypoxanthine incorporation into the parasitic DNA, β-emissions from the tritiated 
hypoxanthine were counted in the Wallac™ 1205 Betaplate scintillation counter. The counts 
per minute (cpm) generated were expressed as percentage of surviving parasites taking the 
controls into account (Equation 2.2). 
 
%	Parasite growth	=
cpm
 treatment – cpm RBC control
cpm
 parasite control – cpm RBC control
 ×100 
Equation 2.2 Percentage parasite growth. 
2.3.10 Drug combination study 
In accordance with WHO treatment guidelines, combination therapies should be used to avoid 
treatment failure and drug resistance (WHO, 2013). A synergistic combination of antimalarial 
agents is more favourable as it would allow for lower doses of the individual drugs and still 
maintain the antimalarial effect, as well as minimise side-effects (Bell, 2005). Whereas, 
combination therapy with two drugs that demonstrate an antagonistic interaction should be 
avoided, as it would result in treatment failure (Bell, 2005). Therefore drug combination 
studies provide new information that may be used in the choice of new drug combinations and 
potentiation of existing classical antimalarial drugs. The interactions of the most active 
colourants against malaria in combination with quinine, were determined by using the 
modified [3H]-hypoxanthine incorporation assay (Section 2.3.9) and the interaction 
interpreted with the construction of isobolograms (Berenbaum, 1978; Berenbaum et al., 
1980). Taking a 20-fold dilution factor into account, two compounds were combined in 
various concentration ratios (10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9 and 0:10), such that 
the concentration of quinine decreased whilst that of the test compound increased. The test 
compounds were 2-fold serially diluted in incomplete experimental medium in duplicate 
wells. 
2.3.10.1 Determination of fractional inhibitory concentrations 
The IC50 values were determined from log sigmoid dose-response curves using the Enzfitter® 
software. The fractional inhibitory concentration (FIC) value was calculated as the 
concentration of the inhibitor present in the combination divided by the concentration of the 
inhibitor alone that gives the same effect (Elion et al., 1954; Bell, 2005). Therefore, the FIC50 
values for each test compound were calculated from the IC50 values of the compound in 
combination and the IC50 value of the compounds alone (Equation 2.3). 
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FIC50	= 
IC50 of compound in combination with quinine
IC50 value of compound alone
 
Equation 2.3 Fractional inhibitory concentrations. 
2.3.10.2 Analysis of drug interactions using isobolograms 
The FIC50 values of quinine were plotted on the x-axis and the test compound on the y-axis in 
an isobologram using GraphPad Prism® version 5.0. A line of best fit or additive isobole 
(solid straight line in Figure 2.4) intersected the x-axis and y-axis at FIC50 = 1, representing 
the IC50 of quinine alone and the IC50 of the test compound alone, respectively (Bell, 2005).  
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Figure 2.4 A general isobologram with classification of possible interactions between two 
drugs (adapted from Gupta et al., 2002). The dotted lines denote cut-off values for marked 
synergism (MS); slight synergism (Slight syn.); additive, slight and marked antagonism (Gupta et al., 
2002; Bell, 2005). 
 
Generally, the FIC50 data points distributed along the solid straight line indicate additivity, 
points displaced to the bottom, synergism and points above the additive isobole, antagonism. 
However, the strength of synergism or antagonism is indicated by the degree of deviation 
from the additive isobole. This was achieved by calculating the mean of the FIC50 values of 
each compound in combination and then adding the mean sum of the FIC50 values and using 
the ƩFIC50 value to classify the overall drug interaction (Equation 2.4) according to cut-offs 
defined by Gupta et al. (2002). 
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ΣFIC50 = mean FIC50  of Quinine + mean FIC50 of Test compound  
Equation 2.4 Sum of mean fractional inhibitory concentrations. 
 
Based on the sum of the mean FIC50 values, the drug interactions were defined as: marked 
synergism (0 > ƩFIC50 < 0.5), slight synergism (0.5 > ƩFIC50 < 1), additive interaction (1 ≥ 
ƩFIC50 < 2), slight antagonism (2 ≥ ƩFIC50 < 4) and marked antagonism (2 ≥ ƩFIC50 < 4) 
(Gupta et al., 2002; Bell, 2005). 
2.3.11 Haemolysis assay 
RBCs consist of skeletal proteins underlying a lipid bilayer with inter-membrane proteins and 
haemoglobin for oxygen delivery to the tissues  (Mohandas and Gallagher, 2008). Anaemia is 
one of the multiple pathologies of human malaria and along with increased lipid peroxidation 
that affects the plasma membrane integrity of both infected and uninfected RBCs. As such, 
one has to be cautious of an increased risk of haemolysis when new compounds are 
administered (Becker et al., 2004; WHO, 2012). Therefore, it was prudent to assess whether 
the antimalarial activity demonstrated by the lead compounds, was due to a selective 
inhibitory effect on the intra-erythrocytic parasite, or due to their haemolytic potential. To 
achieve this, the compounds were screened for haemolytic activity using healthy human 
RBCs (Section 2.3.6). This involved spectrophotometrically measuring free haemoglobin 
released due to haemolysis at a wavelength of 412 nm (Hayat et al., 2011). Consistent with 
the [3H]-hypoxanthine incorporation assay (Section 2.3.9), a 1% human haematocrit was 
prepared from freshly washed blood in complete experimental medium. Fresh blood (or less 
than 4 days old) was used to ensure cell membrane integrity of the RBCs. The test and 
reference compounds were screened at a maximum concentration of 100 µM (or 100 µg/ml). 
The experimental controls included: a positive control with 1% haematocrit and 0.2% Triton 
X-100 (Sigma-Aldrich) in order to achieve 100% haemolysis; a background colour control 
with 250 µl complete experimental media; a colour control for the coloured compounds (25 µl 
compound with 200 µl complete experimental media; as well as a negative control (25 µl 
incomplete experimental media with 200 µl RBC suspension). Test compounds (25 µl) and 
the RBC suspension (200 µl) were transferred to sterile microcentrifuge tubes and incubated 
at 37ºC for 48 h in a humidified candle jar. After the initial 24 h period, 25 µl of incomplete 
experimental medium was added to all the microcentrifuge tubes followed by further 24 h 
incubation. After 48 h, the RBCs were incubated at room temperature for 10 min. The 
microcentrifuge tubes were gently agitated and centrifuged at 284 x g (SANYO® 
microcentrifuge) for 5 min. The supernatant (20 µl) from all the microcentrifuge tubes was 
transferred to duplicate wells in a 96-well microtitre plate and diluted in 80 µl PBS (pH 7.4) 
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and the absorbance read at 412 nm using the iEMS microplate reader (Labsystems) operated 
with Ascent software (version 2.4). The % haemolysis (Equation 2.5) was determined from 
the absorbance (Abs) values. 
 
% Haemolysis =
mean  Abstreatment - mean  Absnegative control
mean  Abs100% haemolysis - mean  Abstreatment
×	100 
Equation 2.5 Percentage haemolysis equation. 
2.3.11.1 Modified haemolysis assay procedure for the colourants 
In the case of the colourants, the 200 µl supernatant was discarded and the remaining RBCs 
were washed three times with PBS of the same volume. The supernatant from the third wash 
was used as a colour control for the test compound. The remaining pellets of RBCs were 
treated with 0.2% (v/v) Triton X-100 in order to achieve 100% haemolysis. The supernatant 
(20 µl) from all the microcentrifuge tubes was transferred to duplicate wells in a non-sterile 
96-well microtitre plate with 80 µl PBS (pH 7.4) and absorbance read at 412 nm using the 
iEMS Microplate Reader MF (Labsystems) operated with Ascent software (version 2.4) and 
the % haemolysis was determined using the modified % haemolysis equation (Equation 2.6). 
 
% Haemolysis =
[100 – (mean  Abstreatment – Abscolour control)] - mean  Absnegative control
mean  Abs100% haemolysis - mean  Absnegative control
 X 100 
Equation 2.6 Modified % haemolysis equation for colourants. 
 
To ensure that haemolysis did not contribute to the antimalarial activity of the most active test 
compounds, the selectivity index (Equation 2.7) was calculated, where a selectivity index ≥ 
10 indicated that the compound’s mechanism of action was selective to the malaria parasite 
and not only toxic to uninfected human RBCs to effect parasite death (Pink et al., 2005). 
 
Selectivity index =
Haemolytic activity (HLC50)
Antimalarial activity (IC50)  
Equation 2.7 Selectivity index for P. falciparum compared to uninfected human RBC. 
2.3.12 Beta-haematin formation inhibition assay 
The pathway involving the biocrystallisation of oxidised free haem (Fe3+-protoporphyrin IX) 
into an inert substance, haemozoin in P. falciparum is a validated drug target (Egan, 2003; 
Kumar et al., 2007). The quinoline family of drugs including chloroquine, quinine and related 
4-aminoquinoline drugs, accumulate into the parasite’s food vacuole and form adducts with 
redox-active free haem molecules, inhibiting the aggregation of haemozoin (Egan, 2006). 
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Failure of the parasite to sequester the increasing haem molecules overwhelms the parasite’s 
detoxification system,  causing oxidative stress and parasite membrane damage, which leads 
to parasite death (Section 1.11) (Wright et al., 2001). The synthetic counterpart of haemozoin, 
β-haematin, can be synthesised in vitro from haemin chloride (Cl-Fe3+-protoporphyrin) by the 
acid-catalysed method which proceeds in an aqueous solution (Slater et al., 1991; Egan, 
2008b). In the current study, the assay was modified according to Chemaly et al. (2007). 
Briefly, haemin chloride (Sigma-Aldrich) stock solution (1 mg/ml) was prepared in DMSO. 
Test compound solutions were diluted in DMSO and used at a maximum concentration ratio 
of 1:4 (haem to drug). The test compounds (25 µl), haemin (25 µl), 50 µl of Milli-Q® water 
and 100 µl of acetate buffer (pH 4.4), were consecutively transferred to a 96-well microtitre 
plate. This was to simulate the acidic conditions prevalent in the digestive vacuole (pH 5-5.2) 
of the malaria parasite. The plate was placed in a humidified, sealed container and incubated 
at 37°C for 24 h. Quinine and chloroquine were used as reference drugs. The β-haematin 
crystals were isolated by centrifugation at 1,877 x g for 10 min and washed three times with 
DMSO to remove un-reacted haemin followed by two washes with Milli-Q® water. These 
DMSO-insoluble crystals were dissolved in 100 µl 2 M NaOH and diluted four-fold in 1 M 
NaOH. The absorbance of the β-haematin formed was measured using the iEMS Microplate 
Reader MF (Labsystems) operated with Ascent software (version 2.4) at a wavelength of 405 
nm (Chemaly et al., 2007).  The percentage of β-haematin formed (Equation 2.8) was 
calculated using appropriate controls. IC50 values of test compounds that inhibited β-haematin 
formation by at least 80% were determined using Enzfitter®. 
 
% β-Haematin formed = mean  Abstreatment 
mean  Abs100% haematin formation
 × 100 
Equation 2.8 Percentage β-haematin formation. 
2.3.13 Drug-sensitivity of erythrocytic stages of P. falciparum 
It has been established that specific plasmodial developmental stages show enhanced 
sensitivity to some antimalarial drugs. In order to determine the stage-specific activity of the 
test compounds against the erythrocytic stages of P. falciparum (Figure 1.2), parasitaemia 
counts and stage identification of the parasites were examined microscopically. The parasite 
suspension (200 µl) adjusted to 2% parasitaemia and 2% haematocrit, prepared in complete 
experimental culture media was aliquoted into 25 cm3 flasks when the parasite were  in the 
early-ring stage and treated with 25 µl test compound or quinine at an inhibitory concentration 
yielding 90% parasite kill (IC90). A drug-free control was included and cultures were 
incubated at 37ºC for 48 h. The parasitaemia count (all stages), parasite stage, and 
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morphological observations were recorded at 8 h intervals over the 48 h period. Samples were 
taken from the flasks using sterile pasteur pipettes and the cultures flushed with a gas mixture 
of 5% CO2, 3% O2 and 92% N2 (Afrox) and returned to the incubator (37ºC). The Giemsa 
stained thin blood smears of each culture were microscopically examined at 1000x 
magnification under oil immersion using a digital microscope with a mounted camera 
(Olympus®) operated with CellSens Dimension software (version 1.7), and images captured. 
2.3.14 Measurement of drug-likeness using physicochemical properties 
For the purpose of this study, log P (partition coefficient) was used as a predictor of lipid-
solubility of the most active compounds compared to reference drugs in an in vitro context. 
The application of the Ro5 (Figure 2.5) included the construction of two-dimensional 
chemical structures of the compounds in their oxidative state (that is excluding the salt moiety 
of the compound). Thereafter, solubility and permeability property predictions were 
performed using the ChemSpider chemical database (www.chemspider.com) accessed from 
the ACD/ChemSketch (freeware version) software application that was used to draw the 
chemical structures. Compounds that violated one or more of the Ro5 parameters were 
classified as non ‘drug-like’ or having poor pharmacokinetic properties for oral administration 
(Figure 2.5) (Bhal et al., 2007).  
 
 
Figure 2.5 Workflow of in silico methodology applying the Lipinski Rule of 5 (adapted 
from Bhal et al., 2007). The Ro5 parameters for the most active synthetic compounds and reference 
drugs were predicted using the ChemSpider chemical database (www.chemspider.com) accessed from 
the ACD/ChemSketch (freeware version) software application. 
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The ionisation constants (pKa values) of the test compounds were predicted in silico using 
ACD/iLab version 2.0 (http://ilab.acdlabs.com/iLab2) (pH 7.0 and 25°C). The estimated 
percentage of ionised drug during second stage ionisation (Equation 2.9) for weak acids (pKa - 
pH) and for weak bases (pH - pKa) at physiological pH 7.4 (RBC cytosol) and pH 5.0 
(parasite’s acidic digestive vacuole), was derived from the Henderson-Hasselbalch equation 
(Equation 2.1) (Knittel and Zavod, 2008).  
%	Ionisation 	=	 1001	+	anti-log (pKa	-	pH) 
Equation 2.9 Percentage ionisation for weak acids and weak bases (pH-pKa). 
2.4 Data analysis  
The IC50 values were determined from log sigmoid dose-response curves generated using the 
Enzfitter® software (version 1.05). The results are reported as the mean of at least 3 replicates 
with standard deviation. Statistical difference between the activity (IC50 values) of the test 
compounds and the control was determined by a one-way ANOVA test, using GraphPad 
Prism® software, version 5.0 (Motulsky, 2003; Glantz, 2005). A p-value less than 0.05 (p < 
0.05) was considered statistically significant. A correlation between the haemolytic, β-
haematin inhibitory activities of the test compounds and their antimalarial activity was 
determined using linear regression with a 95% confidence interval. 
2.5 Results 
2.5.1 Antimalarial activity 
The test compounds displayed variable ability to inhibit parasite growth with 21% inhibiting 
more than 80% parasite growth at a concentration of 100 µM or 100 µg/ml. The in vitro 
antimalarial activity of the test compounds was classified as follows (Clarkson et al., 2004; 
Gathirwa et al., 2008): highly active, IC50 value ≤ 5 µg/ml; promising activity, IC50 value 6-
10 µg/ml; moderate activity, IC50 values 11-50 µg/ml; low activity, IC50 values 51-100 µg/ml; 
inactive, IC50 values > 100 µg/ml. The same classification was applied for all the synthetic 
compounds in molar concentration (µM). 
2.5.1.1 Synthetic colourants 
Only 3 of the 28 colourants inhibited more than 50% of parasite growth. The synthetic 
colourants, safranin O, methylene blue and mercury orange demonstrated in vitro parasite 
growth inhibition of more than 90% at a maximum final concentration of 100 µM (Table 2.1). 
Para red and methyl red showed inhibitory activity below 50%, whilst the least active 
(inhibition < 5%) was acid orange 8.  
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Table 2.1 The in vitro antimalarial activity of synthetic colourants and reference drugs 
chloroquine and quinine. 
Compound 
Antimalarial activity 
IC50 ± S.D. 
 (µM) 
% Parasite growth 
inhibition at 100 µM 
Methylene blue 0.004 ± 0.00* 99.63 ± 0.11 
Safranin O 0.087 ± 0.00 99.88 ± 0.09 
Mercury orange 0.664 ± 0.01 99.44 ± 0.19 
Para red > 100 44.74 ± 0.14 
Methyl red > 100 29.22 ± 0.19 
Palatine chrome black 6BN > 100 16.01 ± 0.05 
Eriochrome black R > 100 10.82 ± 0.11 
Sudan III > 100 10.81 ± 0.01 
Trypan blue > 100 9.60 ± 0.02 
Sunset yellow > 100 9.34 ± 0.06 
Xylidine ponceau 2R > 100 8.05 ± 0.01 
Breibrich scarlet > 100 7.94 ± 0.03 
Ethyl orange > 100 7.80 ± 0.02 
Acid red 88 > 100 7.31 ± 0.03 
Dimethyl yellow > 100 7.11 ± 0.04 
Ponceau 4R > 100 6.63 ± 0.06 
Eriochrome blue black B > 100 6.57 ± 0.05 
Orange II > 100 6.15 ± 0.01 
Acid red 151 > 100 5.30 ± 0.01 
Sudan I > 100 4.03 ± 0.05 
1-Naphthol-4-sulfonic acid > 100 3.97 ± 0.05 
Crocein orange G > 100 3.71 ± 0.03 
Amaranth > 100 3.30 ± 0.04 
Indigo carmine > 100 2.99 ± 0.03 
Tartrazine > 100 2.84 ± 0.01 
Orange G > 100 2.47 ± 0.03 
Eriochrome black T > 100 2.33 ± 0.01 
Tropaeolin O > 100 2.31 ± 0.01 
4-Phenylazophenol > 100 1.81 ± 0.01 
Orange I > 100 1.72 ± 0.00 
Toluidine red > 100 1.04 ± 0.00 
Acid orange 8 > 100 0.60 ± 0.00 
Quinine 0.10 ± 0.01 99.59 ± 0.01 
Chloroquine 0.01 ± 0.00 99.99 ± 0.32 
* p < 0.05 significantly more potent compared to quinine. 
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The highly active compounds, methylene blue, safranin O and mercury orange, inhibited 
parasite growth in a dose-dependent manner (Figure 2.6), in the nanomolar (10-9) range. 
Methylene blue was significantly (p < 0.05) more potent than quinine. Safranin O was 
comparable, whilst mercury orange was significantly (p < 0.05) less potent than quinine. The 
rest of the synthetic colourants were inactive (IC50 values ≥ 100µM). 
 
The in vitro inhibitory activity of the reference drugs; quinine (IC50: 103.92 ± 8.29 nM) and 
chloroquine (IC50: 12.10 ± 1.71 nM) against the P. falciparum chloroquine-sensitive 3D7-
strain in the current study, was comparable to published IC50 values (quinine IC50: 9.73 ± 5.11 
nM; chloroquine IC50: 102.34 ± 31.56 nM) (Vivas et al., 2007). 
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Figure 2.6 In vitro antimalarial activity of synthetic colourants on P.  falciparum. 
Percentage parasite growth (mean ± s.d.) based on 3-treatment replicates on the microtitreplate, from 
three separate experiments (n = 3). 
 
2.5.1.2 Natural colourants 
All the natural colourants, except for curcumin and carbon black (that showed inhibition 
above 99%), were inactive with in vitro parasite growth inhibition below 20% at a screening 
concentration of 100 µg/ml (Table 2.2). Curcumin was highly active, whilst carbon black 
showed moderate activity against P. falciparum, where both were significantly (p < 0.05) less 
potent compared to quinine (Figure 2.7). However, curcumin extract was significantly (p < 
0.05) more potent than carbon black. 
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Table 2.2 Antimalarial activity of natural colourants on P. falciparum. 
Compound 
Antimalarial activity 
IC50 ± S.D. 
(µg/ml) 
% Parasite growth 
inhibition at 100 µg/ml 
Curcumin 2.290 ± 0.18 99.72 ± 0.40 
Carbon black 22.73 ± 2.36 99.63 ± 0.19 
Annatto > 100 16.26 ± 3.70 
Paprika > 100 9.51 ± 3.08 
Carmine > 100 9.09 ± 0.91 
Cochineal > 100 6.24 ± 2.57 
Beet (0611) liquid extract > 100 4.87 ± 2.25 
Beet (P3006) powder extract > 100 1.88 ± 0.22 
Safflower > 100 1.33 ± 0.67 
Quinine 0.04 ± 0.00 100 ± 0.00 
Chloroquine 0.01 ± 0.00 100 ± 0.00 
 
 
-4 -3 -2 -1 0 1 2 3
20
40
60
80
100
120
Carbon black
Curcumin
Quinine
log Concentration (µg/ml)
%
 
Pa
ra
si
te
 
gr
o
w
th
 
Figure 2.7 Antimalarial activity of curcumin and carbon black on the growth of P. 
falciparum parasite compared to quinine. Percentage parasite growth (mean ± s.d.) based on 3-
treatment replicates on the microtitreplate, from three separate experiments (n = 3). 
 
2.5.1.3 Nucleosides and analogues 
Of the 8 nucleosides analogues, only the pyrimidine-based analogues JLP118.1 and JLP093 
inhibited parasite growth by more than 80% at a screening concentration of 100 µM (Table 
2.3). JLP118.1 and JLP093 were highly active (Figure 2.8), although these compounds were 
all significantly (p < 0.05) less potent compared to quinine.  
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Table 2.3 Antimalarial activity of nucleosides analogues. 
Compound 
Antimalarial activity 
IC50 ± S.D. 
 (µM) 
% Parasite growth 
inhibition at 100 µM 
JLP118.1 1.79 ± 0.12 91.81 ± 0.13 
JLP093 2.38 ± 0.11 82.60 ± 2.79 
JLP095.2 > 100 42.24 ± 5.19 
JLP077.1 > 100 40.63 ± 1.63 
JLP089 > 100 20.08 ± 8.11 
JLP090.3 > 100 9.45 ± 3.52 
JLP117.1 > 100 9.23 ± 4.92 
JLP087 > 100 0.50 ± 0.00 
Quinine 0.10 ± 0.01 99.59 ± 0.01 
Chloroquine 0.01 ± 0.00 99.99 ± 0.32 
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Figure 2.8 Inhibitory activity of nucleoside analogues on the P.  falciparum parasite 
growth compared to quinine. Percentage parasite growth (mean ± s.d.) based on 3-treatment 
replicates on the microtitreplate, from three separate experiments (n = 3). 
 
2.5.1.4 Imidazopyridine analogues 
Five of the eight imidazopyridines analogues screened at 100 µM, inhibited malaria parasite 
growth by more than 90%, which was comparable to quinine (Table 2.4). Test compounds IP-
3, -4 and -5 showed moderate antimalarial activities with IC50 values between 10 and 50 µM, 
whilst IP-6 and -7 showed low activity (IC50 values: 51-100 µM). All the most active 
imidazopyridine analogues were significantly (p < 0.05) less potent compared to quinine. 
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Table 2.4 Antimalarial activity of imidazopyridine analogues on P. falciparum. 
Compound 
Antimalarial activity 
IC50 ± S.D. 
 (µM) 
% Parasite growth 
inhibition at 100 µM 
IP-2 > 100 11.20 ± 2.11 
IP-3 20.77 ± 0.72 98.90 ± 0.38 
IP-4 15.30 ± 0.41 99.42 ± 0.64 
IP-5 36.30 ± 1.19 99.91 ± 0.34 
IP-6 67.20 ± 3.05 99.79 ± 0.46 
IP-7 55.30 ± 1.90 99.63 ± 0.51 
IP-8 > 100 27.40 ± 3.22 
Quinine 0.10 ± 0.01 99.59 ± 0.01 
Chloroquine 0.01 ± 0.00 99.99 ± 0.32 
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Figure 2.9 Antimalarial activity of the most active imidazopyridine analogues on the in 
vitro growth of P.  falciparum parasite compared to quinine. Percentage parasite growth 
(mean ± s.d.) based on 3-treatment replicates on the microtitreplate, from three separate experiments 
(n = 3). 
 
2.5.2 Haemolytic activity 
The haemolysis assay results are summarised in Table 2.5 (for synthetic compounds) and 
Table 2.6 (for natural colourants). Of all the compounds tested, mercury orange was the only 
compound to induce haemolysis (99.8 ± 0.56%) significantly (p < 0.05) compared to quinine 
(0.15 ± 0.01%) at the screening concentration of 100 µM. Mercury orange demonstrated a 
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haemolytic activity (HLC50: 16.81 ± 0.56 µM) in a dose dependent manner. The selectivity 
index (S.I. = 25.32) of mercury orange was above 10, which is the minimum concentration 
ratio (1:10, antimalarial activity IC50 to haemolytic activity IC50) for a non-toxic compound 
(Pink et al., 2005). Therefore, mercury orange was selective to P. falciparum at nanomolar 
concentrations (IC50: 0.664 ± 0.01 µM), but demonstrated RBC lysis at higher, micromolar 
concentrations which would in that case contribute to its antimalarial activity.  
 
Although methylene blue (13.92 ± 0.03%) showed minimum haemolytic activity at a 
screening concentration (100 µM), it was significantly higher (p < 0.05) compared to both 
quinine and chloroquine (Table 2.5). Curcumin and carbon black (Table 2.6) did not show 
haemolytic activity, although the degree of haemolysis (6.24 ± 0.18%) caused by curcumin at 
the screening concentration (100 µg/ml) was significantly (p < 0.05) higher than quinine. The 
nucleoside analogues did not show any haemolytic activity similarly to quinine.  
 
Table 2.5 Haemolytic activity of the most active synthetic compounds. 
Compound class Compound Haemolytic activity  HLC50 ± S.D. (µM) 
Synthetic colourants 
Methylene blue >100 (13.92 ± 0.03%) 
Safranin O >100 (0.31± 0.01%) 
Mercury orange 16.81 ± 0.56 
Nucleoside analogues JLP093 >100 (0.35 ± 0.05%) JLP118.1 >100 (0.92 ± 0.04%) 
Nucleosides Guanosine >100 (0.21 ± 0.03%) Inosine >100 (0.1 ± 0.01%) 
Imidazopyridine analogues ND ND 
Reference drugs Quinine >100 (0.15 ± 0.01%) Chloroquine >100 (0.01 ± 0.01%) 
ND, not determined due to limited quantity of compounds. 
 
Table 2.6 Haemolytic activity of natural colourants. 
Compound class Compound Haemolytic activity  HLC50 ± S.D. (µg/ml) 
Natural colourants Curcumin >100 (6.24 ± 0.18%) Carbon black >100 (0.22 ± 0.04%) 
Reference drugs Quinine >100 (0.40 ± 0.01%) Chloroquine >100 (0.02 ± 0.01%) 
 
2.5.3 β-Haematin inhibition activity 
The β-haematin assay results are summarised in Table 2.7 (synthetic compounds) and Table 
2.8 (natural colourants). The synthetic colourants did not inhibit β-haematin formation at a 
maximum concentration of 800 µM. In comparison to quinine, there was no inhibitory 
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activity by methylene blue (0.001 ± 0.02%) and safranin O (10.80 ± 1.07%) at a maximum 
concentration of 800 µM (Table 2.7).  
 
Table 2.7 β-Haematin formation inhibition of the most active synthetic compounds. 
Compound class Compound β-haematin inhibition IC50 ± S.D. (µM) 
Synthetic colourants 
Methylene blue > 800 (0.001 ± 0.02%) 
Safranin O > 800 (10.8 ± 1.07%) 
Mercury orange > 800 (0.001 ± 0.01%) 
Nucleoside analogues JLP093 > 800 (5.80 ± 3.35%) 
JLP118.1 > 800 (0.001 ± 0.02%) 
Nucleosides Guanosine > 800 (24.48 ± 12.08%) 
Inosine > 800 (65.66 ± 7.50%) 
Imidazopyridine analogues ND ND 
Reference drugs Quinine 68.3 ± 4.17 
Chloroquine 38.4 ± 4.77 
ND, not determined due to limited quantity of compounds. 
 
The natural colourant, curcumin inhibited β-haematin formation in a dose-dependent manner, 
but was about 12 to 16-fold less active (p < 0.05) than quinine and chloroquine. Whilst, 
carbon black natural extract, inhibited 40.47 ± 0.83% of β-haematin formation at the 
screening concentration ratio of 1:4 (haem to drug), and thus the IC50 value was > 4,000 
µg/ml.  
 
Table 2.8 β-Haematin formation inhibition activity of natural colourants. 
Compound class Compound β-haematin inhibition  
IC50 ± S.D. (µg/ml) 
Natural colourants Curcumin 320 ± 0.01 
Carbon black > 4000 (40.47 ± 0.83%) 
Reference drugs Quinine 24.65 ± 1.28 
Chloroquine 19.60 ± 2.46 
 
2.5.4 Drug interactions 
The most active synthetic colourants demonstrated additive interactions with quinine, except 
for methylene blue (∑FIC50 < 1) that was synergistic (Figure 2.10a). Methylene blue 
demonstrated a synergistic interaction (∑FIC50 < 1.0), whilst safranin O and mercury orange 
showed additive interactions with ∑FIC50 values between 1.0 and 2.0 (Table 2.9). The 
methylene blue/quinine curve showed a concave shape around the straight line. Most of the 
points in the safranin O/quinine and mercury orange/quinine curves were along and above the 
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straight line. However the ∑FIC50 values between 1.0 and 2.0 were observed for safranin O 
and mercury orange when in combination with quinine. Natural colourants, curcumin and 
carbon black, demonstrated additive interactions, with ∑FIC50 values between 1.0 and 2.0, in 
combination with quinine (Figure 2.10b). The carbon black/quinine curve showed a more 
convex shape than the curcumin/quinine curve, which borders on partial antagonism (ΣFIC50 
≥ 2 and < 4).  
 
 
Figure 2.10 Isobolograms showing the drug interactions between quinine and the most 
active (a) synthetic and (b) natural compounds. 
 
Table 2.9 Drug interactions of the most active colourants in combination with quinine. 
Compound class Combinations with 
quinine 
ƩFIC50 
(mean ± S.D.) 
Interaction 
classification 
Synthetic colourants Methylene blue 0.64 ± 0.31 Slightly synergistic 
Safranin O 1.01 ± 0.09 Additive 
Mercury orange 1.42 ± 0.08 Additive 
Natural colourants Curcumin 1.20 ± 0.07 Additive 
Carbon black 1.78 ± 0.20 Additive 
 
2.5.5 Morphology and drug-sensitivity of development stages 
The Giemsa-stained (Section 2.3.7) parasitised RBC control (Figure 2.11a) demonstrated the 
distinct morphological features of different stages of the erythrocytic life-cycle of the P. 
falciparum malaria parasite. The ring form was early-to-mid stage at 8 h, whilst at 24 and 32 h 
the trophozoite form contained yellow-brown haemozoin crystals, and schizont form showed 
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blue-stained merozoites. The early-ring stage was observed at 48 h, post-invasion of 
merozoites into human RBCs. In contrast, the development of the parasites exposed to 
quinine, was arrested at the late trophozoite stage (Figure 2.11b). Parasites treated with 
methylene blue (Figure 2.11c) progressed up to the schizont stage, which was consistent with 
the parasitised RBC control. However degenerate or ‘crisis form’ parasites were observed at 
48 h, suggesting that the schizont stage was most sensitive. The trophozoite stage was 
particularly sensitive to nucleoside derivative, JLP118.1 (Figure 2.11d) as the parasite did not 
proceed to the schizont stage. The IP-4 treated parasites (Figure 2.11e) underwent 
morphological change from ring to trophozoite stage, but did not proceed to schizont stage 
and appeared vacuolated. 
 
Figure 2.11 Morphological changes and stage-sensitivity of the P. falciparum parasites to 
the most active compounds. The parasites were exposed to: (b) Quinine (IC90: 0.525 µM), MB 
(IC90: 8.4 nM), (c) JLP118.1 (IC90: 3.5 µM) and (d) IP-4 (IC90: 23 µM) being the most active 
compounds from each class compound. The images were taken at 1000x magnification under oil 
immersion. 
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The effect of the test compounds on the total parasitaemia of the cultures over a 48 h exposure 
period is shown in Figure 2.12. Dead parasites were noted as condensed, darkly stained with 
un-differentiated morphological features and were excluded in the parasite count. The 
increase from the 2% parasitaemia seeded in the ring form to 4-6% within the 0-8 h period, 
was attributed to the presence of late schizonts in the culture. The decrease to the total 
parasitaemia after 8 h of exposure to quinine could be due to the sensitivity of the mature 
forms of the parasites. After 16 h post-exposure, JLP118.1 and IP-4 reduced total 
parasitaemia by 1.5-2% compared to the control, whilst the ring forms survived until 
trophozoite stage at 24 h with the quinine and methylene blue treatments (Figure 2.12). The 
inhibitory effect methylene blue and quinine again showed a similar pattern with the total 
parasitaemia decreasing and plateauing around 3-3.5% during schizont stages (32-40 h); 
whilst the control culture’s total parasitaemia increased to about 6.85% during the same 
period. JLP118.1 and IP-4 showed a different inhibitory pattern showing a marked decrease 
pre-invasion stage resulting in reduced parasitaemia (JLP118: 1.8%, IP-4: 3%) during the ring 
stage at 48 h compared to 7.5% observed with the control culture (Figure 2.12). The effect of 
an IC90 concentration of quinine demonstrated a parasitaemia below 10% against the 
laboratory P. falciparum strain TM29 (Monatrakul et al., 2010). In the current study, the 
parasitaemia was ≤ 4% at an IC90 concentration of quinine over the 48 h exposure period. 
Figure 2.12 Effect of methylene blue, JLP118.1 and IP-4 in comparison to quinine at an 
IC90 value on P. falciparum parasite growth over a single 48 h-cycle.  Dead parasites were 
noted as condensed, darkly stained with un-differentiated morphological features and were 
excluded in the parasite count. 
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2.5.6 Structure-activity relationship of analogue compounds 
The chemical structures of the synthetic colourants, both active and inactive were too diverse 
to make structural comparisons that may be related to their antimalarial activity. However, 
structural analysis of the most active synthetic colourants, all the nucleoside analogues as well 
as the imidazopyridine analogue series of compounds, was performed. 
2.5.6.1 Nucleoside analogues 
The overall antimalarial activity of the most active nucleoside analogues was classified as 
highly active (≤ 5 µM). Of all the nucleoside analogues tested, only the pyrimidine-based 
nucleoside analogues, JLP118.1 (contained uracil base) and JLP093 (contained cytosine base) 
were highly active against P. falciparum. The substitution of the tert-butyl-dithiomethyl-
hydroxyl group at R1 and acetate groups at R3 and R4 positions in JLP118.1, with the tert-
butyl-diphenylsilyl and hydroxyl groups (-OH) in JLP093, did not improve the antimalarial 
potency (Table 2.10). When the cytosine base in JLP093 was substituted with uracil at R2 in 
JLP089 it resulted in JLP089 becoming inactive (IC50 > 100 µM). The single substitution of 
the tert-butyl-diphenylsilyl group at R1 position in JLP089 with the tert-butyl-dithiomethyl-
hydroxyl group in JLP090.3 did not improve the antimalarial activity as both compounds 
were inactive. Similarly, the R1 substitution with tert-butyl-diphenylsilyl in JLP118.1 resulted 
in JLP117.1 being inactive. JLP087 contained a uniquely modified uracil nucleobase (at R2 
position) and an acetaldehyde group at R1, but was inactive although the sugar group in 
JLP118.1 was retained. The purine-based nucleosides JLP095.2 (R1 = tert-butyl-diphenylsilyl, 
R2 = adenine) and JLP077.1 (R1 = tert-butyl-dithiomethyl-hydroxyl, R2 = modified 
hypoxanthine) were structurally diverse to compare with only the ribose structure similar in 
both compounds, but were inactive. All the purine-based nucleoside analogues tested against 
P. falciparum were inactive. 
2.5.6.2 Imidazopyridine analogues 
Overall the antimalarial activity of the most active imidazopyridine analogues was classified 
as low (50-100 µM) to moderate (10-50 µM). The cyclohexane (-C6H12) ring at position R1 in 
compounds IP-2 to -4 was substituted by a 1,3-dimethylbenzene ring in compounds IP-5 to -8 
(Table 2.11). Within the R1 cyclohexane ring containing group of compounds, IP-3 and IP-4, 
were the most active of all the imidazopyridines. The increase in compound size and lipid-
solubility with the benzyloxy (-C7H8O) side chains at positions R3 and R4 did not improve the 
antimalarial activity as observed in IP-2. However, replacing of the benzyloxy groups with 
hydroxy groups at R3 and R5 as well as the removal of the formamide (-CH3NO) group at R2 
from IP-3, increased the antimalarial activity of IP-4 by 1.4-fold. On comparing the two 
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hydroxy substituted compounds, IP-4 and IP-5, the only difference between the two 
compounds is the R1 substitute, where the 1,3-dimethylbenzene ring decreased the 
antimalarial activity of IP-5 by 2-fold compared to the cyclohexane ring (Table 2.11).  
 
All the imidazopyridine analogues (except for IP-3) were significantly (p < 0.05) less potent 
compared to IP-4 (IC50: 15.3 ± 0.41 µM). Of the test compounds that contained a 1,3-
dimethylbenzene ring, IP-5 (IC50: 36.3 ± 1.19 µM) was the most active. IP-5 was similar to 
IP-4 in structure with both compounds possessing hydroxyl groups at positions R3 and R5, 
however, IP-5 was found to be at least 2-fold less active than IP-4. The substitution of N,N 
dihydroxymethanamine with a methyl group in IP-7 at R2 decreased the antimalarial activity 
of IP-8 (IC50 > 100 µM) by over 2-fold.  
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Table 2.10 Chemical structure and antimalarial activity of nucleoside analogues. 
R2
O
O
R4R3
R1
deoxyribose
 
Compound R1 R2 R3 R4 Antimalarial 
activity IC50 (µM) 
JLP118.1 
 
O
O
 
N
NH
O
O
 
uracil 
 
OH
O
 
OH
O
 
1.79 ± 0.12 
JLP093 Si
 
N
N
NH2
O
 
cytosine 
O H
 
O H
 
2.38 ± 0.11 
JLP089 Si
 
N
NH
O
O
 
uracil 
O H
 
O H
 
> 100 
(20.08 ± 8.11%) 
JLP090.3 
O
O
 
N
NH
O
O
 
uracil 
O H
 
O H
 
> 100 
(9.45 ± 3.52%) 
JLP117.1 Si
 
N
NH
O
O
 
uracil 
OH
O
 
OH
O
 
> 100 
(9.23 ± 4.92%) 
JLP087 
O
 
N
N O
OO
 
OH
O
 
OH
O
 
> 100 
(0.50 ± 0.00%) 
JLP095.2 Si
 
N
N
NH2
N
N
 
adenine 
O H
 
O H
 
> 100 
(42.24 ± 5.19%) 
JLP077.1 
O
O
 
N
NH
O
NN
N
N
 
O H
 
O H
 
> 100 
(40.63 ± 1.63%)  
The red stick (-) shows the site of attachment to the parent structure. Inhibitory activity of the test 
compound with IC50 value > 100 µM is in parentheses as % parasite growth inhibition. 
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Table 2.11 Chemical structure and antimalarial activity of imidazopyridine analogues. 
NH
N
N
R2
R3
R4R5
R1
 
Compound R1 R2 R3 R4 R5 
Antimalarial 
activity IC50 
(µM) 
IP-2 
 
N
OH
OH
 
O
 
O
 
-H 
> 100 
(11.20 ± 2.11%) 
IP-3 
 
O
NH2
 
O
 
-H 
O
 
20.77 ± 0.72 
IP-4 
 
-H -OH -H -OH 15.30 ± 0.41 
IP-5 
CH3
CH3
 
-H -OH -H -OH 36.30 ± 0.19 
IP-6 
CH3
CH3
 
Br- -CH3OH -H -CH3OH 67.20 ± 3.05 
IP-7 
CH3
CH3
 
N
OH
OH
 
-CH3OH -H -CH3OH 55.30 ± 1.90 
IP-8 
CH3
CH3
 
-CH3 -CH3OH -H -CH3OH 
> 100 
(27.40 ± 3.22%) 
The red stick (-) shows the site of attachment to the parent structure. Inhibitory activity of the test 
compound with IC50 value > 100 µM is in parentheses as % parasite growth inhibition. 
 
Overall, the antimalarial activities of the imidazopyridine analogues as a class was 
significantly varied (p < 0.0001) and the individual antimalarial activities were all 
significantly (p < 0.05) less potent compared to quinine. 
2.5.7 Drug-like properties 
At least three violations of the Lipinski’s Ro5 may be allowed depending on the nature of the 
compound, its permeability and transport to its specific target for a compound to be 
considered drug-like (Lipinski et al., 1997). However, no assumptions were made regarding 
the permeability of the parasites to the test compounds or how they were transported in vitro. 
Therefore, for the purpose of the study, the test compounds had to comply with all the Ro5 
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physicochemical properties, in their non-ionised or neutral states, in order to be considered as 
drug-like. The log P value was predicted for the test compounds in their natural or non-
ionised state. A positive log P value (10:1, organic to aqueous ratio) reflected a lipophilic 
property of the test compound, a negative log P value (1:10 ratio) indicated a hydrophilic 
property and log P = 0 (1:1 ratio) meant the compound was soluble or partitioned equally in 
both lipophilic organic and aqueous phases (Khanna and Ranganathan, 2009).  
 
Table 2.12 Predicted solubility and permeability properties of most active synthetic test 
compounds based on the Lipinski’s Rule of 5 (Lipinski, 2004). 
Compound 
class Compound 
MW 
< 500 
HBA 
< 10 
HBD 
< 5 
0≥ Log P 
≤ 5 
# of Ro5 
violations 
Synthetic 
colourants 
Methylene blue 319.85 3 0 4.09  ± 1.51 0 
Safranin O 315.39 4 4 -0.68 ± 1.46 1 
Mercury orange 483.31 3 1 3.98 ± 1.04 0 
Natural 
colourants 
Curcumin1 368.38 6 3 2.85 ± 0.41 0 
Carbon black ND ND ND ND ND 
Nucleoside 
analogues 
JLP093 481.62 8 4 3.03 ± 0.57 0 
JLP118.1 630.64 12 1 5.13 ± 0.55 3 
Imidazopyridine 
analogues 
IP-3 546.66 7 3 6.05 ± 0.99 2 
IP-4 323.39 5 3 3.26 ± 0.60 0 
IP-5 345.40 5 3 3.87 ± 0.88 0 
IP-6 452.34 5 1 5.68 ± 1.44 1 
IP-7 418.45 8 1 4.75 ± 1.43 0 
Reference drugs Quinine 324.42 4 1 2.82 ± 0.43 0 Chloroquine 319.87 3 1 4.41 ± 0.76 0 
1The chemical structure of curcumin was sourced from Bernabé-Pineda et al. (2004). MW, molecular 
weight; HBA, hydrogen bond acceptors; HBD, hydrogen bond donors; # of Ro5 violations, Number of 
Rule of five violations. All parameters including log P were predicted using ACD/ChemSketch 
software (freeware version). ND, not determined. 
 
All the synthetic test compounds that complied with the Lipinski’s Rule of 5 (Ro5 violations 
= 0) had MWs in the range of 300-484 g/mol and log P values between 0 and 5, comparable 
to quinine (Table 2.12). Nucleoside analogue, JLP118.1, showed the most violations (Ro5 
violations = 3) compared to all the test compounds and did not comply the drug-likeness test. 
IP-3 and -6 showed one to two violations and were excluded as drug-like compounds (Table 
2.12). The negative log P value of safranin O reflected significantly (p < 0.05) poor-solubility 
compared to quinine and chloroquine, and was regarded as not ‘drug-like’. However safranin 
O had a significantly (p < 0.05) smaller molecular size (MW: 315.39) compared to quinine 
and chloroquine. Curcumin complied with the Lipinski’s Ro5 for drug-likeness and was 
highly active (IC50 < 5 µg/ml) against P. falciparum (Table 2.12). Both quinine and 
65 
chloroquine demonstrated drug-like properties and complied with the Lipinski’s Ro5. The 
predicted log P and antimalarial activity (IC50 values) data of the most active synthetic 
compounds, was plotted on a linear graph (Figure 2.13) to determine if there was a correlation 
between the lipid-solubility and activity of the compounds.  
 
Figure 2.13 Correlation between predicted log P values and antimalarial activity IC50 
values. The encircled compounds that complied with all the Ro5 parameters were: quinine, JLP093, 
chloroquine, methylene blue and mercury orange showed high antimalarial activity (≤ 5 µM) and log P 
values were in the 0-5 range.  
 
No significant correlation was observed (r2 = 0.352). However, the compounds that are 
encircled (Figure 2.13) complied with all the Ro5 parameters, and were highly active (IC50 ≤ 
5 µM) against P. falciparum. In addition, the compounds quinine, JLP093, mercury orange, 
chloroquine and methylene blue complied with the Lipinski’s Ro5 parameters (Figure 2.13). 
Although safranin O was highly active (IC50 < 5 µM), it showed a negative log P value, which 
implied it was a hydrophilic compound. 
2.5.8 Predicted ionisation and absorption as a function of pH 
The predicted pKa and (%) ionisation values at physiological pH 7.4 (similar to RBC cytosol) 
and acidic pH 5.0 (similar to the parasite’s digestive vacuole environment) of the most active 
compounds are summarised in Table 2.13. 
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Table 2.13 Predicted percentage ionisation of most active test compounds. 
Compound class Compound pKa 
% Ionisation % Absorption 
at pH 7.4 pH 7.4 pH 5 
Synthetic 
colourants 
Methylene blue -0.60, 0.00 0.00 0.00 100 
Safranin O 5.80 2.45 86.32 97.55 
Mercury orange -1.86, -5.32 0.00 0.00 100 
Natural 
colourants 
Curcumin1 10.50, 8.38 0.08 0.00 99.92 
Carbon black ND ND ND ND 
Nucleoside 
analogues 
JLP093 4.20 0.06 13.68 99.94 
JLP118.12 8.90 3.07 0.01 96.93 
Imidazopyridine 
analogues 
IP-3 6.00 3.83 90.91 96.17 
IP-4 4.10 0.05 11.18 99.95 
IP-5 4.70 0.02 33.39 99.80 
IP-6 5.80 2.45 86.32 97.55 
IP-7 4.90 0.32 44.27 99.68 
Reference drugs Quinine
3
 9.70, 5.07 0.47 54.02 99.53 
Chloroquine4 10.10, 8.10 83.34 99.92 16.63 
1pKa value for ionisable acidic group from Bernabé-Pineda et al. (2004); 2Only pKa value for ionisable 
acidic group was predicted; 3pka values from O’Neil et al. (2001); 4pKa values from O’Neill et al. 
(2012). 
 
2.5.8.1 Synthetic colourants 
Methylene blue (MB+) and safranin O (SO+) are cationic (positively charged) basic dyes and 
usually stabilised with chloride (Cl-) salts (Vennerstrom et al., 1995). In its cationic form, 
methylene blue (pKa1 = 0.00, pKa2 = -0.60) did not show a degree of ionisation (% ionisation: 
0.00) at pH 7.4 and 5.0. The absorption and accumulation into the parasite of methylene blue 
could not be attributed to its weak acid-base properties. In contrast, safranine O (pKa = 5.80) 
showed increasing ionisation down the pH gradient from 2.45% at pH 7.4 to 86.32% at pH 
5.0 and a substantial amount (97.55%) of the non-ionised compound could be absorbed into 
the digestive vacuole. Mercury orange (pKa1 = -1.86, pKa2 = -5.32), a neutral azo dye also 
showed no degree of ionisation at both pH levels, thus a high absorption rate (100%) in both 
the RBC and digestive vacuole compartments was predicted. Quinine (pKa1 = 9.70, pKa2 = 
5.07) showed 54.02% ionisation at pH 5.0 and although chloroquine showed an absorptive 
rate of 16.63% at pH 7.4, all of the non-ionised species were almost completely ionised at pH 
5 (% ionisation: 99.92) leading to increased drug accumulation into the parasite (O'Neil et al., 
2001; O'Neill et al., 2012). 
2.5.8.2 Natural colourants 
Curcumin is a polyprotic acid (an acid that can donate more than one proton) with three 
ionised states giving pKa1 = 8.38, pKa2 = 9.88 and pKa3 = 10.50 (Bernabé-Pineda et al., 2004). 
However, it only showed a low degree of ionisation of 0.08% at pH 7.4, thus yielding a high 
concentration (% ionisation: 99.92) of non-ionised, but acidic compound (Table 2.13). 
Curcumin did not show any degree of ionisation at acidic pH 5.0. 
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2.5.8.3 Nucleosides and nucleosides analogues 
Only the pKa value (8.9) for the acidic group of JLP118.1 was predicted in silico. From this, 
JLP118.1 showed a low ionisation value of 3.1% at basic pH 7.4 and was non-ionised at 
acidic pH 5 (Table 2.13). Overall the absorption rate of the nucleoside analogues was more 
than 90% at basic pH 7.4 and JLP093 showed a significant (p < 0.05) ionisation of 13.7% at 
an acidic pH 5.0 within the compound class. 
2.5.8.4 Imidazopyridine analogues 
The imidazopyridines showed absorption rates (96-100%) comparable to quinine (99.5%) 
(Table 2.13). However, only IP-3 showed a % ionisation value (91%) comparable to 
chloroquine (99%) suggesting good “ion-trapping” within the digestive vacuole compartment 
at acidic pH of 5. IP-6 also showed a high ionisation value of 86.3% at pH 5.0. 
2.6 Discussion 
2.6.1 Antimalarial activity of synthetic colourants 
The results (summarised in Table 2.14) confirmed the potent antimalarial activity of the 
thiazine colourant, methylene blue and phenazinium colourant, safranin O that have been 
previously investigated (Vennerstrom et al., 1995; Atamna et al., 1996; Schirmer et al., 2003; 
Meissner et al., 2006). Vennerstrom et al. (1995) reported similar findings that showed a 
significantly potent (p < 0.05) antimalarial activity of methylene blue (IC50: 3.58 ± 2.22 nM) 
and a significantly (p < 0.05) less potent antimalarial activity of safranin O (IC50: 43.3 ± 29.3 
nM) against the Sierra Leone (D6) chloroquine-sensitive strain in comparison with 
chloroquine (IC50: 24.0 ± 4.92 nM). In the current study, the antimalarial potency of 
methylene blue (IC50: 4.19 ± 0.16 nM) was at least 25-fold more potent than the reference 
drug, quinine (IC50: 103.90 ± 8.30 nM). The morphological studies on parasites treated with 
methylene blue, however suggest that the parasites’ development was arrested at the 
trophozoite stage (Figure 2.11c). In contrast, methylene blue was active against all 
developmental stages but, 8-fold less active against the schizont stage of both chloroquine-
sensitive (3D7) and chloroquine-resistant (K1) strains of P. falciparum (Akoachere et al., 
2005). In the current study, Safranin O (IC50: 86.50 ± 2.61 nM) was significantly (p < 0.05) 
more active, whereas mercury orange was approximately six-fold less active compared to 
quinine. Methylene blue and safranin O showed minimal toxicity to uninfected human RBCs, 
as did quinine (Table 2.14). In contrast, the azo colourant mercury orange, showed significant 
haemolytic activity (p < 0.05) in a dose-dependent manner. However, mercury orange showed 
a selectivity index (S.I.: 25.32) significantly higher (p < 0.05) than 10. In general, a 
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compound that demonstrates a toxic concentration 10-fold (S.I. ≥ 10) or more than its 
effective concentration yielding a 50% response, is regarded as non-toxic (Pink et al., 2005).  
 
Table 2.14 Summary of antimalarial, haemolytic and β-haematin formation inhibitory 
activity of the most active synthetic colourants.  
Compound Antimalarial activity  
IC50 ± S.D. (µM) 
Haemolytic  
activity  
HLC50 ± S.D. (µM)a 
β-Haematin inhibition 
IC50 ± S.D. (µM)a 
Methylene blue 0.004 ± 0.00 >100 (13.92 ± 0.03%) >800 (0.001 ± 0.02%) 
Safranin O 0.087 ± 0.00 >100 (0.31 ± 0.01%) >800 (10.8 ± 1.07%) 
Mercury orange 0.664 ± 0.01 16.81 ± 0.56  
[S.I. = 25.32]b 
>800 (0.001 ± 0.01%) 
JLP118.1 1.79 ± 0.12 >100 (0.92 ± 0.04%) >800 (0.01±0.02%) 
JLP093 2.38 ± 0.11 >100 (0.35 ± 0.05%) >800 (5.8 ± 3.35%) 
Quinine  0.10 ± 0.01 >100 (0.15 ± 0.01%) 68.3 ± 4.17 
Chloroquine 0.01 ± 0.00 >100 (0.01 ± 0.01%) 38.4 ± 4.77 
aHaemolytic activity of test compounds that demonstrated HLC50 values above 100 µM, and aβ-
haematin formation inhibition IC50 values above 800 µM (or > 4 mg/ml) were reported as percentage 
(%) values. bS.I.: Selectivity index. 
 
However, significant haemolysis induced by a compound in comparison to quinine and 
chloroquine, should be considered with caution especially in the context of malaria, which 
increases the risk of anaemia (Müller et al., 2013). The chloro-mercuri reactive group in 
mercury orange is known to have a high binding affinity to non-protein sulfhydryl (thiols) 
groups in glutathione (O'Connor et al., 1988). This would greatly reduce the capability of 
both uninfected and infected RBC, and the parasite itself to prevent oxidative stress, resulting 
in peroxidation of the cell membrane lipids and increased haemolysis, as well as parasite 
death. The risk of methylene blue-induced haemolysis (from four randomised controlled trials 
in Burkina Faso, West-Africa) has been found to be clinically insignificant in glucose-6-
phosphate dehydrogenase (G6PD)-deficient children (below five years of age) with 
uncomplicated P. falciparum malaria (Müller et al., 2013). In the latter study, methylene blue 
did not show haemolysis as a major side-effect in any of the individuals, as was the finding in 
the current in vitro study (Table 2.14). Similarly in another study, healthy adults with class III 
G6PD-deficiency were given a three day oral regimen of a total of 780 mg of methylene blue. 
No occurrence of haemolysis was reported and haemoglobin levels remained stable (Mandi et 
al., 2005). Methylene blue may be combined with classical antimalarial drugs to prevent 
resistance or even sensitise drug-resistant strains of P. falciparum to existing antimalarial 
agents (Schirmer et al., 2003). In the current study, methylene blue interacted in a slight 
synergistic (∑FIC50: 0.64 ± 0.31) manner with quinine (Figure 2.10a). In contrast, Akoachere 
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et al. (2005) reported an additive interaction (mean ∑FIC50: 1) between methylene blue (IC50: 
6.5 ± 1.8 nM) and quinine (IC50: 90 ± 39 nM) when tested against the chloroquine-resistant 
(K1) strain of P. falciparum, whilst Garavito et al. (2007) reported a synergistic effect 
between methylene blue and quinine against the chloroquine-resistant P. falciparum strain 
FcM29 (Garavito et al., 2007). Therefore the discrepancy could be attributed to the difference 
in strains and in some cases the type of assay used and the classification of drug interaction 
applied. The combinations of methylene blue with chloroquine, and all the other quinolines 
tested, as well as with pyrimethamine were antagonistic (Akoachere et al., 2005). 
Antagonistic interactions between methylene blue and quinoline drugs tested in the latter 
study, have been suggested to increase the likelihood of cross-resistance in P. falciparum 
(Akoachere et al., 2005).  
 
Safranin O and mercury orange demonstrated an additive interaction with quinine (Figure 
2.10a). Although the interactions of methylene blue and safranin O were additive when 
combined with quinine, the latter combinations may have potential to prevent cross-resistance 
as the thiazine and phenazinium colourants are putatively effective inhibitors of P. falciparum 
glutathione reductase (PfGR), thus complementing the β-haematin formation inhibitory 
activity of quinine (Färber et al., 1998; Lüönd et al., 1998; Akoachere et al., 2005).  
 
The rest of the azo, naphthalene and sulfonated synthetic colourants were inactive at a 
screening concentration of 100 µM against the P. falciparum parasites. However, anionic 
sulfonated azo dyes such as trypan blue (IC50: 41.3 µM) have been found to inhibit the 
activity of the recombinant triose phosphate isomerase enzyme involved in ATP production 
during glycolysis in P. falciparum (Joubert et al., 2001). In the current study, trypan blue was 
inactive (IC50 > 100 µM) against the whole-parasite. 
2.6.1.1 Physicochemical properties of synthetic colourants 
On analysing the physicochemical properties of synthetic colourants, methylene blue (pKa1 = 
0.0; pKa2 = -0.6) complied with the Lipinski’s Ro5, but did not demonstrate any degree of 
ionisation at a pH of 5 and 7.4 in its cationic form (Table 2.13). However, there was no 
correlation between the log P and antimalarial activity of all the most active test compounds 
(Figure 2.13). Vennerstrom et al. (1995) has suggested that the relative lipid-solubility of the 
thiazine colourants such as methylene blue, may be rather unimportant compared to their 
reduced, neutral forms. This is further evidence to support the hypothesis that the potent 
antimalarial activity of methylene blue and most thiazine analogues is not due to its acid-base 
properties (Vennerstrom et al., 1995). Although methylene blue maintains its positively 
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charged cationic form in a wide pH range (1 to 8), it has demonstrated good absorption in 
humans after oral administration with leucomethylene blue being the only urinary metabolite 
to be isolated (Disanto and Wagner, 1972; Vennerstrom et al., 1995). In fact vital colourants 
such as methylene blue are often classified as “basic” dyes, referring to their cationic nature 
and not their weak-base properties, even though methylene blue is indeed an extremely weak 
base (Vennerstrom et al., 1995). In addition, methylene blue concentrates selectively in 
parasitised RBC although the mechanism that leads to this sequestration is not clear 
(Akoachere et al., 2005).  
 
Based on the theory of histochemical staining techniques, coloured cations of basic dyes stain 
tissue structures rich in anions, such as phosphated DNA and RNA, and carboxylated or 
sulphated mucosubstances due to  electrostatic or Coulombic attractions (Horobin, 2002). 
Although mature RBCs lack DNA, selective staining of malaria parasites by methylene blue 
is well established (Wainwright, 2008). An alternative hypothesis to the stain-tissue affinity 
theory proposed by Buchholz et al. (2012) was based on the redox properties of methylene 
blue. Upon entry into the parasitised RBC, methylene blue is electron-reduced to its neutral 
form, leucomethylene blue, a reaction catalysed by the human glutathione reductase or by a 
spontaneous reaction with NADPH (Buchholz et al., 2008). The more lipid-soluble 
leucomethylene blue would then freely diffuse through the parasite and digestive vacuole 
membranes and be auto-oxidised to the methylene blue cation, and thus be trapped in the 
digestive vacuole (Buchholz et al., 2008). Therefore, the accumulation of MB+ in the 
digestive vacuole would not be a weak base effect, but a redox mechanism. In contrast, 
safranin O (pKa = 5.8), a cationic basic dye showed a negative log P value (-0.68 ± 1.46) 
suggesting poor lipid-solubility compared to quinine (log P: 2.82 ± 0.43) (Table 2.12). In 
addition, safranin O showed an increasing degree of ionisation (from 2.5% to 86.3%) down 
the pH gradient and demonstrated the “ion-trapping” effect at an acidic pH 5.0 (Table 2.13). 
The latter further confirms that the log P value is only an indicator of lipid-solubility of 
compounds and that the pH of the environment, acid-base properties and molecular weight are 
other contributing factors for effective drug absorption (Lipinski, 2004; Bhal et al., 2007). 
Safranin O is putatively a strong reversible, uncompetitive inhibitor (Ki = 0.5 mM) of 
glutathione reductase similarly to methylene blue (Lüönd et al., 1998). Mercury orange 
(pKa1= -1.86, pKa2 = -5.8), a neutral azo compound, did not show ionisation at either basic pH 
7.4 or acidic pH 5.0 level (Table 2.13). In addition, mercury orange showed compliance with 
the Lipinski’s Ro5 (Table 2.12). The log P (< 5) and non-ionisation (% ionisation: 0.00%) of 
mercury orange suggested high lipid-solubility and possible diffusion into the RBC, as well as 
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the parasite’s digestive vacuole; although there was no strong correlation between the log P 
and the antimalarial activity (IC50) of all the most active compounds (Figure 2.13). 
2.6.1.2 Pharmacological effects of methylene blue 
Methylene blue may have multiple modes of action against P. falciparum including inhibition 
of haemozoin formation, increased hexose monophosphate shunt, selective inhibition of the 
malaria parasites’ glutathione reductase enzyme or may be due to its redox activity. Whereas 
the photoactivation therapeutic application of methylene blue, may be more suitable for 
localised skin malignancies and infections (Atamna et al., 1994; Färber et al., 1998; Tardivo 
et al., 2005; Blank et al., 2012). The latter modes of action are discussed within the context of 
the study although methylene blue has been extensively studied - the classical review by 
Clark et al. (1925) that cited 400 references being a case in point (Buchholz et al., 2008). 
2.6.1.2.1 β-Haematin formation inhibition 
The current study showed that none of the most active synthetic colourants inhibited β-
haematin formation and all showed IC50 values greater than 800 µM in comparison to known 
β-haematin inhibitors namely, chloroquine (IC50: 38 ± 4.77 µM) and quinine (IC50: 68.30 ± 
20.39 µM). However, the antimalarial mechanism of action of methylene blue and its 
analogues has been proposed to involve the inhibition of haemozoin formation by forming 
haem-complexes in the parasite’s digestive vacuole, similarly to 4-aminoquinoline drugs such 
as quinine (Atamna et al., 1996; Ginsburg et al., 1998; Schirmer et al., 2003; Kumar et al., 
2007). In contrast, the current study showed that methylene blue, safranin O and mercury 
orange were not inhibitory to β-haematin crystal formation (Table 2.14).  
 
The main difference that could account for this discrepancy in the results is the methodology 
that was used to assess the inhibition of β-haematin formation under in vitro conditions. In the 
study conducted by Atamna et al. (1996), the ability of methylene blue to complex with haem 
was done by monitoring a ‘red-shift’ or a peak absorption (at λ = 605 nm) using a UV-Vis 
spectrophotometer. Therefore, the method used in the latter study did not directly measure β-
haematin formation as compared to the current study, where methylene blue did not show 
inhibition of β-haematin crystal formation, subsequent to incubation under acidic conditions 
(pH 4.4) similar to those in the parasite’s food vacuole (Deharo et al., 2002). The conditions 
of the current assay were not influenced by Cl- salts (used to stabilise methylene blue) as may 
have been proposed earlier (Basilico et al., 1998; Parapini et al., 2000). In addition, β-
haematin formation inhibitory activities previously reported by Hawley et al. (1998) for 
quinine (IC50: 64.8 µM) and chloroquine (IC50: 24.4 µM) were almost comparable to those 
72 
found in the current study (Hawley et al., 1998). Quinine (IC50: 68.3 ± 4.17) and chloroquine 
(IC50: 38.4 ± 4.77) demonstrated β-haematin crystal formation inhibition in the current study 
and a strong correlation (r2 = 0.89 and r2 = 0.99, respectively) to the antimalarial activity was 
observed. However, an alternative hypothesis has been proposed by Blank et al. (2012) on the 
mechanism by which methylene blue may inhibit β-haematin formation (Figure 2.14). 
 
According to Blank et al. (2012), methylene putatively acts as a pro-drug of redox-active 
molecules that are cycled in and out of the acidic digestive vacuole in infected RBCs, thereby 
oxidising major intracellular reductants (NADPH) and subsequently reducing haematin (Fe3+-
PPIX) into Fe2+-PPIX (Figure 2.14) (Blank et al., 2012). The stacking of iron porphyrins 
(haem) decreases their active surface and consequently decreases pro-oxidant capacity (Blank 
et al., 2012). Therefore, redox-active compounds such as methylene blue, that display the 
ability of reducing Fe3+-PPIX to Fe2+-PPIX could inhibit haemozoin formation and lead to 
increased oxidative stress and subsequent death of P. falciparum parasites (Blank et al., 
2012). In addition, with methylene blue acting as a redox-cycling substrate of P. falciparum 
glutathione reductase, each reaction cycle catalysed by P. falciparum glutathione reductase 
leads to the consumption of NADPH and oxygen, and to the production of toxic reactive 
oxygen species, predominantly hydrogen peroxides, which interact with iron in the Fenton 
reaction and result in Fe3+-PPIX decomposition (Figure 2.14) (Blank et al., 2012). 
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Figure 2.14 Putative redox-cycling of methylene blue affecting anti-oxidant systems in P. 
falciparum-infected RBC attributed to antimalarial activity (adapted from Blank et al. 
2012). MB, methylene blue; LMB, leucomethylene blue; HMS, hexose monophosphate shunt; GSH, 
glutathione; GSSG, glutathione disulfide; PfGR, P. falciparum glutathione reductase; NADPH, 
nicotinamide adenine dinucleotide phosphate; NADP+, oxidised form of NADPH; FPIX, 
ferriprotoporphyrin IX; Hb, haemoglobin; metHb, Hb with iron in the ferric (Fe3+); SOD, superoxide 
dismutase; Fenton, Fenton’s reaction step that produces hydroxyl radical (OH•) from hydrogen 
peroxide (H2O2) in the presence of Fe3+. 
 
2.6.1.2.2 Activation of hexose monophosphate shunt 
Although depletion of NADPH via the hexose monophosphate shunt (Figure 2.15) has been 
proposed as a plausible mechanism of action for methylene blue, this pathway is not the main 
cause of  parasite death, but a contributing factor (Atamna et al., 1994). The hexose 
monophosphate shunt is a source of pentose sugars required for nucleotide synthesis and for 
the reduction of NADP+ to NADPH (Atamna et al., 1994). P. falciparum parasites are highly 
dependent on glucose for optimal growth and are very sensitive to oxidative stress (Preuss et 
al., 2012). In fact, human glucose-6-phosphate dehydrogenase (G6PD)-deficiency (G6PD 
being the key enzyme in the hexose monophosphate shunt) protects the human host to a 
certain degree from malaria infections (Preuss et al., 2012). Both the parasites and human 
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RBCs possess a complete hexose monophosphate shunt, but there are major differences 
between the parasite and human G6PD enzyme (Preuss et al., 2012). Studies on the ability of 
methylene blue to recycle methaemoglobin (metHb, Fe3+) to normal haemoglobin (Hb, Fe2+), 
revealed that methylene blue enters RBCs, where it is enzymatically reduced by NADPH-
dependant glutathione reductase to leucomethylene blue (Figure 2.14) at the cost of NADPH, 
and in turn leucomethylene blue then reduces metHb to Hb (Atamna et al., 1996). 
Consequently, NADPH depletion activates the hexose monophosphate shunt pathway (Figure 
2.15) which replenishes NADPH by activation of G6PD, which is the rate limiting enzyme of 
the pathway (Preuss et al., 2012).  
 
NADPH has been reported to spontaneously reduce methylene blue and as a result cytosolic 
NADPH was be depleted at a rate of about 1-5 µM/min if not replenished under in vitro 
conditions (Schirmer et al., 2003). Indeed, hexose monophosphate shunt activity in infected 
RBCs has been found to be 78-fold higher than that of healthy uninfected RBCs (Atamna et 
al., 1994). In addition, the hexose monophosphate shunt activity increased with parasite 
maturation from the ring stage towards the trophozoite stage, and declined at the schizont 
stage (Atamna et al., 1994). This correlates with findings of the current study that showed that 
the parasites were mostly sensitive to methylene blue during the trophozoite stage (Figure 
2.11c). Activation of the hexose monophosphate shunt may be a mode of action of methylene 
blue and not necessarily indicative of toxicity. Methylene blue has  been found to be safe in 
adults and children with and without G6PD-deficiency when administered to subjects at an 
established dose of 12 mg/kg, over a three day period in combination with chloroquine 
(Meissner et al., 2006). Under in vitro conditions, sodium nitrite, a hexose monophosphate 
shunt stimulant, has been shown to elevate hexose monophosphate shunt activity 15-fold with 
significant proteolysis in mature RBCs. Even though methylene blue elevated hexose 
monophosphate shunt activity by as much as 45-fold, it did not cause proteolysis (Baird, 
1984). Therefore, proteolysis could not have contributed to methylene blue’s mechanism of 
action against P. falciparum. 
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Figure 2.15 The hexose monophosphate pathway in P. falciparum (adapted from Preuss 
et al. 2012). The hexose monophosphate pathway replenishes NADHP for the glutathione (GSH) and 
thioredoxin (Trx) detoxification systems in P. falciparum. NADPH formed by GluPho (glucose-6-
phosphate dehydrogenase 6-phosphogluconolatonase) and 6PGD (6-phosphogluconate 
dehydrogenase) are used by both Trx-reductase (TrxR) and glutathione reductase (GR) for the 
reduction of their substrates, thioredoxin (Trx) and glutaredoxin (Grx). Trx and Grx can reduce a 
broad range of protein substrates and are thus involved in the redox regulation of many cellular 
processes. 6PGL, 6-phosphogluconolactonase; G6PD, glucose-6-phosphate dehydrogenase; PfHT, P. 
falciparum hexose transporter (Preuss et al., 2012). 
 
There is  further evidence to suggest that “methylene blue-like” drugs activate the hexose 
monophosphate shunt in the presence of a glutathione reductase inhibitor, and that “ascorbate-
like” compounds fail to do so under the same conditions (Baird, 1984). However, in a study 
by Atamna et al. (1994), antimalarial drugs (chloroquine and quinine, both at 5 µM) and 
radical oxidative species scavengers (uric acid and benzoic acid, both at 4 µM) reduced  
hexose monophosphate shunt activity by 20-44% in infected RBCs (Atamna et al., 1994). The 
latter findings contribute to the argument that the in vitro activation of the hexose 
monophosphate shunt observed in eukaryotic cells and parasites in the presence of methylene 
blue, does not increase to appreciable levels to cause cell death. Therefore, parasite death as a 
result of oxidative stress due to NADPH depletion via the hexose monophosphate shunt 
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within the infected RBC may not be a plausible, singular mechanism of action of methylene 
blue, but may be a secondary contributing factor to parasite death. 
2.6.1.2.3 Inhibition of recombinant P. falciparum glutathione reductase enzyme 
Methylene blue has  been shown to inhibit a recombinant P. falciparum glutathione reductase 
(PfGR) enzyme in a non-competitive manner (Färber et al., 1998). PfGR was the first 
molecule to be identified as a target of methylene blue in the parasite. In a study by Färber et 
al. (1998), the enzymatic activity of recombinant PfGR (optimal pH 6.9-7.2) was reduced by 
60% when exposed to methylene blue (10 µM), but the inhibition was reversible by dilution. 
Whilst a later study by Buchholz et al. (2008) showed that methylene blue inhibited PfGR 
(IC50: 5.4 µM) more potently compared to human glutathione reductase (hGR) (IC50: 16.4 
µM). Glutathione reductase, a dimeric flavoenzyme, catalyses the conversion of reduced 
glutathione, GSSG into GSH, which is necessary for cellular protection against oxidative 
stress, whereby NADPH is oxidised to NADP+ (Preuss et al., 2012). In the RBC cytosol, 
glutathione reductase maintains a concentration ratio of 1:100 for GSSG:GSH (Färber et al., 
1998). Both PfGR and hGR play a crucial role in maintaining the redox homeostasis for the 
intra-erythrocytic growth of the parasite (Färber et al., 1998). Therefore the inhibition of 
PfGR is likely to contribute significantly to the toxicity of methylene blue to the parasite and 
oxidative stress. 
2.6.1.2.4 Methylene blue photo-activation 
Methylene blue activity may be induced by photo-activation to cure infections. In the current 
study, the treated parasites were incubated in the dark and photoactivation did not form part of 
the study. However, as early as the 1930’s, it was shown that phages and viruses stained with 
phenothiazium dyes, such as methylene blue, were killed by light illumination (Tardivo et al., 
2005). However, new therapeutic concepts include locally applied methylene blue for 
treatment of basal carcinoma, Kaposi’s sarcoma, melanoma, viral and fungal infections, and 
subsequent radiation with a light source in the red spectrum region (600-750 nm). When, 
methylene was delivered intravenously, it was found to be reduced and excreted far more 
rapidly than when topically applied (Tardivo et al., 2005). Therefore, although methylene 
blue may be useful in photodynamic therapy, with low toxicity and minimal side-effects, it 
has a limited therapeutic spectrum and as such is not ideal for P. falciparum infections.  
2.6.2 Antimalarial activity of natural colourants 
All the natural colourants, except for curcumin and carbon black, were inactive and showed in 
vitro parasite growth inhibition below 20% at a screening concentration of a 100 µg/ml (Table 
2.2). Curcumin (diferuloylmethane) was highly active, whilst carbon black showed moderate 
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activity against P. falciparum, but were both significantly less potent (p < 0.05) compared to 
quinine (Figure 2.7). Curcumin was however, significantly more potent (p < 0.05) than carbon 
black. The findings of the current study (Table 2.15) confirmed the antimalarial potency of 
curcumin (IC50: 2.29 ± 0.18 µg/ml), although significantly more potent (p < 0.05) than 
previously reported to be in the range of 7-11 µg/ml against both chloroquine-sensitive (IC50: 
~ 9.1 µg/ml against the 3D7 strain) and resistant strains (Cui et al., 2007).  
 
Table 2.15 Summary table showing antimalarial, haemolytic activity and β-haematin 
formation inhibition IC50 values of the most active natural compounds. 
Compound Antimalarial activity 
IC50 ± S.D. (µg/ml) 
Haemolytic activity 
HLC50 ± S.D. (µg/ml) 
β-Haematin inhibition 
IC50 ± S.D. (µg/ml) 
Curcumin 2.29 ± 0.18 >100 (6.24 ± 0.18%) 320 ± 0.01 
Carbon black 22.73 ± 2.36 >100 (0.22 ± 0.04%) >1:4 (40.47 ± 0.83%) 
Quinine  0.04 ± 0.01 >100 (0.41 ± 0.01%) 24.65 ± 1.28 
Chloroquine 0.01 ± 0.01 >100 (0.02 ± 0.01%) 19.6 ± 2.46 
Haemolytic activity of test compounds that demonstrated HLC50 values > 100 µM, and β-haematin 
formation inhibition IC50 values above 800 µM (or > 4 mg/ml) were reported as percentage (%) 
values. 
 
Curcumin showed slight haemolytic activity although significantly higher compared to 
quinine (Table 2.15). This may be of minor clinical significance since at least three different 
Phase I clinical trials involving mice and humans have indicated curcumin’s safety and 
tolerance at maximum doses of 12 g per day (Anand et al., 2007). Peak plasma concentration 
(Cmax) of curcumin has been detected at 300 ng/ml in rats, after oral administration (100 
mg/kg) (Liu et al., 2006). Whereas in human subjects, the Cmax value was 2.30 ± 0.26 µg/ml 
after a single oral dose of 10 g curcumin (Vareed et al., 2008). Of the two natural colourants, 
only curcumin inhibited β-haematin formation significantly (p < 0.05) compared to quinine 
(Table 2.15). Curcumin interfered with the differential staining of the RBC and the parasite; 
as such observations could not be made for the morphology and stage sensitivity studies. The 
excessive staining or high affinity of curcumin to the infected RBC indicated probable, 
targeted antimalarial activity. In the treatment of malaria, combination therapy is essential in 
preventing treatment failure and drug resistance (WHO, 2012). In the current study, both 
curcumin and carbon black showed an additive interaction with quinine (Figure 2.10b). 
Similarly, in a study by Nandakumar et al. (2006), the combination of curcumin and quinine 
showed an additive in vitro effect on P. falciparum (FCK strain) parasites. In the same study, 
an additive in vivo interaction was observed when a combination of curcumin (three day oral 
regimen of 5mg) and artemisinin was administered to P. berghei-infected mice (Nandakumar 
et al., 2006). Although there is no resistance data that has been reported for curcumin, a 
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clinical and parasitological failure of quinine mono-treatment associated with IC50 values up 
to 0.4 µg/ml against isolates originating from South America has been reported (Bertaux et 
al., 2011). The resistance cut-off values for quinine are IC50 values greater than 0.3 µg/ml 
(Bertaux et al., 2011). Therefore, curcumin used in combination with classical antimalarial 
drugs has the potential of delaying the onset of resistance of these drugs and of possibly 
increasing the susceptibility of the parasites. For instance, a single dose of artemether (750 
µg) in combination with curcumin (5 mg) has been shown to give complete protection in P. 
berghei-infected mice (Nandakumar et al., 2006).  
 
Although curcumin has been found to have a low bioavailability and rapid clearance rate in 
humans, a low dose of piperine from pepper can substantially enhance curcumin uptake in 
humans and the combination is well tolerated (Nandakumar et al., 2006). In addition a poly-
ethylene glycol or PEGylated liposome formulation loaded with a molar ratio of 0.6:1 
(artemisinin to curcumin), showed a higher efficacy (60% parasitaemia reduction) in P. 
berghei-infected mice in just three days compared to 80% reduction in parasitaemia over 7 
days with free artemisinin alone (Isacchi et al., 2012). This increased efficacy of artemisinin 
and curcumin combination in the latter study may be attributed to increased bioavailability of 
both drugs. A combination study by Nandakumar et al. (2006) has demonstrated an additive 
interaction between free artemisinin and curcumin against P. berghei. Despite its 
pharmacokinetic properties, curcumin shows potential as a template for new antimalarial 
agents and warrants further research.  
2.6.2.1 Physicochemical properties of natural colourants 
Curcumin (pKa1 = 10.51; pKa2 = 9.88; pKa3 = 10.5), a polyprotic acid as determined by 
Bernabé-Pineda et al. (2004), showed drug-like properties and complied with the Lipinski’s 
Ro5 (Table 2.12). At pH 7.4 curcumin showed a low degree of ionisation (0.1%) and was 
non-ionised at pH 5.0 (Table 2.13). This suggests that curcumin would be absorbed across the 
pH gradient with a low degree of ionisation of accumulation especially at the acid pH 5.0. 
However, poor bioavailability due to poor absorption, rapid metabolism, rapid elimination 
and a half-life of 1-2 h, has been a major drawback in the approval of curcumin as a 
therapeutic agent (Anand et al., 2007; Isacchi et al., 2012). The physicochemical properties of 
carbon black were not determined. 
2.6.2.2 Pharmacological effects of curcumin 
Curcumin (diferuloylmethane), a natural polyphenolic compound, has demonstrated diverse 
pharmacological properties including anti-inflammatory, anti-carcinogenic, anti-bacterial and 
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anti-protozoal activities (Cui et al., 2007). Curcumin demonstrates both anti-oxidant and pro-
oxidant activities which are concentration-dependent (Cui et al., 2007). Its cytotoxicity on 
various cancer cell lines is attributed to its pro-oxidant activity through the generation of 
reactive oxygen species (ROS). The generation of ROS as well as the inhibition of acetylation 
of chromosomal proteins, histones, have been proposed as possible mechanisms of action of 
curcumin (Cui et al., 2007; Croken et al., 2012). Notwithstanding that curcumin has multiple 
therapeutic effects, in addition has a variety of protein targets and inhibits the activity of 
various kinases (Goel et al., 2008). 
2.6.2.2.1 Oxidative damage through increased reactive oxygen species 
According to Cui et al., (2007), at low concentrations (< 1 µM), curcumin appears to reduce 
intracellular ROS levels, whereas at higher concentrations (> 20 µM), it promoted 
intracellular ROS in a concentration-dependent manner. In the latter study, incubation of P. 
falciparum parasites with a combination of curcumin (50 µM) and the anti-oxidants, mannitol 
(at a 1:6 to 8 curcumin to mannitol concentration ratio) or 1 mM ascorbic acid, significantly 
reduced ROS levels and restored parasite growth almost to the parasitaemia of untreated 
controls (Cui et al., 2007). The nucleic and mitochondrial DNA damage observed in the same 
study may be attributed to the generation of ROS by curcumin. As such, the latter results and 
the reported antimalarial activity suggest that ROS generation plays a key role in killing 
malaria parasites (Cui et al., 2007). Curcumin as an anti-oxidant, has the potential to interfere 
with the inhibitory effects of macrophage-induced nitric oxide in vivo and thus exacerbate the 
malaria infection (Cui et al., 2007). Therefore, curcumin’s concentration levels may have to 
be optimally adjusted in order to favour its pro-oxidant activity. 
2.6.2.2.2 Inhibition of histone acetylation and histone acetyltransferase activity 
The inhibitory effects of curcumin on the activity of histone acetyltransferases (HATs), may 
partially account for its antimalarial activity (Cui et al., 2007). In eukaryotic cells, genomic 
DNA is packaged into chromatin (Alberts et al., 2004). Chromatin is a complex of DNA and 
chromosomal proteins, predominantly histones, which condenses into mitotic chromosomes 
(Alberts et al., 2004). The DNA is wrapped around the histone proteins in a “bead on a string” 
pattern, forming nucleosomes (Figure 2.16); the basic units of the chromatin fibre (Alberts et 
al., 2004). The nucleosome consists of about 150 base pairs of DNA wound twice around an 
octameric histone core (Croken et al., 2012). The nucleosome ‘bead’ consists of two copies of 
histones H2A, H2B, H3 and H4 (Cui et al., 2007). The nucleosomes are packed tightly by H1-
H1 histone protein interaction. Chromatin exists in a condensed form with transcription 
silencing and in an expanded form associated with active gene transcription (Goodman, 1998; 
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Miao et al., 2006). However, histone acetylation (Figure 2.16), which is catalysed by HATs, 
alters the chromatin structure, exposing DNA sequences to allow for gene expression, DNA 
replication or repair (Alberts et al., 2004; Cui et al., 2007). The latter process is reversed by 
histone deacetylases or HDACs (Cui et al., 2007). 
 
 
Figure 2.16 Regulation of gene activation and repression by acetylation of histones 
(adapted from Barnes et al., 2005). Histone acetylation is mediated by co-activators that have 
intrinsic histone acetyltransferase (HAT) activity. Acetylation of histones open the chromatin structure 
exposing the DNA strands, thus allowing binding of RNA polymerase II and transcription factors. The 
latter process is reversed by co-repressors, which include which include histone deacetylases 
(HDACs) that reverse acetylation and causing gene silencing or repression. CBP, CREB-binding 
protein; PCAF, p300/CBP-associated factor; NCOR, nuclear receptor co-repressor (Barnes et al., 
2005). 
 
Similarly, malaria parasites have a typical chromatin structure, which plays a key role in 
epigenetic (“heritable changes that alter gene expression levels”) regulation of gene 
expression (Cui et al., 2007; Croken et al., 2012). Cui et al. (2007) previously demonstrated 
that curcumin (25-100 µM) has the ability to reduce nuclear HAT activity of the parasite in 
vitro, as well as to inhibit the HAT activity of the recombinant P. falciparum general control 
non-depressed 5 (PfGCN5) histone acetyltransferase (IC50: ~48 µM). In addition, curcumin 
has demonstrated specific inhibition of the HAT p300/CREB-binding protein and related 
transcriptional activity (Balasubramanyam et al., 2004). Thus, P. falciparum HATs are 
plausible targets for curcumin (Cui et al., 2007). 
2.6.3 Antimalarial activity of nucleoside and analogues 
The most active nucleoside analogues, JLP118.1 (IC50: 1.79 ± 0.12 µM) and JLP093 (IC50: 
2.38 ± 0.11 µM), demonstrated antimalarial activity within the micromolar range, but were 
significantly less potent (p < 0.05) than quinine (Table 2.15). The overall antimalarial activity 
of the most active nucleoside analogues was classified as highly active (≤ 5 µM). Of all the 
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nucleoside analogues tested, only the pyrimidine-based nucleoside analogues, JLP118.1 and 
JLP093 were highly active against P. falciparum. Both compounds showed negligible toxicity 
to human RBCs and showed no ability to inhibit β-haematin crystal formation as a possible 
mechanism of action (Table 2.15). The trophozoite stage was particularly sensitive to 
nucleoside analogue, JLP118.1 as the parasite did not proceed to the schizont stage (Figure 
2.11d). 
2.6.3.1 Physicochemical properties of nucleoside analogues 
JLP118.1 (MW: 630.64 g/mol) a pyrimidine-based analogue, was the bulkiest compound and 
violated three of the Lipinski’s Ro5 parameters (MW > 500, HBA > 10 and log P > 5), 
compared to all the other most active compounds (Table 2.12), yet it demonstrated the most 
potent antimalarial activity in its class. Overall, the absorption rate of both the nucleoside 
analogues was more than 95% at basic pH 7.4 in their un-ionised state. JLP093 showed some 
significant (p < 0.05) ionisation (13.7%) at an acidic pH 5.0, compared to JLP118.1 (Table 
2.13). This suggests that the activity of this class of compounds was not due to their acid-base 
properties, except for JLP093 which could possibly over time accumulate within the digestive 
vacuole’s acidic environment based on the “ion-trapping” effect described earlier by Shore et 
al. (1957). However, nucleosides must first be phosphorylated within the parasite to their 
respective nucleotides in order to be pharmacologically active (Gero et al., 2003). In addition, 
nucleotides are anionic compounds which are unable to translocate cell membranes, whereas 
nucleosides and some analogues are neutral molecules that can cross through cellular 
membranes (Gero et al., 2003). Indeed, the P. falciparum equilibrative nucleoside transporter 
(PfENT1) has been found to facilitate the uptake of both purine and pyrimidine nucleosides 
and nucleobases (Baldwin et al., 2007). When compared to natural nucleosides that are 
transported into cells, nucleoside analogues are often modified to enable passive diffusion or a 
combination of passive diffusion and facilitated transport via nucleoside transporters (Li et 
al., 2008).  
 
Structurally, JLP118.1 was the only uracil-derived analogue tested with a combination of the 
tert-butyl-dithiomethyl-hydroxyl group and the modified ribose structure containing 
acetaldehyde groups. Whilst JLP093 was the only cytosine-derived analogue with the tert-
butyl-diphenylsilyl group and un-modified ribose structure in the nucleoside analogue series 
(Table 2.10). 
 
 
82 
Table 2.16 Summary of antimalarial, haemolytic and β-haematin formation inhibitory 
activity of the most active nucleoside analogues.  
Compound Antimalarial activity  
IC50 ± S.D. (µM) 
Haemolytic  
activity  
HLC50 ± S.D. (µM) 
β-Haematin inhibition 
IC50 ± S.D. (µM) 
JLP118.1 1.79 ± 0.12 >100 (0.92 ± 0.04%) >800 (0.01 ± 0.02%) 
JLP093 2.38 ± 0.11 >100 (0.35 ± 0.05%) >800 (5.8 ± 3.35%) 
Quinine  0.10 ± 0.01 >100 (0.15 ± 0.01%) 68.3 ± 4.17 
Chloroquine 0.01 ± 0.00 >100 (0.01 ± 0.01%) 38.4 ± 4.77 
Haemolytic activity of test compounds that demonstrated HLC50 values > 100 µM, and β-haematin 
formation inhibition IC50 values above 800 µM (or > 4 mg/ml) were reported as percentage (%) 
values. 
2.6.3.2 Pharmacological effects of nucleoside analogues 
Unlike purines that are in abundance in human RBCs, pyrimidines exist in small 
concentrations (Cassera et al., 2011). As a result P. falciparum has retained its capacity for de 
novo synthesis of pyrimidines and developed pathways for the salvage of purines from the 
host RBC, but lacks pyrimidine salvage enzymes (Reyes et al., 1982; Cassera et al., 2011). In 
the current study, pyrimidine-based analogues, JLP118.1 and JLP093 demonstrated 
comparable activity to the purine nucleoside, inosine. In addition, the trophozoite stage was 
particularly sensitive to JLP118.1 since the parasite did not proceed to the schizont stage. 
DNA synthesis in synchronised P. falciparum cultures has been found to peak mostly during 
the trophozoite stage, which has been compared to the S-phase of the cell cycle in mammalian 
cells (Figure 1.3), 28-31 h after merozoite invasion and the DNA content increases for 8-10 h 
(Arnot and Gull, 1998; Downie et al., 2008; Arnot et al., 2011).  
 
Therefore the pyrimidine nucleoside analogues, JLP118.1 and JLP093, may have interfered 
with the nucleic acid synthesis during the trophozoite stage. Although PfENT1, facilitates the 
transport of both purine and pyrimidine nucleosides and nucleobases, the uptake of 
pyrimidines into the RBCs does not benefit the parasites as they lack de novo pyrimidine 
salvage pathways (Baldwin et al., 2007). However, PfENT1 does provide a route for the 
uptake of cytotoxic pyrimidine drugs such as 5-fluoroorotate, which inhibits the de novo 
pyrimidine synthesis pathway of P. falciparum directly (Baldwin et al., 2007). In contrast, 
earlier studies have shown that parasites in P. knowlesi-infected monkeys, failed to 
incorporate 14C-labelled exogenous pyrimidines (thymine, thymidine, uracil and uridine) into 
their nucleic acids (Downie et al., 2008). Natural inosine, one of the purines salvaged from 
the host RBC, is a direct precursor of hypoxanthine (Cassera et al., 2011). Nevertheless, the 
morphology and stage sensitivity studies, confirmed the inhibitory effects of the JLP118.1 
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pyrimidine-based nucleoside analogue as demonstrated in the [3H]-hypoxanthine 
incorporation assay (Figure 2.11, Table 2.16). 
2.6.4 Antimalarial activity of imidazopyridine analogues 
IP-2 to IP-4 of the imidazopyridines analogue series chemical structures contained a 
cyclohexane ring and the other half of the series, IP-5 to IP-8 contained a 1,3-
dimethylbenzene ring (Table 2.11). The most active imidazopyridine analogues (Figure 2.9), 
IP-3 (IC50: 20.77 ± 0.72 µM) and IP-4 (IC50: 15.30 ± 0.41 µM), that contained the 
cyclohexane ring, were generally more potent than IP-5, -6 and -7, that contained the 1,3-
dimethylbenzene ring, but all were about 200 to 300-fold less potent than quinine (IC50: 0.10 
± 0.01 µM). The most active imidazopyridines showed low (50-100 µM) to moderate (10-50 
µM) antimalarial activity and were significantly (p < 0.05) less potent compared to quinine. 
The parasite morphology and stage sensitivity studies, suggest sensitivity of the trophozoite 
stage to IP-4 as they degenerated after the initial 24 h period and failed to proceed to the 
subsequent schizont stage (Figure 2.11e). These compounds were however not tested for 
haemolytic activity and β-haematin formation inhibition in the study due to limited stock. 
Therefore it was not apparent whether parasite death was related to any of these 
aforementioned mechanisms.  
2.6.4.1 Physicochemical properties of imidazopyridine analogues 
Of the most active imidazopyridine analogues only 2 and 1 violations of the Lipinski’s Ro5 
principles were noted for IP-3 and IP-6, respectively. The MWs of the imidazopyridine 
analogue were greater than 500 g/mol, except for IP-4 and IP-5 which were below 400 g/mol. 
So the Ro5 violations were mostly on the MWs and the log P values that were greater than 5. 
However, no correlation pattern was observed between the Ro5 number of violations and 
antimalarial activity; although IP-4, the most active of the class complied with Lipinski’s 
drug-likeness, Ro5 criteria. 
2.6.4.2 Pharmacological effects of imidazopyridines 
The antimalarial activity of the imidazopyridines may be associated with the inhibition of 
CDKs. A high-throughput screen of the AstraZeneca compound library identified a series of 
imidazo[1,2-a]pyridines as a class of potent inhibitors of cyclin-dependent kinase CDK4 with 
the lead analogue demonstrating an IC50 value of 8 µM (Anderson et al., 2003; Enguehard-
Gueiffier and Gueiffier, 2007). In the latter study, the binding mode of these compounds by 
X-ray crystallography of the compound complex with CDK2, led to the synthesis of 100-fold 
more potent compounds against CDK2 (Anderson et al., 2003). The various chemical 
structures tested against P. falciparum demonstrated varying degrees of activity, but were all 
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relatively non-toxic to RBCs except for mercury orange. Curcumin acted by inhibiting β-
haematin crystal formation. The most active compounds could be used as templates for new 
antimalarial agents and further derivatisation. 
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Chapter 3 Mammalian cell toxicity 
3.1 Introduction 
Toxicology is concerned with the deleterious effects of chemical agents on all living systems. 
In humans, adverse effects resulting from exposure to drugs, their safety or potential toxicity 
associated with their use is of critical importance (Plaa, 2005). In vitro cytotoxicity assays 
allow for rapid evaluation of potential toxicity of large numbers of test compounds on cell 
lines, reducing the need for animal experimentation, during the initial stages of drug 
development (Ekwall et al., 1990). For instance, the tritiated ([3H])-thymidine incorporation 
assay in particular, measures cell growth from the amount of [3H]-thymidine incorporated into 
dividing cells (Wagner et al., 1999). The toxic potential of any substance, be it natural or 
chemically synthesised, always remains a concern. The adverse effect profile and efficacy of 
all drugs are known and constantly updated (WHO, 2008). The potentiation of these adverse 
effects as concentrations or dosages reach toxic levels, are documented as well. The potential 
toxic properties of compounds or drugs administered to humans are constantly monitored by 
the WHO and country regulatory bodies such as the Food and Drug Administration (USA) 
and the Medicines Control Council (South Africa) through pharmacovigilance (WHO, 2008; 
National Department of Health, 2013). The safety margin or therapeutic index of administered 
drugs is based on the ratio between the therapeutic dose and the toxic dose (Muller and 
Milton, 2012).  
3.1.1 Selectivity index and in vitro toxicology 
In drug development, the selectivity index, which is the ratio between in vitro efficacy (IC50) 
and in vitro cytotoxicity is used as an early indicator of the toxicity of the test compounds 
(Muller and Milton, 2012; Najahi et al., 2013). It is conceded that the extent of efficacy and 
safety data only increases as a candidate compound progresses from in vitro, to animal and 
then to human studies (Muller and Milton, 2012). In vivo rodent malaria models are an ideal 
starting point for elucidation of toxicology, pharmacokinetic and pharmacodynamic data 
during antimalarial drug discovery (Fidock et al., 2004). In addition, in vitro toxicology 
assays often make use of mammalian cancer cell lines and not naturally dividing cells (Pink et 
al., 2005). However, there has been consideration for a transition from animal screens to more 
in vitro systems and predictive toxicology methods within the 21st century (National 
Toxicology Program, 2004). The vision of the National Toxicology Program and the FDA 
(U.S.A.) is to strive to address the “3Rs” effectively that include: the reduction of the number 
of animals used in research programs, refining the end-points to derive the maximum amount 
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of information with minimum amount of pain and suffering, and replacement of species 
currently used with lower species or in vitro systems (National Toxicology Program, 2004). 
Therefore in vitro cytotoxicity assays with their limitations, do however provide a high-
throughput screening method to determine selectivity of candidate compounds for P. 
falciparum parasites (Fidock et al., 2004; Pink et al., 2005; Muller and Milton, 2012). For 
pure compounds, biological efficacy must have a selectivity index of at least 10 or more (Pink 
et al., 2005). Whereas for crude plants extracts it is more difficult to establish the selectivity 
index value, especially if the specific concentration and identity of the active ingredient is 
unknown and the extract may contain other constituents that contribute to the cytotoxicity 
(Valdés et al., 2008). The attrition rate of new compounds in pre-clinical and clinical phases 
of drug development is largely due to poor efficacy and/or toxicity (McKim, 2010). 
Therefore, it was critical to test the compounds for potential toxicity in the current study. 
3.2 Objectives 
• To evaluate the in vitro cytotoxicity of the test compounds with the most antimalarial 
activity against the transformed human embryonic kidney epithelial (HEK293 cells, 
ATCC CRL11268) and the human chronic myelogenous leukaemic (K562 cells, ATCC 
CCL243) cell lines. 
• Determine the selectivity index of the most active test compounds for P. falciparum and 
their effect on the HEK293 and K562 human cell lines. 
3.3 Methods 
3.3.1 Cell lines 
The K562 human cancer cell line (Highveld Biological) was established in 1970 from a 
pleural effusion of a 53-year old patient with chronic myelogenous leukaemia in blastic crisis 
(Lozzio and Lozzio, 1979). This suspension cell line is of erythroleukaemia type and is 
characterised as a highly undifferentiated cell resembling granulocytes and erythrocytes 
(Lozzio and Lozzio, 1979). The monolayer HEK293 cell line (Highveld Biological), was 
immortalised and derived from the transformation of primary cultures of human embryonic 
kidney (HEK293) cells by exposing cells to sheared fragments of adenovirus type 5 DNA 
(Graham et al., 1977; Shaw et al., 2002). 
3.3.2 Preparation of culture medium 
Sterile-filtered Dulbecco’s Modified Eagle’s Medium (DMEM) and RPMI-1640 growth 
media were used to maintain the HEK293 and K562 cells in culture, respectively. DMEM 
(500 ml; Sigma-Aldrich) was supplemented with 4.5 g/L glucose, 110 mg/L sodium pyruvate 
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and 0.584 g/L L-glutamine. RPMI-1640 (Sigma-Aldrich) was supplemented with 4.5 g/L 
glucose, 0.3 g/L L-glutamine and 2 g/L NaHCO3. The growth media was completed by 
adding 5% (v/v) heat-inactivated (56°C for 1 h) foetal calf serum (Sigma-Aldrich), 
antibiotics: 0.1% (v/v) penicillin (5000 units/100 ml) and streptomycin (5 mg/100 ml) 
(Sigma-Aldrich). Complete experimental medium was supplemented with 5% (v/v) heat-
inactivated foetal calf serum, but excluded antibiotics to prevent any interaction with the test 
compounds; whilst the incomplete experimental medium (for serial dilutions of test 
compounds) excluded both the foetal calf serum and antibiotics. 
3.3.3 Preparation of test compounds and control drugs 
Stock solutions of the natural (10 mg/ml) and synthetic (10 mM) test compounds, the 
reference drugs, quinine (Sigma-Aldrich) and camptothecin (Sigma-Aldrich) were prepared in 
100% (v/v) DMSO (Sigma-Aldrich). Appropriate serial dilutions of test compounds were 
prepared using incomplete experimental medium. The final % DMSO used in the experiments 
did not exceed 1% such as to minimise an inhibitory effect on the cell viability.  
3.3.4 General cell culture maintenance 
The cell lines were aseptically maintained in culture according to cell culture methods 
described by Freshney (1988). A waiver was obtained from the Human Research Ethics 
Committee for use of both cell lines in in vitro studies (Ethical clearance waiver reference 
number: W-CJ-090425-12; Appendix B3). Culture maintenance was carried out in a Class II 
biosafety laminar flow hood. The cultures were incubated at 37°C in a humidified incubator 
(Heraeus Cell) with an atmosphere containing 5% CO2, to maintain the pH (7.44) of the 
culture (Wagner et al., 1999). Sub-culturing of both cell cultures was carried out every 2-3 
days when cells reached confluency and the culture flasks returned to the incubator. The cell 
cultures within the flasks were examined for confluency and morphology using an inverted 
phase contrast microscope (Olympus-CK2) at 200 x magnification. Based on this observation 
the cultures were either prepared for re-seeding of the culture or for experimentation. 
3.3.5 Sub-culturing of HEK293 monolayer cells 
The adherent, monolayer HEK293 cells were re-suspended by treatment with trypsin 
(Freshney, 1988). Spent culture media was discarded and the adherent cells washed twice 
with 2 ml pre-warmed (37ºC) PBS (pH 7.4). Pre-warmed, 2 ml 0.25% trypsin/0.1% versene 
ethylene diamine-tetracetic acid (EDTA, Sigma-Aldrich) was added to the culture flask and 
incubated at 37ºC for 3-5 minutes or until the adherent cells detached from the flask surface. 
Thereafter, 4 ml complete DMEM culture medium was added in order to neutralise the 
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proteolytic activity of trypsin. The cell suspension was centrifuged at 834 x g for 5 min, the 
supernatant aspirated and the cell pellet resuspended in fresh complete culture medium.  
3.3.6 Sub-culturing of K562 suspension cells 
The K562 cells grown in suspension were centrifuged at 834 x g for 5 min. Thereafter, 90% 
(v/v) spent culture medium was aspirated, leaving 10% v/v to retain sufficient growth factors 
and the remaining cell pellet was re-suspended with fresh pre-warmed complete culture 
medium. 
3.3.7 Determination of cell number 
Cells were counted with a Neubauer haemocytometer and cell viability was determined using 
the trypan blue exclusion assay (Freshney, 1988; Strober, 2001). According to the method 
described by Freshney (1988), viable cells with intact membranes do not stain blue with 
trypan blue, whilst dead cells take up the dye and stain blue as observed under a light 
microscope.  Briefly, cultures were transferred into a 50 ml centrifuge tube, centrifuged at 834 
x g for 5 min and re-suspended in 20 ml complete experimental medium. A 20 µl sample of 
cell suspension was transferred to a microcentrifuge tube and stained in a 1:1 volume ratio 
with 20 µl, 0.2% (v/v) trypan blue prepared in PBS (pH 7.4) (Section 2.3.5). The cell 
suspension was transferred into the haemocytometer and covered with a coverslip.  Unstained 
viable cells within the central grid were counted and the mean cell count from the two 
chambers was used to determine the number of cells per volume (ml) (Equation 3.1). 
 
Cell density (cells/ml) = (Mean number of viable cells ×104)	× 2 dilution factor  
Equation 3.1 Cell density. 
 
3.3.8 Tritiated thymidine incorporation assay 
The inhibitory effect of the test compounds on the in vitro cell growth was determined using 
the [3H]-thymidine incorporation assay (Sondak et al., 1984; Coward et al., 1998). Based on 
the principle of the assay, live replicating cells incorporate [3H]-thymidine into their DNA and 
the percentage cell growth is determined by measuring the radioactivity from the precipitated 
[3H]-thymidine. 
3.3.8.1 Seeding of cells 
Cells were seeded into a 96-well microtitre plate at a density of 50,000 cells per well in 180 µl 
cell suspension prepared in complete experimental medium. All assays included untreated 
cells as a negative control containing 20 µl of PBS, along with quinine and camptothecin as 
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the reference drugs. Cells were exposed to serial dilutions (100 µM – 1.56 µM) of the 
compounds and incubated for 72 h at 37ºC in a humidified incubator in 5% CO2 atmosphere. 
The [3H]-thymidine (20 Ci/mmol) isotope was added to a final concentration of 0.5 Ci/ml per 
well after 48 h incubation. The cells were incubated for a further 24 h to allow incorporation 
of the [3H]-thymidine into the DNA of proliferating cells (Sondak et al., 1984).  
3.3.8.2 Cell harvesting 
The cellular [3H]-labelled DNA harvested onto Wallac™ Betaplate glass fibre filter mats 
using a multichannel Titertek™ semi-automatic cell harvester. The isotope incorporated into 
the cellular DNA was measured using the Wallac™ 1205 Betaplate scintillation counter 
(Perkin-Elmer) (Section 2.3.9.2). The scintillation counter results (cpm) were expressed as 
percentage cell growth compared to untreated control (Equation 3.2) and the concentration of 
the test compound causing a 50% cytotoxic effect (IC50) was calculated from log sigmoid 
dose-response curves generated using Enzfitter® software.  
 
% Cell growth =
mean cpm
 treated cells 
mean cpm
 untreated control
 × 100 
Equation 3.2 Percentage cell growth determination. 
 
3.4 Data analysis  
The IC50 values were determined from log sigmoid dose-response curves generated by the 
Enzfitter® software (version 1.05). The results are reported as the mean of at least 3 replicate 
experiments with standard deviation (mean ± s.d.). Statistical difference between the activity 
(IC50 values) of the test compounds and the reference drugs was determined by a one-way 
ANOVA test, using GraphPad Prism® software, version 5.0 (Motulsky, 2003; Glantz, 2005). 
A p-value less than 0.05 (p < 0.05) was considered statistically significant. The anti-
proliferative activity of the test compounds against both the HEK293 epithelial and K562 
erythroleukaemic cell lines were compared using a two-way ANOVA test. A p-value less than 
0.05 (p < 0.05) was considered statistically significant (Motulsky, 2003; Glantz, 2005). 
3.5 Selectivity index 
The selective activity of the most active compounds against the P. falciparum parasites 
compared to their cytotoxicity was determined by calculating the S.I. (Equation 3.3). Both 
synthetic and natural compounds with S.I. values of  > 10 were regarded as non-toxic (Pink et 
al., 2005). 
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Selectivity index	= 
Cytotoxicity (IC50)
Antimalarial activity (IC50)  
Equation 3.3 Selectivity index for P. falciparum compared to human cancer cell lines. 
 
3.6 Results 
3.6.1 Cytotoxic effect of synthetic colourants 
The cytotoxicity results of the synthetic colourants are depicted in Figure 3.1. HEK293 cells 
were more sensitive to all the test compounds compared to the K562 cells. The positive 
control, camptothecin, was potently inhibitory to the HEK293 cell line (IC50: 16.75 ± 1.22 
nM) than the K562 cell line (IC50: 41.64 ± 2.34 nM). The reference drug, quinine was the 
least inhibitory against both cell lines compared to all the synthetic test compounds and more 
than 900-fold less active compared to camptothecin (Figure 3.1).  
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Figure 3.1 Cytotoxic effect of synthetic colourants on the HEK293 and K562 cell lines. 
IC50 data was obtained using the [3H]-thymidine incorporation assay (n = 3). Two-way 
ANOVA test showed significant (p < 0.05, *; p < 0.001, ***) cell growth inhibitory activity against 
the HEK293 cell line compared to the K562 cell line. 
 
Mercury orange (IC50: 0.82 ± 0.01 µM) was the most potent test compound against the 
HEK293 cell line, whilst methylene blue (IC50: 1.92 ± 0.02 µM) was the least effective. 
Safranine O (IC50: 1.26 ± 0.2 µM) inhibited HEK293 cells significantly (p < 0.05) compared 
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to quinine, but was 63-fold less active than camptothecin. The cytotoxicity of mercury orange 
(IC50: 0.82 ± 0.00 µM) on HEK293 cells was comparable to that of safranin O and methylene 
blue (Figure 3.1). The K562 cell line was generally less sensitive to all the test compounds. 
Methylene blue and safranin O showed comparable cytotoxicity against K562 cells and were 
both significantly (p < 0.05) potent compared to mercury orange. Quinine was more than 7-
fold less active compared to methylene blue and safranin O, 2.5-fold less active compared to 
mercury orange against the K562 cells. 
3.6.2 Cytotoxic effect of natural colourants 
The cytotoxicity results of the natural compounds are depicted in Figure 3.2 and presented in 
mass molarity units (µg/ml) since all the most active natural colourants were in a liquid paste 
form when acquired. For comparative analysis, the IC50 values for quinine and camptothecin 
were converted to mass molarity. Camptothecin was equally, significantly (p < 0.05) more 
potent against both cell lines than curcumin, carbon black and quinine.  
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Figure 3.2 Cytotoxic effect of natural colourants on the HEK293 and K562 cell lines. IC50 
values were obtained using the [3H]-thymidine incorporation assay (n = 3). The two-way ANOVA test 
showed significant (p < 0.001, ***) differences in sensitivity of HEK293 and K562 cell line to carbon 
black. 
 
Curcumin was highly cytotoxic (IC50: 1.37 ± 0.11 µg/ml) and 745-fold more potent than 
carbon black and significantly (p < 0.05) more potent compared to quinine (IC50: 6.68 ± 2.24 
µg/ml) against the HEK293 cells. In comparison, curcumin was 137-fold less potent 
compared to camptothecin (IC50: 5.84 ± 0.28 ng/ml) against the HEK293 cells, whilst quinine 
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(IC50: 6.68 ± 2.24 µg/ml) was 668-fold less active compared to camptothecin. There was a 
significant difference (p < 0.001) in the cytotoxic effect of carbon black between the two cell 
lines with K562 being the most sensitive at an IC50 value of 630 ± 180 µg/ml. The 
cytotoxicity activity of curcumin against the K562 cell line was significantly (p < 0.05) more 
potent compared to quinine and carbon black, but 26-fold less active than camptothecin (IC50: 
14.51 ± 0.43 ng/ml). 
3.6.3 Cytotoxicity of nucleoside and imidazopyridine analogues 
The cytotoxic activity results of the nucleoside and imidazopyridine analogues are shown in 
Figure 3.3. The two-way ANOVA test showed that the HEK293 cells were significantly (p < 
0.001) more sensitive specifically to JLP093, IP-4, IP-3 and IP-7 compared to the K562 cells 
(Figure 3.3).  
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Figure 3.3 Cytotoxic effect of nucleoside and imidazopyridine analogues against the 
HEK293 and K562 cell lines. IC50 values were obtained using the [3H]-thymidine 
incorporation assay (n = 3). The two-way ANOVA test showed significant (p < 0.001, ***) 
differences in sensitivity of the HEK293 and K562 cell line to specific compounds.  
 
The cytotoxic effect of the nucleoside (JLP118.1, JLP093) and imidazopyridine analogues 
(IP-4, IP-3, IP-5) against the HEK293 cells was comparable at IC50 values between 9-10 µM, 
except for IP-7 (IC50: 5.28 ± 0.86 µM) which was most potent (Figure 3.3). The test 
compounds were all significantly (p < 0.05) more toxic to HEK293 cells compared to quinine 
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(IC50: 18.51 ± 2.24 µM). IP-7 was 3.5-fold more potent compared to quinine, but 264-fold 
less active compared to camptothecin. The K562 cells showed the least sensitivity to IP-7 
(IC50: 47.20 ± 2.80 µM) compared to all the test compounds (Figure 3.3). The cytotoxic effect 
of JLP118.1 on K562 cells was comparable to that on the HEK293 cells, whilst JLP093 (IC50: 
22.82 ± 0.83 µM) was significantly less inhibitory to K562 cells compared to HEK293 cells. 
The K562 cells were significantly (p < 0.05) less sensitive to both IP-4 and IP-3 compared to 
HEK293 cells. IP-5 did not show any specific activity between the K562 and HEK293 cell 
lines and the IC50 values were comparable (Figure 3.3). 
3.6.4 Selectivity indices of most active test compounds for P. falciparum 
The selectivity of the most active compounds for P. falciparum compared to human cell lines 
(HEK293 and K562) is depicted in Figure 3.4.  
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Figure 3.4 Selectivity indices of the most active compounds for P. falciparum. The S.I. was 
calculated by dividing the cell growth inhibitory IC50 values with the antimalarial IC50 values. Test 
compounds that showed S.I. values > 10 were regard as non-toxic or showing more selectivity for P. 
falciparum compared to the human HEK293 and K562 cell lines. 
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Test compounds with a selectivity index > 10 were regarded as more specific to P. falciparum 
or non-toxic to the human cell lines (Pink et al., 2005). Methylene blue showed markedly 
high selectivity indices, for both the HEK293 (S.I.: 480) and K562 (S.I.: 968) cell lines 
compared to all the test compounds and the S.I. values were almost 2-fold higher than quinine 
(S.I.: 180 for HEK293 and S.I.: 458 for K562 cell lines). The imidazopyridine analogues 
showed the lowest selectivity indices (S.I. range: 0.1-0.9). The nucleoside analogues showed 
selectivity indices below 10 (S.I. range: 1.2-5.5) across both cell lines. The natural colourant, 
curcumin (S.I. range: 0.1-0.6) was poorly selective for P. falciparum compared to carbon 
black (S.I. range: 27.8-44.9), which was significantly (p < 0.05) less toxic to both cell lines. 
Overall, quinine showed a significantly (p < 0.05) high selectivity indices compared to all the 
test compounds with the exception of methylene blue which was more selective to P. 
falciparum compared to both cell lines. 
3.7 Discussion 
The selectivity indices of the active compounds were calculated by dividing the cytotoxicity 
IC50 value by the antimalarial IC50 value. The cut-off selectivity index was ≥ 10, meaning that 
the cytotoxicity IC50  value had to be at least 10 times more than the antimalarial IC50, in order 
for the compounds to be regarded selective for the P. falciparum parasite. The cytotoxicity of 
the active compounds was tested on transformed human kidney epithelial cells (HEK293) and 
the chronic myelogenous leukaemia cell line (K562). 
3.7.1 Selectivity of synthetic colourants for P. falciparum 
3.7.1.1 Methylene blue 
Although methylene blue showed significant (p < 0.05) cytotoxic effect (Figure 3.1) on both 
the HEK293 and K562 cell lines compared to quinine, methylene blue was 25-fold more 
potent against P. falciparum parasites compared to quinine (Table 2.14). Methylene blue 
demonstrated the highest selectivity indices for P. falciparum (S.I.: 480, HEK293 cells; S.I.: 
968, K562 cells) compared to all the test compounds and more than 2-fold selective compared 
to quinine. However, the chemotherapeutic agent, camptothecin (IC50: 0.02 ± 0.01 µM, 
HEK293 cells; IC50: 0.04 ± 0.01 µM, K562 cells) was significantly (p < 0.05) more potent 
than methylene blue (Figure 3.1). In a previous study, Vennerstrom et al. (1995) reported a 
cytotoxic effect of methylene blue (IC50: 1.61 µM) on the KB cell line using the 
sulforhodamine B assay (derived from the human epidermoid carcinoma of the mouth) 
comparable to the cytotoxic effect observed on HEK293 cells (IC50: 1.92 ± 0.2 µM) in the 
current study.  
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The current study confirmed that methylene blue was selective for P. falciparum. In addition, 
methylene blue showed negligible haemolytic activity at a screening concentration of 100 µM 
(Table 2.5). Moreover, the spontaneous cycling of the oxidised and reduced methylene blue 
makes it an effective redox reagent for reducing cellular oxidative stress (Atamna and Kumar, 
2010). The latter chemical property has been taken advantage of in the management of 
methaemoglobinaemia and for the prevention of ifosfamide-induced encephalopathy 
(Schirmer et al., 2003; Atamna and Kumar, 2010).  
 
An open-label randomised controlled Phase II study in children (aged 6-10 years) with 
uncomplicated malaria, demonstrated the efficacy of methylene blue in accelerating parasite 
clearance in artemisinin-based therapies, as well as its tolerability after oral administration of 
methylene blue with artesunate (20 mg/kg: 4 mg/kg drug ratio daily) or methylene blue with 
amodiaquine (20 mg/kg : 10 mg/kg drug ratio daily) over a three day period (Zoungrana et al., 
2008). After more than a century since the antimalarial activity of methylene blue was first 
described, there has been a renewed interest in methylene blue as an antimalarial agent. The 
chemical structure of methylene blue may also serve as a template for the development of 
newer, safer and cheaper drugs, which can also be used synergistically or additively in 
combination therapy with other antimalarial drugs such as artemisinin or quinine. 
3.7.1.2 Safranin O 
Compared to quinine, safranin O was 14.69-fold and 7.53-fold more toxic to HEK293 and 
K562 cells, respectively (Figure 3.1). Although, camptothecin was significantly (p < 0.05) 
more cytotoxic to both HEK293 and K562 cells lines than safranin O. Vennerstrom et al. 
(1995) previously reported comparable cytotoxicity activity (IC50: 0.57 µM) for safranin O on 
KB epidermoid carcinoma cells, as compared to the cytotoxic effect on the HEK293 cells 
(IC50: 1.26 ± 0.89 µM) (Figure 3.1). The selectivity indices for P. falciparum were > 10 but 
significantly (p < 0.05) less than quinine. Importantly, safranin O and other phenazinium dyes 
have been found to bind and intercalate DNA strands selectively at guanine-cytosine 
nucleotide sequences with a higher affinity compared to the adenine-thymine nucleotides 
sequences, thus causing DNA breakage (Saha et al., 2010). In addition, replicating cells in the 
late S-phase or early G2-phase of the cell cycle are most susceptible to DNA intercalators 
compared to non-replicating cells which are more resistant (Ralph et al., 1983). In the current 
study safranin showed more toxicity to the transformed HEK293 epithelial cells than the 
K562 leukaemic cells, but less selective to P. falciparum when compared to quinine. 
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3.7.1.3 Mercury orange 
Mercury orange was 22.57-fold more toxic to HEK293 cells and about 2.48-fold more toxic 
to K562 cells compared to quinine. Although in comparison to camptothecin, mercury orange 
was 41-fold and 285-fold less toxic to HEK293 and K562 cells, respectively (Figure 3.1). 
Nevertheless, mercury orange showed significantly (p < 0.05) low selectivity indices 
compared to quinine and demonstrated poor selectivity for P. falciparum based on the 
selectivity index of HEK293 cells (S.I.: 1.2). Mercury orange was the only compound that 
demonstrated marked haemolysis against uninfected human RBCs in the current study (Table 
2.14). The K562 erythroleukaemic cell line has striking similarities to normal erythrocytes 
such as the cell surface glycoproteins, however mercury orange was about 13-times more  
toxic to the HEK293 cells than to the K562 cells (Andersson et al., 1979). The cytotoxicity 
mechanism of mercury orange may well be attributed to its chloro-mercuri reactive group. 
Mercury containing compounds denature proteins by breaking di-sulphide bonds in proteins 
and inactivate glutathione by binding to thiols, thus reducing the protective role of glutathione 
within the epithelial cells against oxidative stress (O'Connor et al., 1988; Byrns and Penning, 
2011). Amongst other pathologies, acute exposure to mercury salts leads to tubular necrosis in 
kidneys, often resulting in renal failure (Byrns and Penning, 2011). Although mercury salts 
were once used in anti-septics, anti-diuretics, skin-lightening creams and laxatives, they have 
since been replaced with safer and more effective drugs (Byrns and Penning, 2011).  
3.7.2 Selectivity of natural colourants for P. falciparum 
3.7.2.1 Curcumin 
Curcumin (diferuloylmethane), the active natural pigment of the rhizome of Curcuma longa, 
is well known for its diverse therapeutic actions including anti-inflammatory and anti-cancer 
properties (Bhaumik et al., 1999; Goel et al., 2008). Curcumin showed a significantly more 
potent (p < 0.05) cytotoxic effect (IC50 range: 0.26-1.37 µg/ml) on both the HEK293 and 
K562 cell lines compared to quinine (IC50 range: 6.7-10.2µg/ml) (Figure 3.2). Compared to 
camptothecin, curcumin was significantly (p < 0.05) less cytotoxic against both HEK293 and 
K562 cells lines, although curcumin showed a potent cytotoxic IC50 < 1µg/ml against the 
K562 cells. The current study showed that curcumin was poorly selective (S.I.: 0.6 and 0.1, 
HEK293 and K562 cells, respectively) for P. falciparum and toxic to human cells (Figure 
3.4). Curcumin has been found to have both anti-oxidant and pro-oxidant properties 
depending on its concentration (Cui et al., 2007). For instance in P. falciparum parasites, 
curcumin was found to slightly reduce ROS levels at concentrations less than 1 µM and 
promoted ROS levels at higher concentrations. In addition, it has been suggested by Cui et al. 
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(2007) that P. falciparum parasites are more sensitive to curcumin than mammalian cells, 
since the induction of ROS has been found to be a major effector of curcumin in killing 
malaria parasites. The pro-apoptotic, anti-oxidant and anti-inflammatory characteristics of 
curcumin are however, implicated in its anticancer activity (Parsai et al., 2014). For instance, 
in vitro studies by Parsai et al. (2014) have identified several enzymes such as: aldo-keto 
reductase family 1 member B10, serine/threonine-protein kinase, protein kinase C, matrix 
metalloproteinase, cyclooxygenase and epidermal growth factor receptor, to be involved in 
the initiation and progression of cancer as targets for curcumin. 
 
Curcumin has been found to be safe in humans and tolerated at high doses. For instance, in a 
Phase I clinical trial involving 25 adults, up to 8 g/day was administered for three months to 
patients with pre-malignant lesions without any toxic side-effects (Chen et al., 2001; 
Nandakumar et al., 2006). The mean peak serum concentration was 1.77 ± 1.87 µM, 
occurring 1-2 hours after oral intake of the effective dose, and urinary excretion of curcumin 
was undetectable. The results of the latter study, suggested a chemopreventative effect of 
curcumin on cancer (Chen et al., 2001). The main disadvantages of curcumin are its chemical 
instability (under neutral and basic pH conditions), poor aqueous solubility and low systemic 
bioavailability (Nandakumar et al., 2006; Goel et al., 2008; Parsai et al., 2014). However, 
curcumin’s efficacy against P. berghei has been shown to improve when delivered in a 
liposomal formulation (Nandakumar et al., 2006). 
3.7.2.2 Carbon black 
Carbon black showed significantly (p < 0.05) higher cytotoxicity against the K562 cell line 
(IC50: 1020 ± 210 µg/ml) compared to the HEK293 cell line (IC50: 630 ± 180 µg/ml) (Figure 
3.2), but was significantly (p < 0.05) less cytotoxic compared to camptothecin, curcumin and 
quinine. However, carbon black still showed significantly (p < 0.05) better selectivity indices 
(S.I.: 27.8, 44.9 for HEK293 and K562, respectively) on both cell lines compared to curcumin 
(Figure 3.4).  The potential mode of action involved is not clear, but the IARC has classified 
carbon black under group 2B category, meaning that it is a possible carcinogenic to humans 
(Wellmann et al., 2006). Carbon black or vegetable black is an EU approved food colourant 
(E153) derived from carbonised plant material of vegetable origin (European Food Safety 
Authority, 2012). However, benzo[α]pyrene, a polycyclic aromatic hydrocarbon found in 
carbon black, charred food, environmental and tobacco smoke can be enzymatically 
metabolised into mutagenic and highly carcinogenic metabolites possibly associated with 
colon and lung cancers (Denissenko et al., 1996; Le Marchand et al., 2002; Jiang et al., 2007).  
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In the current study, the selectivity indices were 2 to 4-fold higher than the cut-off selectivity 
index of 10, indicating a reasonable selectivity for P. falciparum compared to human cell 
lines. The measurement of benzo[α]pyrene content in the carbon black test compound was 
outside the scope of the project. 
3.7.3 Selectivity of nucleoside analogues for P. falciparum 
The nucleosides analogues, JLP093 (IC50: 10 ± 0.9 µM) and JLP118.1 (IC50: 9.8 ± 1.6 µM) 
demonstrated comparable cytotoxicity to each other on the HEK293 cell line. However, 
JLP118.1 (IC50: 8.4 ± 0.5 µM) was significantly (p < 0.05) more cytotoxic on the K562 cell 
line than JLP093 (IC50: 22.8 ± 0.8 µM) (Figure 3.3). Overall, both nucleoside analogues were 
more cytotoxic than quinine, but significantly (p < 0.05) less cytotoxic compared to 
camptothecin. The selective indices of both nucleoside analogues were < 10 and significantly 
(p < 0.05) poorly selective (37 to 109-fold less selective towards P. falciparum) compared to 
quinine, which showed more selectivity or toxicity towards the parasites than the cell lines 
(Figure 3.4). A potential mode of action would be the interference of DNA synthesis. 
Nucleoside analogues are closely related to normal intermediates or precursors metabolised in 
DNA synthesis and therefore can act as anti-metabolites (Neal, 2005). These agents exert their 
cytotoxic activity by incorporating into and altering DNA and RNA. Nucleoside analogues 
interfere with the function of various enzymes, such as DNA polymerases, ligases and 
endonucleases, involved in synthesis of nucleic acids (Galmarini et al., 2002). This 
contributes to the hypothesis of DNA synthesis inhibition in human cells. In addition, 
nucleoside analogues require specialised nucleoside transporter proteins to enter the cell 
(Galmarini et al., 2002; King et al., 2006). Mammalian cells express nucleoside transporters 
that have been associated with drug transport and activity of nucleoside analogues (Galmarini 
et al., 2002). Intracellular penetration or accumulation of nucleosides may be directly affected 
or limited by the level of expression of nucleoside transport facilitating proteins such as the 
hENT1 protein (Galmarini et al., 2002). 
  
The most active of the nucleoside analogues tested in the current study, the purine-derived 
JLP118.1, exerted its effect on the trophozoite stage of the parasite, where DNA synthesis is 
elevated (Table 2.12). However, other purine analogues such as fludarabine  have cytotoxic 
effects on non-dividing cells, but preferentially target the cells’ DNA repair mechanism 
(Galmarini et al., 2002). 
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3.7.4 Selectivity of imidazopyridine analogues for P. falciparum 
The imidazopyridine analogues: IP-3 (IC50: 9.15 ± 1.5 µM), IP-4 (IC50: 9.14 ± 1.1 µM), and 
IP-7 (IC50: 5.28 ± 0.9 µM) were significantly (p < 0.05) more cytotoxic on HEK293 cells than 
the K562 cells, whilst IP-5 showed consistent cytotoxic effect on both cell lines (IC50: 9.91 ± 
1.3 µM, HEK293 cells; IC50: 9.6 ± 0.5 µM, K562 cells) (Figure 3.3). Of all the 
imidazopyridine analogues, IP-7 showed the lowest selective indices, indicating poor 
selectivity for P. falciparum compared to human cancer cell lines. All the imidazopyridine 
analogues were significantly (p < 0.05) less cytotoxic compared to camptothecin, but more 
cytotoxic than quinine. The imidazopyridine analogues demonstrated poor selectivity for P. 
falciparum with S.I. values < 1, significantly less than quinine (S.I.: 180-458) (Figure 3.4). 
The known pharmacological activity of imidazopyridine analogues is very diverse with their 
activities including the inhibition of enzymes involved in cell cycle regulation, receptor 
ligands of eukaryotic cells, anti-viral and anti-protozoal activity (Enguehard-Gueiffier and 
Gueiffier, 2007; Jones et al., 2008). Some imidazopyridine analogues inhibit cyclin-
dependent kinases, in particular CDK2 and have progressed to clinical trials (Jones et al., 
2008). In an in vitro study by Dahan-Farkas et al. (2011) using the tetrazolium dye assay, a 
range of 6-subtituted imidazo[1,2α]pyridines were able to induce apoptosis in HT-29 and 
Caco-2 colon cancer cell lines after a 24 hr exposure. Moreover, the anti-proliferative activity 
(IC50 values) of the imidazo[1,2α]pyridines against the HT-29 and Caco-2 cell lines ranged 
from 6-22 µM (Dahan-Farkas et al., 2011), comparable to the cytotoxicity activities against 
both the HEK293 and K562 cell lines which ranged from 5-17 µM (except for IP-7 
cytotoxicity on K562 cells), observed in the current study (Figure 3.3). 
 
Overall, methylene blue showed the highest S.I. values demonstrating high selectivity for P. 
falciparum and cytotoxicity effects comparable to safranin O. The natural curcumin colourant, 
was very potent against both the HEK293 and K562 cell lines, and showed potential 
anticancer activity. Carbon black was significantly less cytotoxic and showed selective 
indices 278 to 449-times higher than curcumin. The nucleoside analogues demonstrated poor 
selectivity for P. falciparum (S.I. values < 10), whilst, the imidazopyridine analogues were 
the most poorly selective compounds (S.I. values < 1). 
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Chapter 4 Potential inhibition of PfNek-4 protein kinase by test 
compounds 
4.1 Introduction 
Gametocytes, which are the initial stages of the sexual cycle of P. falciparum, are responsible 
for its transmission back to the mosquito vector from the human host. The latter is critical for 
the maintenance of the malaria life-cycle between host and vector (Drakeley et al., 
2006).Preventing parasite transmission between host and the mosquito vector is recognised as 
a potential strategy to control malaria (Doerig et al., 2010). All the merozoites from a schizont 
are committed to either the sexual or asexual pathway (Doerig and Meijer, 2007; Dixon et al., 
2008). Protein kinases play a key role in regulation of the parasite developmental life-cycle 
and have been identified as possible drug targets (Doerig et al., 2010). Analysis of the 
Plasmodium kinome revealed divergence compared to the counterpart enzymes found within 
the human host, in terms of amino acid sequence and biochemical properties (Doerig and 
Meijer, 2007). Never-in-mitosis Aspergillus nidulans (NIMA)-related kinase, PfNek-4, has 
been identified and is postulated to regulate gametocytogenesis and the maturation of the 
zygote of the P. falciparum parasite (Reininger et al., 2012). PfNek-4 is a serine/threonine  
protein kinase, consists of 310 amino acids, has a molecular mass (Mr) of 36.35 kDa, and an 
isoelectric point of 9.7 (Reininger et al., 2009). 
4.1.1 Catalytic activity of protein kinases 
Protein kinases are critical in the regulation of biochemical processes in eukaryotic cells, 
including cell growth, enzymatic activity, gene expression, metabolism, motility, membrane 
transport, apoptosis and cell signalling (Pollard and Earnshaw, 2004; Alberts et al., 2008c). 
Phosphorylation can either activate or inhibit specific proteins involved in cellular processes.  
In eukaryotes phosphorylation occurs on serine, threonine or tyrosine residues or side chains. 
When linked in series, different kinases form a signalling cascade that amplifies a response to 
a stimulus (Pollard and Earnshaw, 2004). The catalytic domain (Figure 4.1) of eukaryotic 
protein kinases is conserved across species and has highly conserved amino acids and motifs 
(Hanks, 2003). 
 
The catalytic domain of eukaryotic protein kinases (ePK’s) (Figure 4.1) is characterised by a 
highly conserved amino acids distributed in 12 subdomains (Hanks and Hunter, 1995; Hanks, 
2003). The three glycine (G) residues in subdomain I form a hairpin-like structure which 
encloses part of the ATP molecule (Hanks, 2003). A lysine (K) residue in subdomain II, 
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orientates the ATP molecule through contacts with the α- and β-phosphates (Hanks, 2003). A 
glutamate (E) residue in subdomain III forms a salt bridge with the G residue in subdomain I 
(Hanks, 2003). Aspartate (D) and asparagine (N) residues are found within the signature motif 
of ePKs in subdomain VIB, where D is suggested to be the catalytic residue acting as a base 
acceptor (Hanks, 2003). The D residue in the DFG motif of subdomain VII, binds to the 
magnesium (Mg2+) or manganese (Mn2+) cation associated with ATP (Hanks, 2003). Whereas 
the E residue in subdomain VIII, forms a salt bond with the arginine (R) in subdomain XI 
which provides structural stability of the carboxyl (C)-terminal lobe (Hanks, 2003). The D 
residue in in subdomain IX is involved in stabilising the catalytic loop of subdomain IV 
through hydrogen bonds with the backbone (Hanks, 2003).  
 
 
Figure 4.1 The catalytic domain of eukaryotic protein kinases consisting of 12 conserved 
subdomains (adapted from Hanks, 2003).The 12 conserved subdomains are indicated by Roman 
numerals. The positions of amino acid residues and motifs highly conserved throughout the eukaryotic 
protein kinase superfamily are indicated above the subdomains, using the single-letter amino acid code 
with “x” as any amino acid. Important for catalytic function are the invariant K (lysine) in subdomain 
II and the invariant aspartate in subdomain VII that function to anchor and orient ATP, and the 
invariant aspartate in subdomain VIB which is the catalytic base in the phosphotransfer reaction. G, 
glycine; E, glutamine; D, aspartate; N, asparagine; F, phenylalanine; A, alanine; P, proline; R, 
arginine(Hanks, 2003). 
 
4.1.2 PfNek-4 and the P. falciparum sexual cycle 
Once committed, the gametocytes undergo five distinct morphological stages (Figure 4.2). 
Only once the gametocytes have reached maturity stage (after 9-23 days depending on the 
species) can they undergo sexual reproduction after being taken up by the feeding mosquito 
(Dixon et al., 2008). A study using green fluorescent protein (GFP) reporter, detected the 
expression of the GFP-fused PfNek4 in stages II to V of the gametocytes (Figure 4.2), as well 
as in asexual erythrocytic stage parasites undergoing schizogony, suggesting involvement in 
both stages (Reininger et al., 2012).  
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Figure 4.2 P. falciparum erythrocytic stage gametocytes development (adapted from 
Dixon et al., 2008). Stages I-II: early stage gametocytes are morphologically indistinguishable from 
ring stage asexual parasites; stages II-III: gametocytes become elongated due to the formation of a 
network of polar microtubules; stages III-IV: gametocytes have the characteristic crescent shape of the 
P. falciparum gametocyte; stage V: gametocytes lose the polar microtubule network and become more 
rounded, assuming a ‘sausage’ shape; M-stage: mosquito stage gametes before egress from the RBCs. 
The male gametes (microgametes) have flagella. Red = RBCs, blue and grey = parasite and brown = 
haemozoin deposits (Dixon et al., 2008). 
 
4.1.3 Plasmodium NIMA-related kinases and the sexual cycle completion 
The kinome analysis of P. falciparum has revealed a cluster of structurally related serine-
threonine kinases belonging to the Nek family (Doerig et al., 2008). The NIMA-related kinase 
(Nek) family is represented by four members in the P. falciparum kinome, PfNek-1 to 4 
(Doerig et al., 2008). PfNek-1 clusters within the Aspergillus NIMA/human Nek-2 branch in 
phylogenetic trees however this orthology cannot be confirmed with the other three PfNek 
enzymes (Doerig et al., 2008; Reininger et al., 2009). In addition, PfNek-1 is expressed in 
both asexual and sexual stages of the plasmodium development cycle. In contrast, mRNA 
encoding for PfNeks 2, 3 and 4 are exclusively detectable in gametocytes, suggesting a 
possible role in the sexual development of the parasite (Reininger et al., 2009). The P. berghei 
orthologue of PfNek-1, PbNek-4, is only present in male gametocytes and has shown to be 
essential in ookinetes maturation (Doerig et al., 2008).  Previous studies have indeed 
confirmed this theory where P. berghei, rodent malaria parasites, lacking the Nek-4 enzyme 
were unable to complete the DNA replication cycles in the zygote before meiosis (Reininger 
et al., 2009). There is sufficient evidence to suggest that cell cycle progression in the zygote is 
identified as a precondition for its morphological transition to the ookinete and for the 
successful  malaria infection in the mosquito (Reininger et al., 2009; Doerig et al., 2010). 
However, in a recent study, PfNek-4 has been found that it is not strictly gametocyte-specific, 
and is expressed in a small subset of asexual parasites displaying high rate of conversion to 
sexual development (Reininger et al., 2012). In addition, PfNek-4 is not responsible for 
switching erythrocytic schizogony to gametocytogenesis, but rather a molecular marker of 
sexually committed schizonts (Reininger et al., 2012). The identification of compounds that 
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can potentially inhibit PfNek-4 activity may further elucidate the role of PfNek-4 in the P. 
falciparum sexual as well as asexual life cycle. 
4.2 Aim 
The aim was to determine the effect of the most active compounds on the kinase activity of 
recombinant PfNek-4. 
4.3 Methodology 
4.3.1 PfNek-4 expression plasmid 
An expression plasmid containing the full-length PfNek-4 gene was a gift form Dr Luc 
Reininger and Professor Christian Doerig (INSERM U609, Wellcome Centre for Molecular 
Parasitology, University of Glasgow, Glasgow G12 8TA, Scotland, U.K.). Competent 
Escherichiacoli (BL21 strain) cells were transformed with the pGEX-PfNek-4 plasmid by Dr 
L.J. Harmse (University of the Witwatersrand) (Biosafety clearance: 201220701, Appendix 
B4). The pGEX-PfNek-4 plasmid codes for a PfNek-4 protein, fused to glutathione S-
transferase (GST). The predicted molecular weight of the GST-PfNek-4 fusion protein was 
62.35 kDa. The GST-fusion protein was constructed by enzymatically inserting the PfNek-4 
gene into the multiple cloning site of the pGEX-4T-3 vector containing the GST gene 
upstream of the PfNek-4 gene, and the ampicillin-resistant gene (downstream) as described by 
Reininger et al. (2009). Expression in the PfNek-4 GST fusion protein is regulated by a tac 
promoter , which can be induced by the lactose analogue, isopropyl β-D thiogalactoside 
(IPTG) (Studier, 2005). An internal lacIq gene encodes for a repressor protein that binds to the 
operator region of the tac promoter, preventing target protein expression until induction by 
IPTG. The pGEX-4T-3 vector has been engineered so that the GST can be cleaved from the 
fusion protein by digestion with site-specific thrombin protease (Smith and Johnson, 1988). 
4.3.2 2YT broth preparation 
Plasmid containing E. coli bacterial culture was grown in double-strength yeast and tryptone 
(2YT) broth according to methods described by Sambrook, et al. (1989). The broth was 
prepared to 1 litre with 16 g Bacto-tryptone, 10 g Bacto-yeast extract and 5 g NaCl dissolved 
in Milli-Q® water and sterilised by autoclaving. All media was stored at 4°C until use. Before 
use of the broth, carbenicillin was added as a selector to a final concentration of 50 µg/ml. 
4.3.3 Preparation of carbenicillin selector agar plates 
The agar solution was prepared by adding 12 g agar to 1 litre 2YT broth, followed by stirring 
to disperse the agar, sterilised by autoclaving for 10 min at 121°C and allowed to cool down 
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to 60°C (Sambrook et al., 1989). Carbenicillin was added to a final concentration of 50 µg/ml 
to the agar selector plates (carbenicillin-positive) to permit only ampicillin-resistant bacterial 
colonies to grow (Sambrook et al., 1989). The agar solution was allowed to cool and solidify 
in a laminar flow cabinet before replacing the lids. The agar plates were stored inverted, at 
4°C in sealed plastic bags in order to prevent dehydration. Carbenicillin was used instead of 
ampicillin because it is more resistant to β-lactamase produced by E. coli bacteria.  
4.3.3.1 Overnight culture preparation 
Pre-warmed (37°C) 2YT broth (5 ml) was transferred to culture tubes and inoculated with E. 
coli BL21 (DE3) thawed stock cultures containing the plasmid constructs. A control tube 
containing the 2YT broth only was included. The cultures were grown overnight (16-18 h) at 
37°C in a shaking incubator (200 rpm). 
4.3.3.2 Inoculation of agar plates 
In order to obtain isolated colonies on the agar plate, the standard streak technique commonly 
applied in microbiology was used (Sambrook et al., 1989). Carbenicillin-negative plates were 
used as a positive control. The plates were sealed, inverted and incubated overnight at 37°C 
and then stored at 4°C.  
4.3.4 Expression of GST-PfNek-4 fusion protein 
4.3.4.1 Induction of GST-fusion protein expression 
The principle of induced protein expression is based on the inactivation of the repressor 
protein, lacIq, bound to the tac promoter. Adding a lactose analogue, IPTG, during the log 
phase of bacterial growth, allows RNA polymerase to bind to the tac promoter, and 
expression of the genes which synthesise the GST-fusion protein (Sambrook et al., 1989; 
Studier, 2005). Protein expression was induced with the addition of IPTG (1 mM, final 
concentration) to a culture in the log phase of growth. A 10 mM stock of IPTG was prepared 
in Milli-Q® water, sterile filtered and stored frozen. The 2YT broth (100 ml) supplemented 
with carbenicillin (50 µg/ml), was inoculated with 100 µl overnight cultures grown from 
single colonies harvested from the agar selector plates. The cultures were grown for 4 h at 
37ºC and shaken at 200 rpm, until the culture reached optical density at 600 nm (OD600) of 
0.5-0.7, which indicated that the bacterial growth was in log phase. Protein expression was 
induced by adding IPTG to a final concentration of 1 mM to the cultures and further 
incubation overnight (15-18 h). 
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4.3.4.2 Harvesting of bacteria  
Bacteria were harvested by splitting the cultures into two 50 ml tubes and centrifugation at 
421 x g for 5 min at 4ºC and the supernatant discarded. The bacterial cells were re-suspended 
and washed twice with PBS, and the supernatant discarded. 
4.3.4.3 GST-PfNek-4 fusion protein purification by affinity chromatography 
The packed bacterial cells were re-suspended in complete BugBuster® Master Mix (Novagen) 
protein extraction reagent (5 ml per gram of wet cell paste), supplemented with 
phenylmethanesulfonyl fluoride (phenylmethanesulfonyl fluoride (PMSF), Sigma-Aldrich) 
and a single Complete™ tablet (Roche) that contained a cocktail of protease inhibitors. 
Protease inhibitors are required to prevent degradation of the isolated target protein by 
proteolytic enzymes once the bacteria are lysed. The cell suspension was incubated on a 
rotating mixer at room temperature. The bacterial lysate was centrifuged at 10 528 x g for 30 
min at 4ºC in 15 ml culture tubes to remove insoluble cell debris. The soluble extract 
(supernatant) was transferred into clean 15 ml culture tubes using a pipette and the pellet 
discarded. A sample (60 µl) of soluble extract was transferred into microcentrifuge tubes and 
mixed with 40 µl sample loading buffer for later analysis by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) (Section 4.3.5.1). 
 
GST-fusion proteins were purified from the soluble extracts by affinity chromatography using 
glutathione immobilised to a Sepharose matrix (Amersham-Biosciences, 2002). GST-PfNek-4 
fusion proteins bind to the beads, allowing purification of the GST-PfNek-4 proteins by 
centrifugation and several washing steps as discussed below (Amersham-Biosciences, 2002). 
The Glutathione Sepharose™ 4B beads (Amersham) suspension (133 µl) were washed three 
times by centrifugation (SANYO® MSE centrifuge) at 284 x g for 1 min with 1 ml PBS and 
then loaded directly to 5 ml of soluble bacterial lysate.  
 
The lysates and beads were incubated at 4ºC overnight on a blood tube rotator to bind the 
GST-PfNek4 fusion protein to the Sepharose beads. The lysates were centrifuged at 284 x g 
for 2 min to sediment the Sepharose beads and the supernatant was discarded. This was 
repeated three times. The GST-fusion protein was eluted from the Sepharose beads using 200 
µl of elution buffer which consisted of 40 mM reduced glutathione in 50 mM Tris, pH 8.0 and 
the sepharose bead suspension centrifuged at 284 x g for 2 min before use of the eluates and 
stored at 4ºC in microcentrifuge tubes. 
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4.3.5 Analysis of the GST-PfNek-4 protein 
4.3.5.1 SDS-polyacrylamide gel electrophoresis 
The purified GST-tagged PfNek-4 protein samples were analysed by discontinuous SDS-
PAGE (Laemmli, 1970). In principle, SDS confers a negative charge to denatured proteins 
which then separate in the gel matrix according to their molecular weights. (Sambrook et al., 
1989). These proteins migrate within a moving boundary of leading high-mobility chloride 
ions (Cl-) and trailing glycine ions (Gly-), created by an electric current passed between the 
negative cathode and positive anode electrodes (Sambrook et al., 1989). The SDS-polypeptide 
complexes then concentrate into a very thin stack of on the surface of the resolving gel. The 
higher pH of the resolving gel increases the charge of Gly- ions that migrate past the stacked 
polypeptides and travel through the resolving gel. The polypeptides move through the 
resolving gel in a zone of uniform voltage and pH and separate according to size by sieving. 
The ability of the discontinuous stacking and resolving buffer systems to concentrate all the 
polypeptide complexes into a small volume greatly increases the resolution of SDS-PAGE 
gels. (Laemmli, 1970; Sambrook et al., 1989). 
• Preparation of SDS-Polyacrylamide gels 
The SDS-PAGE discontinuous gel system consisted of a 12% resolving gel overlayed by a 
5% stacking gel. The resolving gel was buffered to  pH 8.8 with 1.5 M Tris and the stacking 
gel to pH 6.8 with 0.5 M Tris using 12% (v/v) HCl. Both stacking and resolving gels were 
prepared using Milli-Q® water and contained 30% (w/v) total acrylamide (Bio-Rad 
Laboratories), 2.7% (w/v) bisacrylamide (Bio-Rad Laboratories), 10% SDS (Sigma-Aldrich), 
10% ammonium persulfate (Bio-Rad Laboratories) and N,N,N′,N′-tetramethylenediamine 
(TEMED, Promega). TEMED accelerates the polymerisation of acrylamide and bisacrylamide 
by catalysing the formation of free radicals from ammonium persulfate (Sambrook et al., 
1989). The gels were cast on a vertical casting apparatus (Bio-Rad Laboratories) and allowed 
to polymerise.  
• Protein sample loading and running the gel 
Proteins were denatured by heating protein extract samples in SDS gel-loading buffer 
(100mM dithiothreitol or DTT, 2% w/v SDS, 0.1% w/v bromophenol blue, 10% v/v glycerol 
in 50 mM Tris, pH 6.8). Heating protein samples in SDS, confers a negative charge to the 
polypeptide backbone (Sambrook et al., 1989). DTT, a reducing agent, further denatures the 
protein sample by reducing the disulphide bonds preventing tertiary folding and denaturing 
quaternary structures. The eluted protein samples (20 µl) were mixed with 10 µl loading 
buffer in labelled microcentrifuge tubes and kept on ice. Milli-Q® water (300 ml) was brought 
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to a boil in a glass beaker and protein samples were denatured in the boiling water for 5 min 
and returned to ice for 10 min to prevent re-folding of the linear, polypeptide. Protein samples 
(10 µl per well) were loaded into the gel assembly mounted onto a Bio-Rad mini-gel 
electrophoresis tank filled with electrophoresis buffer (0.025 M Tris pH 8.3, 0.192 M glycine, 
0.1%  w/v SDS), and pre-cooled to 4°C. The gel was run at 200 Volts until the bromophenol 
blue tracking dye reached the bottom of the gel. Thereafter, the glass plates were removed and 
pried apart using a clean plastic wedge (Bio-Rad Laboratories). The orientation of the gels 
was marked by cutting from the bottom-right corner of the gel. Two gels were run 
simultaneously: the one gel was equilibrated for Western blotting whilst the other gel was 
routinely stained with coomassie blue. 
4.3.5.2 Coomassie blue gel staining 
The gels were fixed and stained by immersion into Coomassie blue staining solution (0.125% 
w/v Coomassie blue R-250, 50% v/v methanol, 10% v/v acetic acid) for 2 h with gentle 
agitation (Sambrook et al., 1989). The Coomassie stain solution was filtered through 
Whatman® grade 2 filter papers before use. The gels were placed in 20 ml destain solution-I 
(50% v/v methanol, 10% v/v acetic acid) and thereafter in destain solution-II  (7% v/v acetic 
acid, 5% methanol) for 1 h in each, in order to visualise the protein bands on the gel. 
4.3.5.3 Western blotting of separated proteins 
Western blotting, as described by Towbin et al. (1979), is an electrophoretic technique used to 
detect specific proteins immobilised on a membrane by using antibodies as probes (Sambrook 
et al., 1989). The technique, frequently referred to as immunoblotting, involves the transfer of 
proteins separated by SDS-PAGE to an adsorbent membrane like polyvinylidene fluoride 
(PVDF) or nitrocellulose, forming a replica of the SDS-polyacrylamide gel. The proteins 
immobilised on the membrane are then detected using enzyme-labelled or radiolabelled 
antibodies specific to the protein antigen (Towbin et al., 1979). Therefore, the aim of assaying 
the proteins using the Western blotting technique was to confirm if the PfNek-4 GST-tagged 
protein band identified by size and mobility during SDS-PAGE is the protein of interest by 
probing with an anti-GST antibody conjugated to horse-radish peroxidase enzyme (Kurien 
and Scofield, 2006).  
• Post-electrophoresis wet protein transfer 
Following electrophoresis the unstained SDS-polyacrylamide gel was equilibrated in transfer 
buffer (48 mM Tris, pH 8.3, 39 mM glycine, 0.1% SDS and 20% v/v methanol). At pH 8.3, 
the proteins would not blot or transfer to the membrane therefore 0.1% SDS was added to the 
transfer buffer to increase the negative charge of the denatured proteins. The PVDF 
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membrane (Millipore) was pre-wetted in 100% methanol before equilibration in transfer 
buffer. The PVDF membrane, two pieces of filter paper (cut to the size of the SDS-gel) and 
the two fibre pads were soaked in transfer buffer for 10 min. The gel “sandwich” (Figure 4.3) 
was assembled without trapping air bubbles. The assembly was transferred to the Mini-Trans 
Blot™ Cell (Bio-Rad Laboratories) with ice cold transfer buffer and a frozen cooling unit. 
The apparatus was placed on a magnetic stirrer and transfer took place at a constant voltage of 
100 Volts and 350 mA for at least 1 h. 
 
 
Figure 4.3 Assembly of the “gel-sandwich” for electrophoretic protein transfer to a 
PVDF membrane (Bio-Rad, 2013). 
 
• Blocking of the PVDF membrane 
In order to prevent unspecific binding of horse-radish peroxidase conjugated anti-GST 
primary antibodies, the membrane was incubated in 20 ml blocking buffer for 1 h at room 
temperature on a rocker (Sambrook et al., 1989). The blocking buffer contained 5% bovine 
serum albumin (BSA, Sigma-Aldrich) dissolved in Tris buffered saline-Tween-20 solution 
(TBST) prepared from 50 mM Tris, 150 mM NaCl, 0.1% (v/v) Tween-20, adjusted to a pH of 
7.5 using 12% HCl. 
• Immuno-detection 
The membrane was then washed once for 5 min with TBST followed by overnight incubation 
at 4ºC with HRP-conjugated goat anti-GST polyclonal antibodies (Amersham) diluted to 1:15 
000 by adding 2 µl antibody serum  in 30 ml blocking buffer, diluted to 2% (v/v) BSA in 
TBST. This was to allow the antibodies to bind to the GST-fusion protein that is immobilised 
on the membrane for visualisation later using chemiluminiscent detection. The membrane was 
washed 6 times for 10 min with 25 ml TBST in order to reduce the background. Filter paper 
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was used to blot excess reagent from the membrane before subjecting it to 
chemiluminiscence. 
• Chemiluminiscence 
The membrane was incubated for 60 seconds in 3 ml Western Lightning™ (Perkin-Elmer) 
chemiluminiscence reagent (luminol reagent and oxidising reagent mixed in 1:1 ratio). The 
principle of the method (Figure 4.4) is that the HRP-conjugated to the anti-GST antibody, 
oxidises the luminol substrate (whilst the oxidising agent is reduced), emitting blue 
luminescence (Sambrook et al., 1989). The chemiluminiscent signal was visualised by 
exposing the PVDF membrane to Hyperfilm®-MP multipurpose film (Amersham) for 
differential periods of 0.5, 1 and 2 min in a dark room. The film was developed at the 
Charlotte Maxeke Hospital, Radiography Department, using an automated X-ray processor. 
 
 
 
Figure 4.4 Chemiluminiscent visualisation of the GST-tagged proteins using horse-
radish peroxidase conjugated primary antibodies. HRP-conjugated anti-GST primary 
antibodies recognise and bind to a compatible GST site expressed on the target GST-tagged protein 
that was immobilised on the PVDF membrane. Once a chemiluminiscent substrate is added, the HRP 
enzyme oxidises the substrate. This oxidation reaction emits luminescent signal that can be detected 
and visualised by exposure to X-ray film.  
 
4.3.5.4 Determination of the protein molecular weight 
The MW of the expressed GST-tagged PfNek-4 protein was determined from the SDS-PAGE 
gel. The protein sample was separated alongside a set of MW Perfect™ protein standards 
(Qiagen) by electrophoresis. A linear graph of log MW versus relative migration distance, or 
retention factor (Rf), was generated, using GraphPad Prism (version 5.0) software. An r2 value 
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≥ 0.99 was regarded a significant correlation between the control variable (x-values) and 
response variable (y-values) and for interpolating y-values. The Rf values were determined 
from the ratio of the migration distance of the protein and the migration distance of dye front. 
The linear curve was described by the equation y = mx + c where, where y is the log MW, m 
is the slope, x is the Rf value, and c is the y-intercept. Therefore, in order to verify that the 
protein expressed was the correct size, the MW was calculated by expressing the linear 
equation as the anti-log of MW, such that MW = 10y. 
4.3.5.5 Determination of the protein concentration 
The concentration of the GST-fusion protein eluted from the GST Sepharose beads was 
determined by using the Bio-Rad Protein Assay, which is based on the dye-binding method 
and described by Bradford et al (1976). The Bradford assay involves a differential colour 
change of Coomassie blue-G dye as it binds to protein. Accordingly, the peak absorbance 
wavelength of the acidic Coomassie dye shifts from 465 nm to 595 nm when protein binding 
occurs.   Briefly, six dilutions of standard BSA between 200 and 1400 µg/ml were prepared in 
triplicates in Milli-Q® water. The protein standards and recombinant protein samples were 
mixed with the Bio-Rad dye reagent and incubated for 5 min at room temperature. The 
reaction solutions (1 ml) were transferred to a plastic cuvette and the absorbance of the 
protein-dye complex measured using a Perkin-Elmer™ UV-Visible spectrophotometer at a 
wavelength of 595 nm (Bradford, 1976). A standard curve of Abs595 versus concentration 
(µg/ml) of protein standards was constructed using GraphPad Prism 3.0 software program. 
The absorbance values of the recombinant protein samples were expressed in µg/µl using the 
standard curve and used to determine the amount of protein in the protein extracts prior to 
kinase assays. 
4.3.6 Kinase assay 
The kinase activity of GST-PfNek-4 was measured according to the method described by 
Reininger et al. (2009). The kinase assays were performed in a standard 30 µl reaction 
containing 20 mM Tris-Cl (pH 7.4), 20 mM MgCl2, 10 mM NaF, 10 mM glycerol 2-
phosphate, 2 mM MnCl2, 54 mg/ml casein from bovine milk as substrate, in the presence of 
10 µM ATP (reagents purchased from Sigma-Aldrich), 5 mCi/ml [γ-32P]-ATP (American 
Radiolabeled Chemicals) and 0.5-3 µg recombinant kinase (Table 4.1). Co-factors, MgCl2 and 
MnCl2, activate and enhance kinase activity, whilst NaF and glycerol 2-phosphate inhibit 
phosphatases. Non-radioactive labelled ATP was added as an additional substrate to prevent 
substrate depletion. The final concentration of the isotope in the 30 µl standard kinase 
reaction was 0.08 µCi/µl. The GST-PfNek-4 enzyme was exposed to final concentrations of 
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10 µM of the synthetic compounds or 10 µg/ml final concentrations of the natural compounds 
for 30 min at 37°C. The reaction was started by adding the GST-PfNek-4 enzyme last. 
Separate casein (without enzyme and test compound) and GST-PfNek-4 kinase (without test 
compound) controls were performed in order to detect kinase activity and incorporation of 32P 
into the casein substrate by phosphorylation. Standard precautions when working with 32P 
radioisotope were observed. The kinase reaction was terminated by adding 10 µl, SDS-
loading buffer (Section 4.3.5.1) and the reaction tubes placed on a pre-heated (100°C) metal 
heating block for 5 min to denature the protein. The reaction tubes were incubated on ice for 
10 min and 20 µl reaction samples were subjected to SDS-PAGE (Section 4.3.5.1). The gels 
were stained with coomassie blue and dried before exposure to Hyperfilm®-MP 
autoradiographic film (Amersham). 
 
Table 4.1 List of stock reagents and volumes of the 30 µl single kinase reaction solution. 
Stock reagents Volume 
20 mM Tris-Cl (pH 7.4) Kinase buffer  3 µl 
20 mM MgCl2 3 µl 
10 mM NaF 3 µl 
10 mM Glycerol 2-phosphate 3 µl 
2 mM MnCl2 3 µl 
54 mg/ml Casein substrate 0.5 µl 
0.5-3 µg Recombinant kinase 5 µl 
10 µM ATP a 0.5 µla 
100 µM or 100 µg/ml Test compound 3 µl 
5mCi/ml ATP [γ-32P] 0.5 µl 
Milli-Q® water 5.5 µl 
aNon-radioactive ATP was added to prevent limitation of the kinase reaction. 
• Drying of SDS-polyacrylamide gels and autoradiography 
SDS-polyacrylamide gels containing proteins radiolabelled with 32P were dried before 
autoradiography  to prevent quenching (Sambrook et al., 1989).The stained gels were placed 
and oriented on a piece of  Whatman™ paper and the gel was covered with plastic wrap. The 
sandwich of filter paper, gel and plastic wrap was placed on the gel dryer slab with the plastic 
wrap being the uppermost layer. The gels were dried under vacuum for 40 min at 50°C using 
the Slab Gel Dryer (Hoefer Scientific Instruments). The dried gels were removed from the 
dryer and the kinase activity was visualised by exposing the gels to Hyperfilm®-MP 
autoradiographic film (Amersham) overnight (16-18 h) in a dark room. The autoradiographic 
films were developed at the Charlotte Maxeke Hospital, Radiography Department, using an 
automated X-ray processor. 
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4.3.7 Plasmid isolation 
Plasmid DNA was isolated and purified from bacterial cells by using the QIAprep® Spin 
Miniprep Kit (Qiagen) by following the manufacturer’s instructions. The kit provided buffers 
optimized for efficient isolation of plasmid DNA and removal of contaminants from a pellet 
of bacterial cells. The RNAse enzyme activity was monitored by a colour change of Lyseblue 
indicator, from blue to colourless-cloudy appearance. The DNA was adsorbed to a silica-
membrane in spin-columns, whilst the contaminants passed through the column during 
centrifugation. Impurities were washed away, and the plasmid DNA was eluted into 
microcentrifuge tubes using nuclease-free water. 
4.3.8 Restriction digest of PfNek-4 containing plasmids 
A sample of plasmid (3 µl) was subjected to restriction digest master-mix solution (17 µl) 
with SalI and BamHI at 37°C for 3 h. The restriction digest master-mix solution was prepared 
with 138 µl nuclease-free water, 2 µl acetylated BSA and 20 µl buffer D (that consisted of 60 
mM Tris-Cl pH 7.9, 1.5 M NaCl, 60 mM MgCl2 and 10 mM DTT) (Promega). The restriction 
enzymes, SalI and BamHI (Promega) were added (5 µl each) into the restriction digest 
master-mix solution, with BamHI added last. The reaction was terminated by denaturing the 
restriction enzymes by heat-inactivation at 65°C for 15 min. The restriction products were 
analysed by agarose gel electrophoresis (Sambrook et al., 1989) or stored at -20°C. 
4.3.9 Agarose gel electrophoresis of restriction products 
Agarose gel electrophoresis as described by Sambrook et al. (1989) was used to analyse the 
products from the restriction digest of the plasmid. A 1.5% agarose gel was prepared by 
adding 0.45 g agarose (Promega) to 30 ml tris-acetate EDTA (TAE) buffer (40 mM Tris, 20 
mM acetic acid, and 1 mM EDTA, pH 8.0) and heating until the agarose was in solution. The 
gel mixture was heated in a microwave oven and swirled until all of the translucent agarose 
particles were dissolved. The molten agarose solution was allowed to cool to 50-60°C and 3 
µl of 1 µg/ml ethidium bromide (EtBr) was added and the gel solution mixed thoroughly 
before the gel was cast. EtBr intercalates DNA at the major grooves and under UV light, EtBr 
fluoresces giving an intense orange colour, thus allowing for visualisation of DNA.  
 
The agarose gel was cast in a horizontal agarose gel casting unit (Bio-Rad) with a 15-toothed 
plastic comb, and allowed to solidify. The gel was submerged in TEA buffer in the 
electrophoresis tank. Bromophenol blue tracking dye (2 µl) was added to restriction digest 
reaction samples (10 µl), control reactions, 50 base pair (bp) DNA ladder (1 µl) (New 
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England BioLabs). All the samples were loaded into the wells using a pipette. The gel was run 
at 25 Volts until the bromophenol blue tracking dye reached the end of the gel. 
4.3.10 DNA sequencing 
DNA sequencing involves establishing the order of nucleotides or deoxynucleotide 
triphosphates (dNTP) in the DNA fragment of interest. The most widely used DNA 
sequencing method, referred to as the chain termination method was earlier described by 
Sanger et al. (1977). In the current study, the sequencing of the full-length DNA sequence of 
the plasmids was outsourced to Inqaba Biotec. The aim was to verify the DNA sequence of 
the inserts and exclude any base sequence errors. Sequencing was performed using an ABI 
3500XL genetic analyser (Applied Biosystems), which is a fully automated, capillary 
electrophoresis instrument for high quality base calling, assembly and single base change 
detection. The ABI BigDye®Terminator V 3.1 Cycle Sequence kit (Applied Biosystems) 
containing primers, polymerases, fluorescent-dideoxynucleotides and deoxynucleotide 
triphosphates, in a 6:1 ratio, was used together with pGEX single primers (pGEX3: 
GGAGCTGCATGTGTCAGAGG; pGEX5: GGCAAGCCACGTTTGGTG). Agar plates 
containing single colonies of PfNek4-A and B clones were provided to Inqaba Biotec for 
plasmid isolation, primer design and automated sequencing. The resulting consensus DNA 
sequences were subjected to bioinformatics analysis. 
4.3.11 Bioinformatics 
The DNA sequence obtained from Inqaba Biotech was subjected to bioinformatic analysis to 
verify the integrity of the sequence. Nucleotide sequence alignment and the amino acid 
sequence prediction were performed in silico using the basic local alignment search tools 
(BLAST’s) designed by Altschul et al., (1990). BLAST’s are algorithms, that allow 
comparison and alignment of primary biological sequences of the molecule of interest such as 
proteins (by using blastp or blastx) or nucleotide sequences DNA  (by using blastn), against a 
library of sequences or database (Altschul et al., 1990). The query sequence was used as input 
in text format and the indexed library sequences can be accessed with an identifier number. 
Sequences showing similarity to the query sequence were reported in order of similarity 
scores, identity % and E-values. The native gene record was accessed by performing a text 
search on the PfNek-4 gene (identifier: PF3D7_0719200) from the PlasmoDB database 
(www.plasmodb.org). The National Centre for Biotechnology Information database 
(www.ncbi.nlm.nih.gov) provides access to biomedical and genomic information as well as 
BLAST tools. The consensus nucleotide sequence of PfNek4-A DNA was used to retrieve the 
amino acid sequence of the polypeptide chain by using blastx.  
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4.4 Results 
4.4.1 Expression of PfNek4 
The coomassie blue stained SDS gel (Figure 4.5) showed that IPTG-induced overnight protein 
expression at 37°C (lane 2), was much more efficient (demonstrated by the darker bands) 
compared to the IPTG-induced overnight protein expression at 30°C (lanes 3-6). The protein 
concentration yield from the expression induced overnight with 1mM IPTG at a higher 
temperature (37°C), was on average higher (1.7 µg/µl) compared to expressions carried out at 
30°C, which yielded on average, 1.3 µg/µl. SDS-polyacrylamide electrophoresis showed at 
least two distinct bands of proteins, which corresponded to the predicted sizes of the GST-
PfNek-4 and GST proteins. The smaller bands in lanes 2-6 are most likely truncated GST 
protein. The pGEX-4T-3 expression vector yields fusion proteins with the GST-tag on the 
amino-terminus and the protein of interest, in this case, PfNek-4 at the carboxyl-terminus.  
 
 
Figure 4.5 Coomassie blue-stained SDS-PAGE gel depicting the isolated GST-PfNek-4 
(clone A) protein bands alongside molecular weight markers. Lane1: non-induced control, 
lane 2: overnight IPTG-induced protein expression at 37°C, lanes 3-6: overnight IPTG-induced protein 
expression at 30°C and lane MW: Perfect™ protein standards (15-150 kDa). The isolated 26 kDa GST 
protein in all the lanes, suggest cleavage of the GST tag by the E. coli host enzymes from the fusion 
protein and/or basal level expressions from the lac. 
 
 
The linear curve (Figure 4.6) of log MW versus Rf was plotted by using the migration 
distances of the Perfect™ protein standards and of the expressed protein bands (GST-PfNek-4 
and GST) measured from the SDS-PAGE gel (Figure 4.5). The log MW values of the 
unknown protein were interpolated by applying the linear equation using Prism 5.0 software. 
The MW’s were calculated by expressing the linear equation as a function of the anti-log of 
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Y. The Rf values for Protein X (Rf = 0.23) and Protein Y (Rf = 0.88) were substituted into as 
x-values into the linear equation. The strong linear relationship (r2 > 0.99) between the 
proteins’ MW and Rf values demonstrates the reliability of the elucidated MW values of the 
expressed proteins. The calculated MW’s 61.26 kDa and 26.41 kDa, corresponded to the 
predicted sizes of the GST-PfNek-4 and GST proteins, respectively. 
 
0.0 0.5 1.0 1.5
0.0
0.5
1.0
1.5
2.0
2.5
r² = 1.0 GST
Rf
Lo
g 
M
W
 
(k
D
a) GST-PfNek-4 (clone A)
 
Figure 4.6 A linear curve of the log MW versus Rf values used to determine the MW of 
expressed proteins. 
 
4.4.2 Western blot 
Protein transfer to the PVDF membrane was successful by inclusion of 0.1% SDS in the 
transfer buffer, to confer a negative charge to the proteins. SDS is usually not added to the 
transfer buffer, however in this case the predicted isoelectric point (pI: 8.9) of the expressed 
GST-PfNek-4 fusion protein whilst the pH of the transfer buffer was 8.2, thereby reducing the 
nett charge on the GST-PfNek-4 fusion protein for effective protein transfer. Upon probing 
the expressed proteins, two GST-tagged proteins were detected on the PVDF membrane using 
polyclonal anti-GST HRP-conjugated antibodies, and visualised on the Hyperfilm®-MP films 
(Figure 4.7). In addition, GST (26.41 kDa) encoded by the Schistosoma japonicum gene 
(NCBI identifier: P08515.3) and GST-PfNek-4 (36.35 kDa) encoded by the gene 
PF3D7_0719200 (www.plasmodb.org), have been previously characterised and published. 
The expressed Protein Y (26.41 kDa) separated during SDS-PAGE, correlated with the GST 
protein detected on the Western blot. Therefore, by immuno-detection and arithmetic 
inference, Protein X (61.26 kDa), was confirmed to be the GST-PfNek-4 protein since its total 
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MW would include the GST protein: MWPfNek-4(34.85 kDa) = MWGST- PfNek-4 protein (61.26 kDa) 
- MWGST (26.41 kDa). 
 
 
Figure 4.7 Western Blot of the GST-PfNek4 (A) protein kinase. Lane1: non-induced sample 
control, lane 2: overnight IPTG-induced protein expression at 37°C, lanes 3-6: overnight IPTG-
induced protein expression at 30°C. The circled area in lane 1 showed a faint band with the same 
migration distance as the 61 kDa protein and a 26 kDa GST protein suggest cleavage of the GST tag 
by the E. coli host enzymes from the fusion protein and/or possible basal level expressions from the 
lac promoter. 
 
4.4.3 Protein concentration 
The concentration of the GST-PfNek4 protein expressed was determined using the Bio-Rad 
Protein Assay. The sample of the expressed protein used in the kinase assay gave a mean 
absorbance value of 1.19 at a wavelength of 595 nm. The Y-value (protein concentration), 
was interpolated from the standard curve (Figure 4.8) by entering the X-value 
(absorbance595nm = 1.19) in the data table in GraphPad Prism version 5.0. The kinase protein 
concentration value computed was 1.63 µg/µl. Therefore, taking into consideration a dilution 
factor of 7, the final amount of the GST-PfNek4 in the kinase assay reaction was 1.16 µg. The 
strong linear relationship (r2 = 0.99) between the absorbance595nm values and the 
concentrations (µg/ml) of the BSA protein standards demonstrated the reliability in predicting 
the concentration of the GST-PfNek4 (A) protein sample.  
117 
0 200 400 600 800 1000 1200 1400
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
r² = 0.99
Concentration (µg/ml)
Ab
so
r
ba
n
ce
59
5 
n
m
 
Figure 4.8 Standard curve of BSA protein standard concentrations and absorbance595nm 
values. 
4.4.4 Kinase activity and inhibition 
The kinase activity of the various GST-fusion protein kinase isolates were screened without 
the test compounds. The GST-PfNek4 fusion protein stained blue with coomassie blue on the 
SDS-PAGE gel. The phosphorylated casein substrate is demonstrated as a dark band on the 
autoradiograph (Figure 4.9).  
 
 
Figure 4.9 Kinase activity of various isolates of the recombinant GST-PfNek-4 protein 
kinase. Both the (a) Coomassie stained SDS-PAGE gel and the (b) autoradiogram of the coomassie 
stained gel: Lane 1: casein control; Lanes 2-5: various isolates of the recombinant GST-PfNek-4 
kinase with the casein substrate.  
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Figure 4.10 The kinase assays with most active compounds. Panels (a) Dried SDS-PAGE gel 
and (b) autoradiograph, Lane 1: casein control (without enzyme), lane 2: kinase control (without test 
compound). Panel (b), lane 3: methylene blue, lane 4: safranin O, lane 5: mercury orange, lane 6: 
JLP118.1, lane 7: JLP093, lane 8: Guanosine, lane 9: inosine, lane 10. Not shown are: carbon black, 
lane 11: curcumin, lanes 12-19: IP 1-8 and lane 20: quinine, which were on a separate gel.  
 
However at the time of performing the kinase inhibition assay, phosphorylation of the casein 
substrate was not visualised in the kinase control (lane 2: without test compound) suggesting 
that the isolated recombinant protein had no kinase activity (Figure 4.10a). The casein protein 
was visualised in the coomassie stained SDS-PAGE gel (Figure 4.10a), however there was no 
corresponding band in the autoradiograph (Figure 4.10b). This indicates that the GST-PfNek4 
recombinant protein kinase had no enzymatic activity. The kinase assay was repeated in three 
separate experiments using different GST-PfNek4 isolates, and all were inactive. 
4.4.5 Plasmid isolation and restriction analysis of PfNek4 
As a first step to determine the reason for the loss of kinase activity, plasmids were isolated 
from six different colonies and then subjected to restriction digest to allow analysis of the 
PfNek4 DNA insert. Restriction digests of isolated plasmid were carried out by exposure to 
BamHI and SalI restriction enzymes. Agarose gel electrophoresis of the product samples 
demonstrated the presence of a band corresponding to the size of the PfNek4 insert which is 
933 bp. Included was the undigested plasmid control which shows the undigested plasmid 
(Figure 4.11). Although the 50 bp low molecular DNA ladder electrophoresed along the 
plasmid extracts did not resolve well, the 1,350 bp and 916 bp high-intensity bands were 
visualised. PfNek4 DNA insert band with a predicted size of 933 bp was positioned between 
1,350 bp and 916 bp bands. The additional smaller fragments seen in Figure 4.11 (lanes 2-7) 
indicate potential “star” (non-specific) activity of the restriction enzymes or may be an 
indication of plasmid instability (Godiska et al., 2010). Although both BamHI and SalI were 
supplied with pH 7.4 buffers (25°C), the optimum pH levels for 100% activity are pH 8.0 for 
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BamHI and pH 7.5 for SalI at 37°C. The restriction digest reactions in the current study were 
performed at pH 7.9, 37°C. 
 
 
Figure 4.11 Agarose gel electrophoresis of plasmid extracts fragmented with site-specific 
restriction digest enzymes, BamHI and SalI. Lane1: 50 bp DNA ladder, lanes 2-4: PfNek-4 (A) 
plasmid restriction digest, lanes 5-7: PfNek-4 (B) plasmid restriction digests and lane 8: 100 bp DNA 
ladder undigested plasmid control, lane 9:  PfNek-4 (A) undigested plasmid control. 
 
4.4.6 Nucleotide sequence analysis 
Since the restriction digestion showed a band of the correct size of 933 bp, the DNA sequence 
of the insert and surrounding plasmid was determined. The plasmid was sequenced across the 
insert sites in order to determine if the reading frame of the PfNek-4 sequence was 
maintained. The PfNek-4 insert DNA nucleotide sequence was compared to the plasmid 
sequence as well as the published PfNek-4 complete coding sequence. The chromatographs 
(Appendix B4) show the nucleotide sequencing results of both PfNek-4 A and B clones 
produced by Inqaba Biotec. Consensus sequence data from both forward and reverse 
sequences of PfNek-4 (clones A and B) was edited and generated by Inqaba Biotec and was 
used for sequence analysis.  
 
The BLASTn results for the PfNek-4 (clone-A) nucleotide sequence (Figure 4.12) showed 
that the plasmid was inserted in the correct orientation with the start codon (ATG) in the 
correct position (23rd position, after the primer sequence). In addition the PfNek-4 (clone-A) 
insert sequence was 100% identical to the published sequence. The open reading frame (ORF) 
and restriction sites (BamHI and SalI) identified and annotated using the CLC Main 
Workbench (version 6.8.1) software, further confirmed that the PfNek-4 DNA insert was in 
frame (Figure 4.13). 
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Score Expect Identities Gaps Strand 
1724 bits(933) 0.0() 933/933(100%) 0/933(0%) Plus/Plus 
 
Clone-A  11   ATGAATAAATATGAAAAGATTAGAGATATAGGAAAAGGAAATTATGGAAATACAATACTT  70 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  1    ATGAATAAATATGAAAAGATTAGAGATATAGGAAAAGGAAATTATGGAAATACAATACTT  60// 
 
Clone-A  851  CCTTTAAAAGAAAAGCCAGCTATTGAAAATGAAAATTCAGGAGCCAACGAACAAGAAGTA  910 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  841  CCTTTAAAAGAAAAGCCAGCTATTGAAAATGAAAATTCAGGAGCCAACGAACAAGAAGTA  900 
 
Clone-A  911  AAAACATTACTTCTGGATGTTGTTGATACTTAA  943 
              ||||||||||||||||||||||||||||||||| 
PfNek-4  901  AAAACATTACTTCTGGATGTTGTTGATACTTAA  933 
 
Figure 4.12 Nucleotide sequence alignment of PfNek-4 (clone-A) consensus sequence. 
BLASTn results of PfNek-4 (clone-A) showing 100% alignment with the coding sequence of PfNek-4 
on the NCBI database. The pipe (|) shows nucleotide alignment. PfNek-4 (A) 5′ sequence showing 
ATG = start codon (1st position), TAA = stop codon (position 930). Results are truncated (//), the full 
results are shown in Appendix D1. 
 
 
 
Figure 4.13 Open Reading Frame showing the DNA insert of PfNek-4 (clone-A) and 
restriction sites. The restrictions sites for the PfNek-4 were BamHI and SalI. The start and stop 
codon are underlined in red. 
 
Similarly, PfNek-4 (clone-B) BLASTn results showed a 100% nucleotide sequence alignment 
with the coding sequence for PfNek-4 gene (Figure 4.14). The insert sequence was identified 
within the ORF (Figure 4.15). 
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Score Expect Identities Gaps Strand 
1724 bits(933) 0.0() 933/933(100%) 0/933(0%) Plus/Plus 
 
Clone-B  21   ATGAATAAATATGAAAAGATTAGAGATATAGGAAAAGGAAATTATGGAAATACAATACTT  80 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  1    ATGAATAAATATGAAAAGATTAGAGATATAGGAAAAGGAAATTATGGAAATACAATACTT  60// 
 
Clone-B  861  CCTTTAAAAGAAAAGCCAGCTATTGAAAATGAAAATTCAGGAGCCAACGAACAAGAAGTA  920 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  841  CCTTTAAAAGAAAAGCCAGCTATTGAAAATGAAAATTCAGGAGCCAACGAACAAGAAGTA  900 
 
Clone-B  921  AAAACATTACTTCTGGATGTTGTTGATACTTAA  953 
              ||||||||||||||||||||||||||||||||| 
PfNek-4  901  AAAACATTACTTCTGGATGTTGTTGATACTTAA  933 
 
Figure 4.14 Nucleotide sequence alignment of PfNek-4 (clone-B) consensus sequence. 
BLASTn results of PfNek-4 (clone-B) showing 100% alignment with the coding sequence of PfNek-4 
on the NCBI database. Results are truncated (//), the full results are shown in Appendix D2. 
 
 
 
Figure 4.15 Open Reading Frame showing the DNA insert of PfNek-4 (clone-B) and 
restriction sites. The restrictions sites for the PfNek-4 were BamHI and SalI. The start and stop 
codon are underlined in red. 
 
4.4.7 Protein sequence analysis 
The recombinant PfNek-4 (clone-A) nucleotide sequence was used to obtain the predicted 
amino acid sequence by using the basic local alignment search tools (BLASTx) tool on NCBI. 
PfNek-4 (clone-A) showed no mutations on the amino acid residues and showed 100% 
alignment with the P. falciparum Nek-4 protein kinase amino acid sequence ( 
Figure 4.16). The BLASTx results for clone-B (Figure 4.17) matched 100% identities and no 
mutations were identified on the amino acid residues.  
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Clone-A  11   MNKYEKIRDIGKGNYGNTILVRDRKNDHYVMKIINISQMSQKEKRQCLKEVELLSKLNHP  190 
              MNKYEKIRDIGKGNYGNTILVRDRKNDHYVMKIINISQMSQKEKRQCLKEVELLSKLNHP 
PfNek-4  1    MNKYEKIRDIGKGNYGNTILVRDRKNDHYVMKIINISQMSQKEKRQCLKEVELLSKLNHP  60 
 
Clone-A  191  FIVKYIESYIEGDTLRIVMKHCKGGDLYHYIQNKKKQNTPIKEKRILIWLTQILTALKFL  370 
              FIVKYIESYIEGDTLRIVMKHCKGGDLYHYIQNKKKQNTPIKEKRILIWLTQILTALKFL 
PfNek-4  61   FIVKYIESYIEGDTLRIVMKHCKGGDLYHYIQNKKKQNTPIKEKRILIWLTQILTALKFL  120 
 
Clone-A  371  HSNHILHRDMKSLNILIDSDKRVRLCDFGISKVLENTLDYANTLIGTPYYLSPELCKDKK  550 
              HSNHILHRDMKSLNILIDSDKRVRLCDFGISKVLENTLDYANTLIGTPYYLSPELCKDKK 
PfNek-4  121  HSNHILHRDMKSLNILIDSDKRVRLCDFGISKVLENTLDYANTLIGTPYYLSPELCKDKK  180 
 
Clone-A  551  YSWPSDVWATGCLIYELATFRTPFHSTKGIQQLCYNIRYAPIPDLPNIYSKELNNIYKSM  730 
              YSWPSDVWATGCLIYELATFRTPFHSTKGIQQLCYNIRYAPIPDLPNIYSKELNNIYKSM 
PfNek-4  181  YSWPSDVWATGCLIYELATFRTPFHSTKGIQQLCYNIRYAPIPDLPNIYSKELNNIYKSM  240 
 
Clone-A  731  LIREPSYRATVQQLLVSDIVQRQLKLLIEEKIREKQSMKKPLKEKPAIENENSGANEQEV  910 
              LIREPSYRATVQQLLVSDIVQRQLKLLIEEKIREKQSMKKPLKEKPAIENENSGANEQEV 
PfNek-4  241  LIREPSYRATVQQLLVSDIVQRQLKLLIEEKIREKQSMKKPLKEKPAIENENSGANEQEV  300 
 
Clone-A  911  K  913 
              K 
PfNek-4  301  K  301 
 
Figure 4.16 Alignment of translated amino acid sequence of clone-A to PfNek-4. The 
BLASTx results showed no mutations on amino acid residues. The amino acid sequence was 
represented in a single-letter amino acid code (Appendix E).  
 
Clone-B  21   MNKYEKIRDIGKGNYGNTILVRDRKNDHYVMKIINISQMSQKEKRQCLKEVELLSKLNHP  200 
              MNKYEKIRDIGKGNYGNTILVRDRKNDHYVMKIINISQMSQKEKRQCLKEVELLSKLNHP 
PfNek-4  1    MNKYEKIRDIGKGNYGNTILVRDRKNDHYVMKIINISQMSQKEKRQCLKEVELLSKLNHP  60 
 
Clone-B  201  FIVKYIESYIEGDTLRIVMKHCKGGDLYHYIQNKKKQNTPIKEKRILIWLTQILTALKFL  380 
              FIVKYIESYIEGDTLRIVMKHCKGGDLYHYIQNKKKQNTPIKEKRILIWLTQILTALKFL 
PfNek-4  61   FIVKYIESYIEGDTLRIVMKHCKGGDLYHYIQNKKKQNTPIKEKRILIWLTQILTALKFL  120 
 
Clone-B  381  HSNHILHRDMKSLNILIDSDKRVRLCDFGISKVLENTLDYANTLIGTPYYLSPELCKDKK  560 
              HSNHILHRDMKSLNILIDSDKRVRLCDFGISKVLENTLDYANTLIGTPYYLSPELCKDKK 
PfNek-4  121  HSNHILHRDMKSLNILIDSDKRVRLCDFGISKVLENTLDYANTLIGTPYYLSPELCKDKK  180 
 
Clone-B  561  YSWPSDVWATGCLIYELATFRTPFHSTKGIQQLCYNIRYAPIPDLPNIYSKELNNIYKSM  740 
              YSWPSDVWATGCLIYELATFRTPFHSTKGIQQLCYNIRYAPIPDLPNIYSKELNNIYKSM 
PfNek-4  181  YSWPSDVWATGCLIYELATFRTPFHSTKGIQQLCYNIRYAPIPDLPNIYSKELNNIYKSM  240 
 
Clone-B  741  LIREPSYRATVQQLLVSDIVQRQLKLLIEEKIREKQSMKKPLKEKPAIENENSGANEQEV  920 
              LIREPSYRATVQQLLVSDIVQRQLKLLIEEKIREKQSMKKPLKEKPAIENENSGANEQEV 
PfNek-4  241  LIREPSYRATVQQLLVSDIVQRQLKLLIEEKIREKQSMKKPLKEKPAIENENSGANEQEV  300 
 
Clone-B  921  K  923 
              K 
PfNek-4  301  K  301 
 
Figure 4.17 Alignment of translated amino acid sequence of clone-B to PfNek-4. The 
amino acid sequence was represented in a single-letter amino acid code (Appendix E).  
 
A protein search (BLASTp) on the PfNek-4 (clone-A) predicted amino acid sequence 
returned 100 hits. Of the 100 matches, only four from the Plasmodium species showed a 
maximum score (difference of the sum of identities/mismatches and sum of gap penalties) 
greater than or equal to 1000 (Table 4.2). The highest ranking match (100% identities) was 
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with Plasmodium falciparum (3D7) Nek-4 protein kinase (maximum score: 1618), with the 
lowest expect (E) value. The Homo sapiens Nek4 (hNek4) showed the least orthology (42%) 
which shows differences or uniqueness of the P. falciparum NimA-related protein kinase 
structures as compared to the hNek4 protein kinase. The results (Table 4.2) again ruled out 
any mutations within the nucleotide sequence of the recombinant PfNek-4 DNA.  
 
Table 4.2 Homologous protein sequences to PfNek-4 (clone-A). 
Accession Source Length Score Identities (%) E-value 
XP_002808785.1 Protein kinase, Plasmodium 
falciparum (isolate 3D7), 
PfNek-4 
310 1618 100.0 0.0 
XP_677620.1 Serine/threonine protein 
kinase 2, putative, 
Plasmodium berghei (strain 
ANKA) 
310 1571 96.0 0.0 
XP_001612826.1 Serine/threonine protein 
kinase NEK4, putative, 
Plasmodium vivax (strain 
Salvador I)  
310 1570 96.0 0.0 
GAB64821.1 Serine/threonine protein 
kinase NEK4, Plasmodium 
cynomolgi strain B 
361 1508 82.0 0.0 
XP_002261112.1 Serine/threonine protein 
kinase 2, putative, 
Plasmodium knowlesi (strain 
H) 
307 1372 87.0 0.0 
AAH15515.1 NEK4, Homo sapiens 451 228 42.0 8x10-67 
Protein sequences that showed a maximum score ≥ 1000 and lowest E-values, are listed from a 100 
hits generated from a BLASTp protein search on the NCBI database.  
 
4.5 Discussion 
The SDS-PAGE gels confirmed the MW of the GST-PfNek-4 fusion protein in line with the 
predicted size and the MW of the GST and PfNek-4 protein, by elucidation (Figure 4.6). The 
GST-tagged PfNek-4 (clones A and B) protein were identified and visualised by Western 
immunoblotting (Figure 4.7). Since the GST-PfNek-4 fusion protein did not show any kinase 
activity, the plasmids were isolated and the PfNek-4 DNA insert analysed in order to 
determine factors that may have contributed the kinase inactivity. Restriction enzyme digest 
products analysed using agarose electrophoresis showed plasmid inserts with the correct size 
(933 bp) as well as smaller fragments, due to potential star activity of restriction enzymes or 
plasmid instability (Godiska et al., 2010). Thereafter, agar plates with bacterial cells 
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containing the plasmids with the PfNek-4 DNA insert were submitted to Inqaba Biotech, for 
nucleotide sequencing of the plasmids. The nucleotide sequence alignment of the PfNek-4 
DNA insert with the published coding sequence for the PfNek-4 gene (PlasmoDB identifier: 
PF3D7_0719200, formerly MAL7P1.100), confirmed the match to the native gene (Figure 
4.12). Therefore no mutations were identified in the nucleotide residues. The kinase assay 
results, however, did not demonstrate any kinase activity of PfNek-4 (A) on the casein 
substrates (Figure 4.10b). As a result, the inhibitory activity of test compounds could not be 
evaluated. The functionality of a recombinant protein can be affected by post-transcriptional 
modifications of the protein itself. These modifications include folding of the newly formed 
polypeptide chain into its tertiary, three-dimensional and quaternary (spatial arrangements of 
subunits) structures and are critical to the functioning of a protein (Pollard and Earnshaw, 
2004). Protein folding is determined by the amino acid sequence of the protein. Efficient 
protein folding requires additional factors called chaperones, which bind to newly formed and 
misfolded proteins to stabilise partially folded polypeptides and assist in their folding or 
refolding. (Pollard and Earnshaw, 2004). Although the E. coli BL21 expression vector was the 
most efficient vector for the expression of PfNek-4 protein kinase, it was still not identical to 
the P. falciparum organism.  
 
However, basal level expression (expression in the absence of an inducer, in this case IPTG) 
of the PfNek-4 enzyme was detected on the Western Blot (Figure 4.7), meaning that the 
expression of the PfNek-4 enzyme was not tightly regulated by the repressor and promoter 
genes. Some, basal level expression is associated with most inducible promoters (Amersham-
Biosciences, 2002). This basal level expression has been shown to affect the outcome of 
cloning experiments for toxic inserts by selecting against inserts cloned in the proper 
orientation (Amersham-Biosciences, 2002). However, in the current study, the PfNek-4 DNA 
insert was in frame and the fusion protein was expressed. 
 
The casein protein was visualised with coomassie staining of the SDS-gel (Figure 4.10a), 
although it would have been detected on the autoradiograms provided the PfNek-4 was 
functionally capable of phosphorylating the protein. Casein from bovine milk consists of four 
subunits: α-s1, α-s2, β-casein and κ-casein and their MWs range from 19-25 kDa, and PfNek-
4 has the ability to autophosphorylate and phosphorylate exogenous β-casein substrate, with 
the exception of myelin basic protein and histone-1 substrates as previously reported (Pardo 
and Natalucci, 2002; Reininger et al., 2009). However, no kinase activity was detected.  
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The test compounds were not tested on the whole gametocytes of the P. falciparum parasites 
as it was beyond the scope of the current study and it would have only been considered if any 
of the test compounds were shown to inhibit GST-PfNek-4 kinase activity. A study by 
Reininger et al. (2012), suggests that PfNek-4 is not responsible for switching erythrocytic 
schizogony to gametocytogenesis, but rather a molecular marker of sexually committed and 
sexually pre-committed schizonts (Reininger et al., 2012). Nevertheless, NimA-related 
kinases putatively involved in the regulation of the gametocyte stages, are still critical drug 
targets to prevent human host-vector transmission. 
 
In order to ensure protein kinase activity, future studies could include re-transformation of the 
E. coli cells with the pGEX-4T-3 vectors containing the PfNek-4 DNA insert. In addition the 
kinase assay conditions such as pH can be optimised, taking into consideration the isoelectric 
point of the protein kinase. 
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Chapter 5 Conclusions 
The aim of the study was to investigate the in vitro antimalarial activity of 56 select 
compounds against the intra-erythrocytic stages of P. falciparum, alone and in combination 
with the classical antimalarial drug, quinine using the [3H]-hypoxanthine incorporation assay. 
Drug interactions were classified as marked synergism (0 > ƩFIC50 < 0.5), slight synergism 
(0.5 > ƩFIC50 < 1), additive interaction (1 ≥ ƩFIC50 < 2), slight antagonism (2 ≥ ƩFIC50 < 4) 
and marked antagonism (2 ≥ ƩFIC50 < 4) (Gupta et al., 2002; Bell, 2005). The screening 
concentration of compounds was at 100 µM for synthetic compounds and at 100 µg/ml for 
natural compounds. The malaria parasites were exposed over a 48 h single-cycle to the test 
compounds which included synthetic and natural colourants, novel nucleoside analogues and 
imidazopyridine analogues. Stage and morphology studies were carried out in order to 
determine which parasite stages were most sensitive to the most active test compounds from 
each compound class. The haemolytic activity was investigated to test whether the host RBC 
cell membrane’s integrity was affected by most active test compounds, thereby eliminate 
haemolysis as a mechanism of action. The ability of the most active test compounds to inhibit 
the haemozoin formation pathway, which is an ideal drug target similarly to classical 
antimalarial drugs such as quinine and chloroquine, was investigated.  
 
In order to identify test compounds with low toxicity, the selectivity of the most active 
compounds for P. falciparum rather than human cells was investigated. The selectivity index 
was calculated by dividing the antimalarial IC50 by the cytotoxicity IC50 values (obtained 
using the [3H]-thymidine incorporation assay) against the transformed human HEK293 and 
leukaemic K562 cell lines. A test compound that demonstrated a selectivity index greater than 
10 was regarded as more selective to P. falciparum relative to human cell lines. The study 
also aimed to investigate the inhibitory activity of the most active compounds against the 
recombinant NIMA-related PfNek-4 protein kinase activity.  
5.1 Synthetic colourants 
Methylene blue was significantly (p < 0.05) more potent against P. falciparum compared to 
quinine (Table 5.1). Both methylene blue and safranin O displayed negligible toxicity to 
uninfected human RBCs (Table 2.5). Combination studies with methylene blue and quinine 
demonstrated a synergistic interaction, whilst safranin O showed an additive interaction with 
quinine (Table 5.1). Therefore, there is potential for the latter compounds to be used in 
combination with quinine without compromising the overall antimalarial activity. Both 
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methylene blue and safranine O did not demonstrate inhibitory activity against the in vitro 
formation of β-haematin crystal formation, although literature has reported that methylene 
blue can inhibit β-haematin formation within the parasite’s food vacuole (Atamna et al., 
1996). The schizont stage (32-40 h) was most sensitive to methylene blue at IC90 
concentration, indicating that it may have other modes of action, which need to be explored 
further. Methylene blue demonstrated the highest selectivity indices (480-968, 2-fold selective 
compared to quinine) indicating low toxicity to human cells but selective inhibitory effects on 
P. falciparum (Table 5.1). In comparison, safranine O was 33 to 22-fold less selective that 
methylene blue, although both selective indices were above 10 (Table 5.1). Both methylene 
blue and safranin O showed ‘drug-like’ properties based on the Lipinski’s Rule of Five (Ro5). 
The predicted % ionisation values at pH 5.0, showed that safranin O would accumulate within 
the parasite’s digestive vacuole similarly to chloroquine and quinine, whilst methylene blue 
was not ionisable at the same acidic environment (Table 2.13). Therefore, methylene blue’s 
mode of action could not have been facilitated by its acid-base properties. The current study 
confirmed the potent antimalarial activity of methylene blue and its selectivity for P. 
falciparum. In addition, the chemical structure of methylene blue may serve as a template for 
the development of safer and affordable drugs, which can be used in combination therapy 
with other antimalarial drugs such as artemisinin or quinine. 
5.2 Curcumin 
The natural colourant, curcumin (diferuloylmethane) was significantly (p < 0.05) less potent 
against P. falciparum than quinine (Table 5.2) and showed slight haemolytic activity (at 100 
µg/ml) although this haemolysis was significantly (p < 0.05) higher than for quinine (Table 
2.6). However, curcumin’s haemolytic activity is of no clinical significance since a low peak 
plasma concentration (Cmax: 2.30 ± 0.26 µg/ml after a single oral dose of 10 g) has previously 
been reported without adverse events in human subjects (Vareed et al., 2008). The 
antimalarial activity of curcumin in combination with quinine, showed an additive interaction, 
which did not compromise the drug potency of quinine (Table 5.2). Curcumin was 78-fold 
more active in inhibiting β-haematin formation than quinine, indicating a possible mechanism 
of action. Study findings by Cui et al. (2007) suggest that curcumin has the potential to 
disable gene transcription within the P. falciparum parasite, by inhibiting nuclear histone 
acetyltransferase activity, as well as inhibit parasite growth by generating ROS. The predicted 
% ionisation of curcumin showed that it would be absorbed down the pH gradient of 7.4-5.0 
with a low degree of ionisation or accumulation in the parasite’s digestive vacuole (Table 
2.13). In comparison to quinine, curcumin was significantly (p < 0.05) toxic to both HEK293 
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and K562 cell lines and showed selectivity indices below 1, indicating poor selectivity for P. 
falciparum (Table 5.2). The current study confirmed the antimalarial potency of curcumin 
similarly to that reported in a previous study on the chloroquine-sensitive 3D7 strain of P. 
falciparum (Cui et al., 2007). In addition, curcumin showed potential as an anticancer agent 
as it significantly (p < 0.05) inhibited the in vitro growth of the K562 leukaemic cell line 
compared to the HEK293 transformed epithelial cells and was only 26-times less potent than 
the anticancer drug, camptothecin, as compared to quinine at 1021-times less cytotoxicity. 
5.3 Nucleoside analogues 
The most active pyrimidine-based nucleoside analogues, JLP118.1 and JLP093 (cytosine 
nucleobase), demonstrated inhibitory activities (IC50 < 3 µM) significantly (p < 0.05) less 
potent than quinine and both showed negligible haemolytic activity (Table 5.1). The 
trophozoite stage of P. falciparum parasites was particularly sensitive to JLP118.1, but not as 
a result of the inhibition of β-haematin crystal formation (Table 2.16). The uracil nucleobase 
containing JLP118.1, had a tert-butyl-dithiomethyl-hydroxyl group and a modified 
deoxyribose sugar containing acetate groups, whilst on the JLP093 chemical structure (with a 
cytosine nucleobase), there were tert-butyl-diphenylsilyl and hydroxyl group substitutions 
(Table 2.10). Both nucleosides were significantly (p < 0.05) more toxic to HEK293 and K562 
cells than quinine and showed selectivity indices below 6, indicating poor selectivity for P. 
falciparum parasites (Table 5.1). The promising antimalarial activity of the nucleoside 
analogues, JLP118.1 and JLP093, warrants further investigation and targeted compound 
design in order to enhance antimalarial potency, as well as reduce toxicity to human cells.   
5.4 Imidazopyridine analogues 
The most active imidazopyridine analogues, IP-3 and IP-4, demonstrated the least potent 
antimalarial activity (IC50 range: 15-21 µM) of all the synthetic compounds tested and were 
significantly (p < 0.05) less active than quinine (Table 5.1). IP-4 arrested the development of 
the intra-erythrocytic parasites at the trophozoite stage. The imidazopyridine analogues were 
not tested for haemolytic activity and β-haematin crystal formation inhibition due to limited 
availability of stock. IP-3 and -4 were significantly (p < 0.05) more toxic to HEK293 and 
K562 cell lines than quinine. However, the K562 leukaemic cell line was significantly (p < 
0.05) less sensitive to both IP-3 and -4 (Table 5.1). In addition, the selective indices of IP-3 
and IP-4 were below 1, indicating poor selectivity for P. falciparum (Table 5.1). Therefore, 
the potential of these imidazopyridine analogues as antimalarial could not be established, but 
may be investigated further for their anticancer properties.  
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5.5 Potential inhibition of PfNek-4 protein kinase activity 
The inhibitory activity of all active compounds, against the PfNek-4 protein kinase activity, 
could not be determined since the kinase activity of the recombinant GST-fused PfNek-4 
protein was lost. Following troubleshooting experiments and nucleotide sequencing, the long 
storage period (4 days) at 4°C in the elution buffer pH 8.0 (instead of freezing in 50% 
glycerol), was attributed to the denaturing of the GST-PfNek-4 protein kinase. Freezing in 
50% glycerol would have retained kinase activity. However, time constraints did not permit 
for the establishment and optimisation of the kinase activity. Nevertheless, future screening of 
novel compounds targeted for protein kinases involved in gametocytogenesis and the sexual 
stages may yield results in blocking the transmission of P. falciparum from infected human 
hosts to the mosquito vectors. This would contribute in controlling if not eradicate the virulent 
malaria infections caused by P. falciparum. 
 
Overall, the test compounds displayed variable ability to inhibit parasite growth with 21% of 
the test compounds inhibiting more than 80% parasite growth at a concentration of 100 µM or 
100 µg/ml. The study highlights the potential of synthetic and natural colourants, and 
nucleoside analogues as antimalarial agents. Other modes of action such as lipid peroxidation 
and free radical scavenging activity and inhibitory activity against PfNek-4 and other P. 
falciparum targets can be explored. (Motulsky, 2003) 
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Appendices 
Appendix A Chemical structures of test compounds 
Appendix A1 Nucleoside analogues 
 
 
 
 
Figure A1 Chemical structures of the nucleoside analogues tested. 
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Appendix A2 Imidazopyridine analogues 
 
 
 
 
 
Figure A2 Chemical structures of the imidazopyridine analogues tested. 
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Appendix A3 Least active synthetic colourants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3.1 Chemical structures of the least active synthetic colourants tested. 
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Figure A3.2 Chemical structures of the least active synthetic colourants tested. 
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Appendix B Biosafety and ethical clearances 
Appendix B1 Biosafety clearance for use of P. falciparum 
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Appendix B2 Ethical clearance for use of human plasma 
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Appendix B3 Ethical clearance for drawing of human blood from volunteers 
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Appendix B4 Ethical clearance waiver for use of human cell lines 
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Appendix B5 Biosafety clearance for use of recombinant PfNek-4 protein kinase 
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Appendix C pGEX 4T-3 Vector map 
 
 
 
Figure C1 Vector map of pGEX 4T-3 used to construct the GST-PfNek-4 protein. The 
GST gene fusion vector has: an ampicillin-resistant gene, Amp; an internal lac Iq gene to 
repress expression of target protein in E. coli host cell; a tac promoter for chemically 
inducible high-level expression, Ptac; the GST gene; a multiple cloning site with a thrombin 
protease recognition site as well as BamHI and SalI enzyme restriction sites. (Amersham-
Biosciences, 2002) 
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Appendix D PfNek-4 nucleotide sequence chromatographs 
Appendix D1 PfNek-4 clone-A forward and reverse nucleotide sequences 
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Appendix D2 PfNek-4 clone-B forward and reverse nucleotide sequences 
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Appendix E PfNek-4 nucleotide sequence alignments 
Appendix E1 PfNek-4 clone-A consensus sequence alignment 
 
Clone-A  11   ATGAATAAATATGAAAAGATTAGAGATATAGGAAAAGGAAATTATGGAAATACAATACTT  70 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  1    ATGAATAAATATGAAAAGATTAGAGATATAGGAAAAGGAAATTATGGAAATACAATACTT  60 
 
Clone-A  71   GTTAGAGATCGAAAAAATGACCATTATGTAATGAAAATAATAAACATTTCACAAATGTCT  130 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  61   GTTAGAGATCGAAAAAATGACCATTATGTAATGAAAATAATAAACATTTCACAAATGTCT  120 
 
Clone-A  131  CAGAAAGAAAAGAGGCAATGTTTAAAAGAAGTTGAATTATTATCCAAATTAAATCATCCT  190 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  121  CAGAAAGAAAAGAGGCAATGTTTAAAAGAAGTTGAATTATTATCCAAATTAAATCATCCT  180 
 
Clone-A  191  TTTATTGTAAAATATATTGAAAGTTATATTGAAGGGGATACACTTAGAATAGTTATGAAG  250 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  181  TTTATTGTAAAATATATTGAAAGTTATATTGAAGGGGATACACTTAGAATAGTTATGAAG  240 
 
Clone-A  251  CACTGTAAAGGAGGTGATTTATATCATTACATCCAAAATAAAAAGAAACAAAATACGCCT  310 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  241  CACTGTAAAGGAGGTGATTTATATCATTACATCCAAAATAAAAAGAAACAAAATACGCCT  300 
 
Clone-A  311  ATAAAAGAAAAACGTATACTCATCTGGCTAACTCAAATATTAACTGCTCTTAAATTTCTT  370 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  301  ATAAAAGAAAAACGTATACTCATCTGGCTAACTCAAATATTAACTGCTCTTAAATTTCTT  360 
 
Clone-A  371  CACTCAAATCATATTCTTCATAGAGATATGAAGTCTCTAAACATTTTAATAGACAGCGAT  430 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  361  CACTCAAATCATATTCTTCATAGAGATATGAAGTCTCTAAACATTTTAATAGACAGCGAT  420 
 
Clone-A  431  AAAAGAGTTAGACTGTGCGATTTCGGAATATCTAAAGTTCTAGAAAATACTTTAGATTAT  490 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  421  AAAAGAGTTAGACTGTGCGATTTCGGAATATCTAAAGTTCTAGAAAATACTTTAGATTAT  480 
 
Clone-A  491  GCTAATACCTTAATAGGTACTCCTTATTATTTAAGTCCAGAATTATGTAAAGATAAAAAA  550 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  481  GCTAATACCTTAATAGGTACTCCTTATTATTTAAGTCCAGAATTATGTAAAGATAAAAAA  540 
 
Clone-A  551  TATAGTTGGCCTTCAGATGTATGGGCAACTGGTTGTCTAATATATGAACTAGCCACTTTT  610 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  541  TATAGTTGGCCTTCAGATGTATGGGCAACTGGTTGTCTAATATATGAACTAGCCACTTTT  600 
 
Clone-A  611  AGAACCCCTTTTCATTCAACCAAAGGAATACAACAATTATGTTATAATATTAGATATGCT  670 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  601  AGAACCCCTTTTCATTCAACCAAAGGAATACAACAATTATGTTATAATATTAGATATGCT  660 
 
Clone-A  671  CCAATACCTGATTTACCAAATATCTATTCAAAAGAACTTAATAACATTTATAAGAGCATG  730 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  661  CCAATACCTGATTTACCAAATATCTATTCAAAAGAACTTAATAACATTTATAAGAGCATG  720 
 
Clone-A  731  TTAATACGAGAACCAAGTTACAGAGCAACCGTACAACAATTGCTAGTTTCTGATATTGTG  790 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  721  TTAATACGAGAACCAAGTTACAGAGCAACCGTACAACAATTGCTAGTTTCTGATATTGTG  780 
 
Clone-A  791  CAGAGACAACTAAAATTACTGATTGAAGAAAAAATCAGAGAAAAGCAAAGTATGAAAAAA  850 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  781  CAGAGACAACTAAAATTACTGATTGAAGAAAAAATCAGAGAAAAGCAAAGTATGAAAAAA  840 
 
Clone-A  851  CCTTTAAAAGAAAAGCCAGCTATTGAAAATGAAAATTCAGGAGCCAACGAACAAGAAGTA  910 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  841  CCTTTAAAAGAAAAGCCAGCTATTGAAAATGAAAATTCAGGAGCCAACGAACAAGAAGTA  900 
 
Clone-A  911  AAAACATTACTTCTGGATGTTGTTGATACTTAA  943 
              ||||||||||||||||||||||||||||||||| 
PfNek-4  901  AAAACATTACTTCTGGATGTTGTTGATACTTAA  933 
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Appendix E2 PfNek-4 clone-B consensus sequence alignment 
Clone-B  21   ATGAATAAATATGAAAAGATTAGAGATATAGGAAAAGGAAATTATGGAAATACAATACTT  80 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  1    ATGAATAAATATGAAAAGATTAGAGATATAGGAAAAGGAAATTATGGAAATACAATACTT  60 
 
Clone-B  81   GTTAGAGATCGAAAAAATGACCATTATGTAATGAAAATAATAAACATTTCACAAATGTCT  140 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  61   GTTAGAGATCGAAAAAATGACCATTATGTAATGAAAATAATAAACATTTCACAAATGTCT  120 
 
Clone-B  141  CAGAAAGAAAAGAGGCAATGTTTAAAAGAAGTTGAATTATTATCCAAATTAAATCATCCT  200 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  121  CAGAAAGAAAAGAGGCAATGTTTAAAAGAAGTTGAATTATTATCCAAATTAAATCATCCT  180 
 
Clone-B  201  TTTATTGTAAAATATATTGAAAGTTATATTGAAGGGGATACACTTAGAATAGTTATGAAG  260 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  181  TTTATTGTAAAATATATTGAAAGTTATATTGAAGGGGATACACTTAGAATAGTTATGAAG  240 
 
Clone-B  261  CACTGTAAAGGAGGTGATTTATATCATTACATCCAAAATAAAAAGAAACAAAATACGCCT  320 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  241  CACTGTAAAGGAGGTGATTTATATCATTACATCCAAAATAAAAAGAAACAAAATACGCCT  300 
 
Clone-B  321  ATAAAAGAAAAACGTATACTCATCTGGCTAACTCAAATATTAACTGCTCTTAAATTTCTT  380 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  301  ATAAAAGAAAAACGTATACTCATCTGGCTAACTCAAATATTAACTGCTCTTAAATTTCTT  360 
 
Clone-B  381  CACTCAAATCATATTCTTCATAGAGATATGAAGTCTCTAAACATTTTAATAGACAGCGAT  440 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  361  CACTCAAATCATATTCTTCATAGAGATATGAAGTCTCTAAACATTTTAATAGACAGCGAT  420 
 
Clone-B  441  AAAAGAGTTAGACTGTGCGATTTCGGAATATCTAAAGTTCTAGAAAATACTTTAGATTAT  500 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  421  AAAAGAGTTAGACTGTGCGATTTCGGAATATCTAAAGTTCTAGAAAATACTTTAGATTAT  480 
 
Clone-B  501  GCTAATACCTTAATAGGTACTCCTTATTATTTAAGTCCAGAATTATGTAAAGATAAAAAA  560 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  481  GCTAATACCTTAATAGGTACTCCTTATTATTTAAGTCCAGAATTATGTAAAGATAAAAAA  540 
 
Clone-B  561  TATAGTTGGCCTTCAGATGTATGGGCAACTGGTTGTCTAATATATGAACTAGCCACTTTT  620 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  541  TATAGTTGGCCTTCAGATGTATGGGCAACTGGTTGTCTAATATATGAACTAGCCACTTTT  600 
 
Clone-B  621  AGAACCCCTTTTCATTCAACCAAAGGAATACAACAATTATGTTATAATATTAGATATGCT  680 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  601  AGAACCCCTTTTCATTCAACCAAAGGAATACAACAATTATGTTATAATATTAGATATGCT  660 
 
Clone-B  681  CCAATACCTGATTTACCAAATATCTATTCAAAAGAACTTAATAACATTTATAAGAGCATG  740 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  661  CCAATACCTGATTTACCAAATATCTATTCAAAAGAACTTAATAACATTTATAAGAGCATG  720 
 
Clone-B  741  TTAATACGAGAACCAAGTTACAGAGCAACCGTACAACAATTGCTAGTTTCTGATATTGTG  800 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  721  TTAATACGAGAACCAAGTTACAGAGCAACCGTACAACAATTGCTAGTTTCTGATATTGTG  780 
 
Clone-B  801  CAGAGACAACTAAAATTACTGATTGAAGAAAAAATCAGAGAAAAGCAAAGTATGAAAAAA  860 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  781  CAGAGACAACTAAAATTACTGATTGAAGAAAAAATCAGAGAAAAGCAAAGTATGAAAAAA  840 
 
Clone-B  861  CCTTTAAAAGAAAAGCCAGCTATTGAAAATGAAAATTCAGGAGCCAACGAACAAGAAGTA  920 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
PfNek-4  841  CCTTTAAAAGAAAAGCCAGCTATTGAAAATGAAAATTCAGGAGCCAACGAACAAGAAGTA  900 
 
Clone-B  921  AAAACATTACTTCTGGATGTTGTTGATACTTAA  953 
              ||||||||||||||||||||||||||||||||| 
PfNek-4  901  AAAACATTACTTCTGGATGTTGTTGATACTTAA  933 
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Appendix F Single-letter amino acid code 
Table F1 Single-letter amino acid code. 
Amino acid Abbreviation 
Three-letter Single-letter 
Nonpolar (hydrophobic) 
Alanine Ala A 
Proline Pro P 
Valine Val V 
Leucine Leu L 
Isoleucine Ile I 
Methionine Met M 
Phenylalanine Phe F 
Tryptophan Trp W 
Polar, uncharged 
Glycine Gly G 
Serine Ser S 
Threonine Thr T 
Cysteine Cys C 
Asparagine Asn N 
Glutamine Gln Q 
Tyrosine Tyr Y 
Basic 
Lysine Lys K 
Histidine His H 
Arginine Arg R 
Acidic 
Aspartate Asp D 
Glutamate Glu E 
 
 
 
 
 
 
 
 
 
 
 
 
 
